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Summary
In coronary heart disease, the blood supply to the myocardium is insufficient for its 
needs and leads to cardiac ischaemia, which is often accompanied by the onset of 
lethal cardiac arrhythmias. Electrical communication between cardiac myocytes 
occurs across gap junctions located in intercalated discs. Gap junctions are specialised 
structures of the plasma membrane which facilitate direct and rapid communication 
between adjacent cells. Connexin 43 (Cx43) is the most widely expressed of the 
connexin family and is the main connexin in the heart. A cardiac ischaemia model 
system was developed to study the various aspects of cardiac myocyte biology.
Simulated ischaemia caused neonatal cardiac myocytes to cease synchronous 
contractions after 3-4 hours and was accompanied by the reversible 
dephosphorylation o f Cx43 after 5 hours. Cx43 dephosphorylation was then reversed 
by reoxygenating the cells for 30 minutes. In hypoxia the myocytes continued to beat 
and Cx43 remained phosphorylated.
Rotigaptide, an antiarrhythmic peptide with protracted action, increased intercellular 
dye transfer in cardiac myocytes, atrial HL-1 cells and HeLa cells expressing Cx43. 
The communication-modifying effect of rotigaptide was confined to cells expressing 
Cx43 since the peptide had no effect on dye transfer in HeLa cells expressing Cx32 
and Cx26. Rotigaptide had little effect on cell beating rate or Cx43 expression. 
Phosphorylation of Cx43 in normoxic and ischaemic cells was also unaffected.
Simulated ischaemia induced cardiac myocytes to release a peak of ATP after 80 
minutes that was blocked by the connexin mimetic peptide GAP 26 and the gap 
junction inhibitor 18-a glyccyrrhetinic acid. This suggested that the release of ATP 
occurred through connexin hemichannels (CxHcs). The rotigaptide analogue AAP10 
increased the transient peak of ATP release caused by ischaemia.
The model developed has provided a platform to study the effects of simulated 
ischaemia on Cx43 dependent functions in the heart. Rotigaptide and AAP10 emerge 
as novel peptides with therapeutic potential for treating heart arrhythmias.
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Chapter 1
General Introduction
1.1 Intercellular communication
There has always been the question o f how complex organisms coordinate the activity 
o f the many different cells constituting tissues and organs. The release of chemical 
factors and hormones provided an explanation for some o f the observed cooperative 
behaviour o f cells. However, it is evident that cells have mechanisms that allow 
direct communication with their neighbours. Gap junctions ensure the intercellular 
communication that operates at regions o f cell contact and adhesion. The gap junction 
is a specialised structure o f the plasma membrane which facilitates direct and rapid 
communication between adjacent cells. These junctions are ubiquitous in vertebrates 
and perform a variety o f functions in different tissues. Gap junctions provide a 
regulated pathway linking the cytoplasms o f attached cells, ensuring integration o f 
metabolic activities and creating a network o f directly communicating cell assemblies. 
Gap junctions can facilitate electrical coupling, calcium wave spread or the passage o f 
small signalling or biochemical molecules.
1.1.1 The structure o f gap junctions
Gap junctions were first described as plasma membrane areas that were closely 
apposed with a distinct 2-4 nm gap (Revel & Kamovsky 1967). The presence o f gap 
junctions in the form o f hexagonally packed subunits was first shown between the 
plasma membranes o f Mauthner cells o f goldfish brain (Robertson et al., 1963). 
Similar structures were found in rat liver plasma membrane by thin-section electron 
microscopy (Benedetti & Emmelot 1965; Revel & Kamovsky 1967). Revel and 
Kamovsky saw that their objects o f interest were “cell junctions in which there is a 
minute gap between the external leaflets.” They showed that these junctions were 
present in non-neuronal tissues such as liver and heart. Soon afterwards, they
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published an abstract in which they first referred to the structures as gap junctions, an
oxymoron that has stuck ever since.
Figure 1.1: Electron micrographs of gap junctions
a) Electron micrograph of rat heart gap junctions after splitting through the bilayer by 
freeze-fracture. The concentric flower-like depressions are thought to correspond to 
connexons (hemichannels). Magnification x 117 000. Reproduced from Shibata, 
Kyushu University, Japan.
b) Gap junction plaque isolated from rat liver, viewed en-face by electron microscopy 
after negative staining with sodium silicatungstate showing the characteristic 
hexagonal lattice of subunits. The inset illustrates an unstained junction optically 
filtered image that shows the crystalline hexameric subunits. Magnification x 220 000. 
Reproduced from unpublished data WH Evans.
Later studies by Goodenough & Revel (1970) used negative staining and freeze- 
fracture electron microscopy to show that these structures comprised packed arrays of 
numerous intra-membrane particles. It was confirmed by X-ray diffraction techniques 
that these particles were comprised of a pair o f apposed hexameric protein structures 
(one provided by each apposing cell). These component structures of gap junctions 
were subsequently known as connexons and later CxHcs (the term used in this thesis), 
and demonstrated a tilt of up to 20°-30° (Makowski et al., 1977). Gap junctions are 
formed by protein sub-units that have subsequently been named connexins (Cx) 
(Beyer et al., 1987). When gap junctions form the CxHcs interlock with apposing 
CxHcs from the adjacent cell as they are skewed by 10° (Baker et al., 1985).
3
Electron crystallography techniques have produced a slightly higher resolution o f the 
gap junction structure (Perkins et al., 1998). It was later shown that each CxHc tilts at 
30° thereby allowing interdigitation and docking o f the two apposed connexons when 
gap junctions form. Electron cryomicroscopy has been employed to examine a 
recombinant form o f Cx43 with the intracellular carboxyl terminus removed (Unger et 
al., 1997) and it appears that this truncation does not modify substantially channel 
structure (Sosinsky & Nicholson 2005). These studies have produced a widely 
accepted three-dimensional structure (Figure 1.2) with a 7A resolution that 
demonstrated that the gap junction is comprised o f interlocking CxHcs that are tilted 
and skewed within the plasma membrane as previously shown and arranged around a 
central pore diameter present in each CxHc. The central pore is predominantly 
formed from alpha helix structures contributed in the main by the third 
transmembrane domain o f the constituent connexin (Unger et al., 1997). Other 
approaches such as cysteine scanning mutagenesis revealed that parts of the first 
transmembrane domain are accessible from the extracellular space and therefore are 
part o f the channel pore lining, (Zhou et al., 1997) and also the flux limiting or narrow 
part o f the channel. (Hu & Dahl 1999; Fleishman et al., 2006). Alterations in calcium 
concentrations have been shown to induce further tilting o f the connexin subunits 
within the connexon; indeed, such a conformational change was proposed to alter 
channel permeability (Unwin & Ennis 1984).
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Figure 1.2: A 3D density map showing the molecular organization of a
recombinant gap junction channel.
a) A full side view of the channel is shown, and (b) the density has been cropped to 
show the channel interior. The approximate boundaries for the membrane bilayers 
“M”, extracellular gap “E”, and the cytoplasmic space “C” are indicated. The red 
asterisk in (b) marks the narrowest part of the channel where the aqueous pore is 
~15A in diameter. The white arrows identify the locations of the cross sections 
shown in (c), are parallel to the membrane bilayers. The red contours indicate data to 
a resolution of 15 A and define the boundary of the connexon. The yellow contours 
include data to a resolution of 7.5 A. The roughly circular shape of these contours 
within the hydrophobic region of the bilayers is consistent with 24 transmembrane 
helices per connexon. Reproduced from Unger et al., 1999.
1.1.2 Connexin protein structure and topography
Hydropathy plots of connexin linear sequences suggest the presence of four regions 
with high hydrophobicity usually signifying membrane spanning domains, and 
hydrophilic regions forming two extracellular loops and the carboxyl tail (Figure 1.3) 
(Paul 1986). Circular dichroism studies suggested that the protein is 60% alpha-helix 
(Cascio et al., 1990; Unger et al., 1997). Proteolytic studies and application of a range 
of site-specific anti-peptide antibodies confirmed that the amino and carboxyl termini 
of connexins are located intracellularly (Milks et al., 1988; Zimmer et al., 1987). The
two extracellular loops contain three cysteine residues in a characteristically 
conserved sequence (CX6CX5C in E l; CX4CX5C in E2), with perhaps just one 
exception to these sequences in Cx31 (Hoh et al., 1991). These cysteine residues form 
intramolecular disulphide bonds linking the two extracellular loops o f connexin32 
(Rahman & Evans 1991). Mutations in these crucial cysteine-flanking regions 
generally abolish the ability o f the connexin to form functional gap junction channels 
(Foote et al., 1998). The intracellular amino terminus is similar in length in all 
connexins. The major difference between all connexins is in the intracellular loop and 
carboxyl tail with both regions in some connexins varying in length and/or sequence.
Twenty or more connexin isoforms have been identified by genomic screening 
especially in humans and mice (Willecke et al., 2002). As the human and mouse 
genomes are now known, it seems unlikely that many new mammalian connexin 
isoforms will be discovered. The connexin isoforms show approximately 40% 
sequence homology with the main amino acid differences in the C-terminal tail.
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Figure 1.3: Topological representation of connexin in the membrane.
Hydropathy plots predict four membrane spanning regions (M1-M4), two extracellular 
loops (ELI and EL2) and three cytoplasmic portions, the amino-terminal and 
carboxyl-terminal domains and central intracellular loop (IL). The putative role of 
different domains is inferred from the results of structure/function studies with specific 
point mutations and chimeras with swapped domains.
Gap junction channels made up from different connexin isoforms (Figure 1.4) have 
distinct properties with differing conductance, differing gating properties and different 
expression levels in various cell types (Elfgang et al., 1995). Combined with the 
structural diversity, it suggests that gap junction channels fulfil and coordinate the 
different roles required for programmes of cellular differentiation (Willecke et al., 
2002).
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Figure 1.4: Diagram illustrating possible arrangem ents of connexins in gap
junction channels.
Six connexin subunits (blue or green) can form connexons in various configurations. 
Connexons may be homomeric (composed of six identical subunits) or heteromeric 
(composed of more than one connexin species). CxHcs from neighbouring cells 
associate end to end to form a gap junction channel. The channel may be homotypic 
(if connexons are identical) or heterotypic (if two connexons are different). For 
example, a cell expressing two types of connexins allows 196 different combinations 
resulting in a possible variation in gap junction channel selectivity.
1.1.3 Connexin protein nomenclature
An early nomenclature used to describe gap junctions was based on their functional 
and evolutionary characteristics with connexins described as either a , p or y. Also at 
this time, a nomenclature based on molecular weight was also widely used with each 
connexin described by its apparent or predicted molecular weight. For example Cx32 
has a predicted molecular weight from the cDNA of approximately 32kD. Minor 
variation in apparent molecular weight may occur when the proteins are run on SDS 
gels. However, connexins in different species are functionally and biologically 
similar but have slightly different molecular mass, due for example to conservative 
amino acid substitutions. For example, mouse Cx32 is 32,003Da and the human 
equivalent is 32,024Da. Given these slight variations and the increasing laboratory 
use of mouse genetic models, many have argued that the classification should be 
mainly based on mouse proteins. However, others argued in favour of a purely 
biochemical classification or one based on the human connexin proteins. A group of
cell biologists in the gap junction field has accepted a nomenclature that reaches a 
compromise. In this nomenclature the name o f the connexin is made up o f a prefix 
letter denoting the species, for example “m” or “h” for mouse or human respectively. 
This is followed by “Cx” and then by the molecular weight in kDa. For example 
hCx43 is human connexin 43 and in the heart, mCx30.2 is homologous to hCx31.9 
(Bukauskas et al., 2006). There is also a further nomenclature based on the genetics 
o f connexins and is known as the “Gja/Gjb” system and has been adopted by the 
NCBI (National Centre for Biotechnology Information), but it is not so widely used as 
the “Cx” nomenclature outside the genetic community. Using the genetic 
nomenclature Cx43 is GJA1, Cx32 is GJB1 and Cx26 is GJB2.
1.1.4 The Functions of Gap junctions
Gap junctions facilitate electrical communication between cells, as demonstrated in 
the cardiovascular and nervous system. Gap junctions also allow for the transmission 
of biochemical messengers in both excitable and non-excitable tissues. For example, 
using a model in which cardiac myocytes were coupled to ovarian granulosa cells, it 
was concluded that cAMP diffused across the gap junction (Lawrence et al., 1978). 
To establish the extent to which cells are functionally coupled and therefore 
biochemically connected by gap junctions, the technique o f dye transfer has been used 
extensively (Elfgang et al., 1995; Martin et al., 2001). This involves the injection o f 
small fluorescent dyes, especially Lucifer yellow into cells to determine if  the dye 
passes into the neighbouring cells (Stewart 1981). Dye transfer studies have been 
used to determine any size or charge discrimination o f the channel illustrating that 
molecules within a range o f 0.2-1.0kD can pass through the gap junction channel. 
These investigations were performed mainly on HeLa cells expressing gap junction
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channels constructed from various recombinant connexin isoforms, mainly Cx43, 
Cx32 and Cx26 (Cao et al., 1998; Elfgang et al., 1995; Nicholson et al., 2000).
Fluorescent calcium sensitive dyes in conjunction with ever advancing live-cell 
imaging technology have revealed that gap junctions have a more direct intercellular 
signalling role. Intercellular signalling, reflected by changes in intracellular calcium 
levels, is demonstrated by rapid and direct propagation to neighbouring cells via gap 
junction channels (Giaume & Venance 1998; Sanderson et al., 1994). Confluent 
monolayers o f HeLa cells expressing recombinant connexins labelled with GFP 
(green fluorescent protein) were studied to show increases in intracellular calcium 
levels and especially Ca2+ wave transmission by gap junctions (Figure 1.5) 
(Paemeleire et al., 2000). Intercellular calcium wave propagation can be initiated by 
chemical, electrical and mechanical stimulation (Isakson et al., 2001). The use of 
caged IP3 has also provided investigators with a non-invasive route to induce calcium 
wave changes resulting in their propagation through gap junctions (Leybaert & 
Sanderson 2001). In another study by Paemeleire et al. (2000), the calcium 
distribution was monitored following its release from the intracellular stores in HeLa 
cells expressing GFP labelled connexins. The calcium wave approaches the gap 
junction plaque and then instantly appears from the same fluorescently labelled gap 
junction plaque in the neighbouring cell, as shown in figure 1.5 (panels B2-B4) 
(Paemeleire et al., 2000). It has been proposed that calcium actually passes through 
the gap junction (Saez et al., 1989). However, on the contrary, it has long been 
accepted that high levels o f calcium cause gap junctions to close (Rose & 
Loewenstein 1976). Alternatively, it has been suggested that IP3 passes across gap
10
junctions, as in epithelial cells, with IP3 subsequently inducing the spread of calcium
waves (Boitano et al., 1992).
AF/F(%)
Figure 1.5: Intercellular calcium signalling
Calcium Waves transmitted between contacting HeLa cells by two routes; In A, the 
spread o f the calcium wave in HeLa cells lacking gap junctions occurs by the release 
of ATP, thus providing an extracellular route. In B, the HeLa cells express 
fluorescent Cx43 GFP (white arrows) and the spread of the calcium wave occurs via 
a fluorescent gap junction to a neighbouring cell. This occurred in the presence of 
apyrase to prevent ATP acting as a mediator. A l and B1 show the distribution of 
the endoplasmic reticulum using ER-tracker fluorescence (green). Changes of fluo- 
3 fluorescence at 488nm excitation, corresponding to changes in [Ca2+]I, are 
represented in pseudocolour, according to the scale bar. Reproduced from Evans 
and Martin, 2002.
1.1.5 The biogenesis of gap junctions
The majority of membrane proteins have a half life of around 24 hours. In contrast, 
connexin proteins have rapid turnovers with half lives o f 2-5 hours (Laird 2006). 
Connexin turnover and trafficking can be influenced by several factors, including 
cAMP and growth factors (Paulson et al., 2000). Biogenesis of a functional gap 
junction unit involves a series of events.
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CxHcs are delivered to the plasma membrane by vesicular trafficking from the 
endoplasmic reticulum via the Golgi; the classical secretory pathway. Monomeric 
connexins are synthesized by membrane bound ribosomes and inserted into the 
endoplasmic reticulum, achieving the correct membrane topology. Vesicular 
trafficking then delivers the protein to the Golgi apparatus. However, unlike most 
other membrane proteins, connexins are not glycosylated during transit through the 
Golgi owing to the luminal topographical orientation o f the amino acid residues that 
are often glycosylated. The oligomerisation o f connexins into hexameric CxHcs 
proceeds stepwise via association into dimeric and tetrameric connexin intermediates 
(Ahmad et al., 2001). However, the sub-cellular location where oligomerisation 
occurs is still controversial. Musil & Goodenough (1993) suggested that Cx43 
oligomerisation was delayed until the proteins had entered the distal regions o f the 
Golgi, a result that contradicted the traditional view that membrane proteins are folded 
and oligomerised once inserted into the ER (Hurtley & Helenius 1989). However, 
more recent reports have shown that connexin oligomerisation is a sequential event, 
starting in the ER or the endoplasmic-Golgi-intermediate compartment (ERGIC) and 
has been completed by arrival at the Golgi (Diez et al., 1999; Falk et al., 1997; George 
et al., 1999).
A further important aspect o f gap junction biogenesis is the evidence that more than 
one pathway for the delivery o f specific connexins to the plasma membrane may 
exist. An alternative pathway for Cx26 gap junctions has been described suggesting 
the existence of a Golgi independent mechanism o f biogenesis. Brefeldin A, a fungal 
derived agent that disrupts the Golgi, inhibited Cx32 and Cx43 trafficking to gap 
junctions but not Cx26 (Martin et al., 2001). This alternative pathway can also be
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induced by lowering the temperature o f the cell cultures by 15°C (George et al.,
1999). By contrast, Cx26 trafficking was blocked by nocodazole, a drug that 
disassembles microtubules, whereas Cx32 and Cx43 trafficking were relatively 
unaffected (Martin et al., 2001). Cx43 interacts with tubulin but the short C-terminus 
o f Cx26 precludes this interaction (Giepmans 2004). Earlier studies using subcellular 
fractionation approaches to separate the membrane components of the secretory 
pathway had also suggested that Cx26 had more than one trafficking pathway (Diez et 
al., 1999; George et al., 1998). The first transmembrane domain has emerged as 
having an important role in determining the trafficking route and post translational 
insertion into membranes o f Cx26 and Cx32. A single site amino acid mutation was 
introduced into the first transmembrane domain, but not the fourth transmembrane 
domain, in Cx32 so that it resembled amino acid sequences in Cx26. This single site 
mutation resulted in the post translational behaviour o f Cx26 as well as Brefeldin A 
insensitivity being conferred to the modified Cx32 (Martin et al., 2001).
The use o f fluorescent reporter tags attached to the carboxyl tail o f connexins has 
enabled the intracellular trafficking and life cycle o f gap junctions to be studied in live 
cells and in real time. Despite approximately doubling the molecular mass o f the 
protein, the addition o f fluorescent proteins to connexins has been shown not to alter 
trafficking characteristics significantly (Bukauskas et al., 2000; Martin et al., 1998; 
Paemeleire et al., 2000). The Golgi is an important transit organelle for the 
intracellular movement o f Cx43 as its disruption by Brefeldin A arrested the delivery 
to the plasma membrane (George et al., 1999; Laird et al., 1995). Connexin 
trafficking is also influenced in various but often critical ways by the cytoskeletal 
network (Giepmans et al., 2001; Johnson et al., 2002; Martin et al., 2001). Connexins
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are trafficked in highly mobile vesicles o f 0.5 pm diameter to the plasma membrane 
(Jordan et al., 1999; Lauf et al., 2002). CxHcs are inserted over a large area o f the 
plasma membrane and diffuse laterally, attaching as CxHcs to the periphery o f gap 
junction plaques (Gaietta et al., 2002).
The assembly and degradation o f gap junctions is a dynamic process, with new 
channels added continuously to the edge o f the gap junction plaque and “older” paired 
CxHcs are removed from central regions o f the plaque (Gaietta et al., 2002; Lauf et 
al., 2002). The breakdown of connexins occurs by lysosomal or proteosomal 
degradation, pathways which are ubiquitin-dependent (Laing et al., 1997; Rutz & 
Hulser 2001). Endosomes have been implicated in the transfer o f connexins from the 
plasma membrane to lysosomes (Pol et al., 1997), but there is also evidence 
suggesting that gap junction plaques can be internalised in their entirety by autophagy 
(Jordan et al., 2001).
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Figure 1.6: The biogenesis and degradation of gap junctions.
Diagrammatic representation of the classical biogenetic pathway by which connexins 
inserted into the rough endoplasmic reticulum form CxHcs that dock at specific parts 
of the plasma membrane to form gap junction channels. Portions from the centre of 
gap junction plaques (blue units) form autophagosomes consisting of paired CxHcs 
packed into vesicles sometimes referred to as annular gap junctions. Much remains to 
be learnt about the mechanism resulting in the rapid breakdown of gap junctions. 
Reproduced from Evans et al., 2006.
1.1.6 Gap junction channel gating
Gap junction channels are gated by pH (a decrease) (Figure 1.7) (Ek-Vitorin et al., 
1996) and voltage (a change in potential difference between cells) (Qu & Dahl 2002). 
Connexins with short intracellular carboxyl tails, e.g. Cx26, or mutant connexins with 
truncated tails, do not display pH gating, but their gating is restored by addition of 
peptide sequences from the carboxyl tail projecting into the cell cytoplasm (Morley et
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al., 1996). These observations suggest that the mechanism responsible for pH gating 
is an intramolecular interaction between carboxyl tail and intracellular loop, i.e. a 
“ball and chain” mechanism. Voltage gating appears to occur via a different gating 
mechanism and is thought to involve the following regions: the amino terminus, the 
first transmembrane domain and the first extracellular loop (Pfahnl & Dahl 1998; 
Verselis et al., 1994). Voltage gating has been proposed to change the selectivity o f 
channels to allow propagation o f electrical impulses but preventing larger signalling 
molecules proceeding through the channel (Qu & Dahl 2002). This mechanism 
allows electrical synchronisation o f cells, while restricting the flow o f second 
messengers and metabolites (such as ATP). This mechanism o f gating could be 
utilised to prevent the loss of important molecules (i.e. ATP) from healthy cells to 
adjacent damaged cells, such as may occur during ischaemia and reperfusion.
An additional mechanism for regulating the permeability or selectivity o f gap 
junctions could be the formation heteromeric or heterotypic channels composed o f 
different connexin isoforms (Figure 1.4). Cx40 and Cx43 heteromeric channels 
display a variety o f permeability traits whilst heterotypic channels exhibit different 
conductance states and dye permeability depending on the composition of each CxHc 
unit (Cottrell & Burt 2001; Cottrell et al., 2002). The permeability of heterotypic 
Cx40-Cx43 channels show an intermediate permeability rather than an unique 
permeability (Valiunas et al., 2002).
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Figure 1.7: Channel gating and permeability
a) A representation of the conformational change in the channel leading to closure by 
reduction in the central pore, and b) a diagram illustrating size selectivity of connexin- 
based channels allowing permeation by molecules up to a molecular weight of lOOODa.
1.1.7 Pannexins and Innexins
The pannexins and innexins are two families of proteins that are also capable of 
forming gap junction channels. The pannexins share little homology to connexins and 
are expressed in vertebrates as well as invertebrates (Litvin et al., 2006). To date, 
three pannexin proteins have been identified in rodents and humans: Panxl, Panx2 
and Panx3 (Baranova et al., 2004). Panxl is expressed in multiple organs of rodents 
and humans, including the nervous system. Panx2 expression is observed in many 
organ systems of mice and rats but is limited to the nervous system in humans, while 
Panx3 has been found in the skin of rats (Bruzzone et al., 2003). Channels 
constructed of pannexin proteins share many similarities with connexin channels, such
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as the propagation o f Ca2+ waves by glial cells and the synchronisation of 
hippocampal and cortex brain cells (Litvin et al., 2006).
The innexins are the gap junction forming proteins o f invertebrates and were 
originally characterized as “gap junction communication channels” in the arthropod 
(Adams et al., 2000) and the nematode Caenorhabditis elegans (C.elegans sequencing 
consortium 1998). More recently, innexin homologues have been identified in 
representatives o f the other major invertebrate phyla (Phelan 2005). The Drosophila 
fly genome currently has 8 identified innexin genes (Stebbings et al., 2002) and the 
worm has 25 genes (Stanch et al., 2001).
1.2 Connexin hemichannels (CxHcs)
CxHcs (also referred to as connexons) were long thought to be mere structural 
intermediates o f gap junctions, but have now emerged as channels by which cells can 
regulate the release o f  various signalling molecules (John et al., 2003; Stout et al.,
2004). Studies on lens Cx46 expressed in Xenopus oocytes revealed that CxHcs had 
high unitary conductance (300pS) and a large permeability, especially to cations. 
CxHcs were closed during high external H* and Ca2+ levels, but were opened by low 
extracellular Ca2+ (Ebihara et al., 1999; Ebihara & Steiner 1993). Another study on 
horizontal cell dendrites o f skate retina showed that CxHc (constructed o f Cx35) 
regulate transmitter binding to cone receptors (Malchow et al., 1993). Further 
research has examined other vertebrate connexins, including zebra-fish Cx35, chicken 
Cx56 and Cx45.6, and showed that these CxHcs also opened when exposed to low- 
Ca2+ or Mg2+ (Ebihara et al., 1999; 2003; Puljung et al., 2004; Ripps et al., 2004; 
Srinivas et al., 2005; Valiunas et al., 2000; 2004). Small fluorescent dyes (e.g.
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propidium iodide) have also been used to detect open CxHcs since they are taken up 
by these channels (De Vuyst et al., 2006; Li et al., 1996).
CxHcs are functionally altered by genetic mutations. For example, mutations in the 
C-terminus o f Cx32 that are linked to CMTX (Charcot-Marie-Tooth X-linked 
disease), caused the dysfunctional CxHcs to become leaky (Castro et al., 1999; Liang 
et al., 2005). Cx43Hcs containing six different single amino acid mutations produced 
changes in the entry o f dye through the channels, and are linked to oculodentodigital 
dysplasia -  a development disorder with craniofacial and limb disorders (Flenniken et 
al., 2005; Lai et al., 2006). These mutations are discussed in greater detail in section 
1.5.
1.2.1 CxHc properties
Many o f the properties o f CxHcs are similar to those o f entire gap junction channels, 
especially their permeabilities (Harris 2001; Verselis et al., 2000). However, there are 
slight structural differences to the extracellular domains o f free CxHcs, as revealed by 
atomic-force microscopy (Thimm et al., 2005). Other reports suggest that CxHcs are 
arranged in a less ordered fashion within the cell membrane and partition into lipid 
rafts (Locke et al., 2005; Tillman & Cascio 2003).
In physiological environments, CxHc are maintained in a closed conformation (Figure 
1.8d), but when extracellular Ca concentration is lowered, they change to an open 
conformation with pore diameter increasing from 1.8 (closed) to 2.8nm (open) 
(Thimm et al., 2005). It has been suggested that the hydrophobic extracellular
 ^I
domains are important regions in the regulation o f the Ca -dependent conformational
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changes that are illustrated diagrammatically in Figure 1.8 (Gomez-Hemandez et al., 
2003). Owing to the easier accessibility o f CxHcs relative to gap junctions, it has 
been possible to study closely the nature o f the amino acid sequence lining the 
channels, by techniques such as SCAM (substitute cysteine accessibility mutagenesis) 
(Kronengold et al., 2003). Current thinking is that the first extracellular loop 
contributes to the extracellular end o f the CxHc pore, the second transmembrane 
domain to the transmembrane part o f the channel and the amino terminal and/or part 
o f the intracellular loop, at the cytoplasmic end o f the pore (Gomez-Hemandez et al., 
2003; Kronengold et al., 2003). A Ca2+ binding site has also been detected on the 
extracellular aspect o f CxHcs (Gomez-Hemandez et al., 2003).
1.2.2 Regulation of CxHcs
CxHcs located in the plasma membrane are opened by specific stimuli, such as low 
extracellular Ca2+, membrane depolarisation, mechanical membrane stress and 
metabolic inhibition (Evans et al., 2006). It has been observed universally that CxHcs 
are modulated by extracellular Ca2+, as zero or low extracellular Ca2+ environments 
have been used as a common experimental strategy to activate their opening 
(Contreras et al., 2003; Quist et al., 2000). Additional studies have revealed that other 
extracellular ions also influence CxHc opening, such as Mg2+, non physiological 
bivalent ions like Ba2+ and Sr2+ (Contreras et al., 2003), univalent cations such as Na+ 
(Kondo et al., 2000; Srinivas et al., 2006) and anions like Cl' (Kondo et al., 2000). 
Depolarisation is another stimulus that opens CxHcs, with cells being depolarised by 
several methods including point mechanical stimulation (Bao et al., 2004; Romanello 
et al., 2003), sheer stress (Cherian et al., 2005), negative pressure by patch pipette 
(Bao et al., 2004) and changes in osmolarity (Quist et al., 2000). CxHcs in heart cells
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must have regulation mechanism to limit the passage o f Ca when the cells are 
depolarised during the heart beat. CxHcs composed o f Cx26, Cx30, Cx32, Cx35, 
Cx37, Cx38, Cx43, Cx44, Cx46, Cx50 and Cx56 open when exposed to one or more 
o f the several experimental conditions mentioned above (Harris 2001; Saez et al.,
2005). CxHcs can be influenced by additional factors, such as pH (intra- and extra­
cellular) (Harris 2001), redox status (Contreras et al., 2002) and phosphorylation 
status (King & Lampe 2005; Solan & Lampe 2005). It has been demonstrated that 
ATP is released by cells through CxHcs (Cotrina et al., 1998; Gomes et al., 2005; 
Stout et al., 2002). This phenomenon is discussed in greater detail in chapter 5 o f this 
thesis, especially its specific blockage by connexin mimetic peptides. Further studies 
have revealed that other small metabolites that can function as biochemical 
messengers also pass through CxHcs, such as glutamate released by astrocytes 
(Parpura et al., 2004; Ye et al., 2003), prostaglandins released from osteoclasts 
(Bruzzone et al., 2001; Cherian et al., 2005) and NAD+ released by fibroblasts 
(Bruzzone et al., 2001).
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Figure 1.8: Diagram illustrating the CxHc Ca2+-sensitive gating of CxHcs
analysed by atomic-force microscopy.
The top two images show high resolution three-dimensional height images of the 
extracellular face of (a) an open CxHc, imaged in nominally Ca2+-free buffer and (b) a 
closed CxHc imaged in the presence of 1.8 mM [Ca2+]. The two putative extracellular 
loops for each of the six connexin subunits forming a hemichannel are denoted by the 
numbers 1-6. The model shown in c and d  is a mechanism of channel closing; when 
the tertiary structure of the open connexon (c) is unbalanced by the Ca2+ absorbed on 
the extramembranous surface, the refolding of the El and E2 loops hides the 
hydrophobic domains and at the same time closes the channel (d). Modified from 
Thimms et al., 2005 and Evans et al., 2006.
1.3 Gap junction regulation by phosphorylation
Connexins are phosphorylated by multiple protein kinases, and dephosphorylated by 
phosphatases, and these post-translational modifications form a widespread mechanism 
for functional modification of connexin based channels. Phosphorylation of connexin 
channels leads to a broad range of effects, including stabilisation of open or closed 
states as well as changing the kinetics of the transition between states.
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The majority o f connexins are phosphoproteins, with Cx31, Cx32, Cx37, Cx40, Cx43, 
Cx45, Cx46, Cx50 and Cx56 shown to be subject to phosphorylation by changes in 
electrophorectic mobility and 32P incorporation (Lampe & Lau 2000; Saez et al., 
1998). The only connexin that is not phosphorylated is Cx26 (Traub et al., 1989), 
which is most likely due to the shortness o f its C-terminus, leaving only a few amino 
acids free to interact with cytoplasmic signalling elements. Since Cx26 is assembled 
into functional gap junction channels, it is clear that phosphorylation is not a general 
prerequisite for channel function. Indeed, Cx43 with truncated carboxyl tails has been 
shown to form functional channels (Fishman et al., 1991; George et al., 1999), and 
restoration o f the carboxyl tail resulted in the return o f certain functional 
modifications, including v-Src tyrosine kinase activity and cytoplasmic acidification 
(Calero et al., 1998). In summary, the carboxyl tail thus appears to be the primary 
target for phosphorylation of connexins.
Activation o f cAMP-dependent protein kinase (PKA) is associated with an increase in 
gap-junctional conductance in several cell types that express Cx32 and Cx40 
(Chanson et al., 1996; van Rijen et al., 2000). Cx32 is phosphorylated by PKA and 
protein kinase C (PKC) at S233 (Saez et al., 1990). Epidermal growth factor and 
Ca2+/calmodulin-dependent kinase II both phosphorylate Cx32 (Diez et al., 1998; 
Saez et al., 1990). Phosphorylation o f Cx45 has been shown to modulate channel 
conductance (van Veen et al., 2000). In another study, the last 26 amino acids 
(involving nine serine residues) were either deleted or substituted (by glycine or 
alanine), resulted in a 90% reduction in phosphorylation and loss of communication 
between cells (Hertlein et al., 1998). In the vertebrate lens, Cx46 and Cx50 gap
23
junctions have been demonstrated to change communication properties with changes 
in phosphorylation status that is modulated by various protein kinases including 
casein kinase I and II, and PKC (Berthoud et al., 2000; Cheng & Louis 2001; Yin et 
al., 2001).
1.3.1 Cx43 Phosphorylation
Cx43 has an extended (156 amino acid) carboxyl tail projecting into the cytoplasm that 
undergoes extensive phosphorylation during its assembly into gap junctions (Figure 
1.9). Phosphorylation o f Cx43 can influence gap-junctional communication in both a 
positive and negative manner (Berthoud et al., 1992; Musil et al., 1990). Cx43 
phosphorylation occurs primarily on multiple serine residues located on the carboxyl 
tail and is mediated by several protein kinases, including, PKA and PKC as discussed 
above and below. In addition, Cx43 has been shown to be a substrate for src- family 
protein kinases (Lin et al., 2001), mitogen-activated protein kinase (MAP-K) (Wam- 
Cramer et al., 1996), p34 kinase (Lampe et al., 1998) and casein kinase 1 (Cooper & 
Lampe 2002) as shown in Table 1.1. The carboxyl tail o f Cx43 contains 21 serine 
residues and the amino tail contains 2 serine residues, with the known phosphorylation 
sites indicated in Figure 1.9. Cx43 usually exists in a highly phosphorylated state in 
cardiac myocytes in vivo and in culture (Kwak et al., 1999; Laird et al., 1991; Lau et 
al., 1991).
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Figure 1.9: The phosphorylation sites of Cx43
Known phosphorylation sites on Cx43 targeted by different protein kinases. For 
explanation of abbreviations, see main text and abbreviations list. Reproduced from 
Lampe & Lau 2004.
Electrophysiological studies in cardiac myocytes have shown that non-phosphorylated 
and phosphorylated Cx43 gives rise to channels that have different unitary 
conductances. Electrophoresis of phosphorylated Cx43 resulted in bands between 43- 
45 kDa, which gave channels with a unitary conductance of around 60-70pS. In 
contrast, Cx43 treated with alkaline phosphatase produced a single band at 41 kDa 
after electrophoresis, and channels with conductance of 90-lOOpS (Moreno et al., 
1994). Cx43 channel conductance in fibroblasts was altered from approximately 
lOOpS to 45pS when phosphorylated at S368 by PKC, a change not seen in channels 
formed by mutated Cx43 (S368A) (Lampe et al., 2000). A recent study by Ek-Vitorin 
et al. (2006) demonstrated that the selective permeability of Cx43 gap junctions is
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modulated by PKC dependent phosphorylation o f S368, treatment with, a PKC 
inhibitor reduced phosphorylation at S368, dye transfer and the prevalence lower 
conducting Cx43 channels (55-70pS). Cx43 phosphorylated at S368 showed 
enhanced expression in ischemic hearts and was observed to reside at the intercalated 
disks (Ek-Vitorin et al., 2006).
Residue Kinase or signaling
phosphoiyiated pathway responsible
Y247 pp60Bt
S255 MAP-K and cyclin
S262 CydmW pW *2
Y265 pp60«
$279 MAP-K
S282 MAP-K
S325 CK1
S328 CK1
S330 CK1
S364 PKA or PKA-dependent kinases
S365 FSH stimulation (PKA?)
S368 PKC
$369 FSH stimulation (PKA?)
S373 FSH stimulation (PKA?)
Table 1.1
Protein Kinases that phosphorylate Cx43 and their sites o f action. Table modified 
from Lampe and Lau, 2004.
PKC activation results in the phosphorylation o f Cx43 at S368 (Lampe et al., 2000) 
and S372 (Saez et al., 1997). In neonatal cardiac myocytes, TPA (12- 
tetradecanoylphorbol-13-acetate) a PKC activator, induced increased PKC 
phosphorylation of Cx43, and resulted in increased gap-junctional conduction (Kwak 
et al., 1995) or no change (Spray & Burt 1990). However, increased Cx43 
phosphorylation due to PKC activation causing decreased gap-junctional 
communication has been observed in several cell types and has been linked to 
enhanced tumourigenesis (Berthoud et al., 1992; Brissette et al., 1991; Reynhout et
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al., 1992). The reasons for these differences in observed PKC activity caused by TPA 
could be due to several factors, including cell type and the different isoforms o f PKC 
present, the state o f Cx43 phosphorylation when exposed to TPA as well as 
differences in experimental techniques. An interesting observation in TPA treated 
cardiac myocytes was that despite overall gap-junctional conduction increasing, the 
lower conduction state o f Cx43 channels (50pS rather than lOOpS) was favoured and 
dye transfer between cells was reduced (Kwak et al., 1995).
Specific isoforms o f PKC have been the focus o f a few studies in the gap junction 
field. In cardiac myocytes PKCa and PKCe were associated with Cx43 (Bowling et 
al., 2001) and in fibroblasts inhibition o f gap-junctional communication was 
dependent to varying extents on PKC a, (3 and 8 (Cruciani et al., 2001). In lens 
epithelial cells, plasma membrane Cx43 was reduced and it co-immunoprecipitated 
with PKCy following TPA treatment (Wagner et al., 2002). Cardiac myocyte gap- 
junctional permeability was reduced and Cx43 phosphorylation increased by 
fibroblast growth factor-2, and was associated with Cx43 colocalising with PKCe 
(Doble et al., 2000). As different cells express distinct PKC isotypes, it is 
undoubtedly necessary to examine the actual sites o f phosphorylation on Cx43’s 
carboxyl tail in order to elucidate consequences o f these phosphorylation events 
(Axelsen et al., 2006).
Increased levels o f cAMP are associated with elevated levels o f Cx43 phosphorylation 
and gap-junctional communication (Darrow et al., 1995), as well as an increase in 
size, number and assembly of gap junctions (Atkinson et al., 1995; Paulson et al., 
2000), enhancements that appear to be PKA mediated (Paulson et al., 2000). The
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S364 site on the carboxyl tail o f Cx43 appears to be an important phosphorylation site 
for cAMP enhanced gap junction assembly (TenBroek et al., 2001). Despite this, 
PKA interacts with Cx43 weakly compared to PKC or MAP kinase, leaving the 
possibility that PKA could phosphorylate S364 indirectly by activating an additional 
kinase, or that it directly phosphorylates the site inefficiently thereby indicating an 
advantage o f Cx43 being a poor substrate (Shah et al., 2002). A further study using a 
Cx43 mutant (S364P) has shown alteration in the sensitivity of Cx43 pH gating in 
Xenopus oocytes (Ek-Vitorin et al., 1996). Clearly, the phosphorylation o f Cx43 is an 
extremely complex process that appears to vary between different cells. Consensus 
on the relationship between phosphorylation and channel gating is difficult to 
decipher.
1.4 The pharmacology of cardiovascular gap junctions
There are many agents, both intrinsic and extrinsic, that modulate connexin-based 
communication. Some pharmacological substances alter channel opening and closing, 
while others affect the synthesis or expression o f connexin channels. Many cations, 
including H+, Na+, Ca2+ and Mg2+ have been shown to influence gap junction channels 
and CxHcs, usually exerting their effects directly and causing a reduction in
'y j
communication (Firek & Weingart 1995). The effects o f Ca on CxHcs have already 
been discussed in detail in 1.2.2.
1.4.1 Pharmacological closure of cardiovascular gap junctions
Traditionally, lipophilic agents such as heptanol and octanol have been used as gap 
uncouplers to inhibit intercellular communication (Evans & Boitano 2001). More 
recently, fatty acids such as palmitoleic acid, oleic acid and arachidonic acid have
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been used at pM concentrations to inhibit gap-junctional communication (Dhein et al., 
1999; Hirschi et al., 1993; Schmilinsky-Fluri et al., 1997). The mechanism o f action 
is thought to be due to the incorporation o f these agents into the lipid bilayer o f the 
plasma membrane causing a reversible impairment of the gap junction channel pore 
(Takens-Kwak et al., 1992). Some anesthetics are thought to have a similar 
mechanism of action. For example, halothane caused a 90% reduction in junctional 
conductance in rat neonatal cardiac myocytes (Burt & Spray 1989). However, their 
specificity towards connexin channels relative to other membrane channels can be 
questioned.
The glycyrrhizic compounds derived from liquorice root are inhibitors o f connexin- 
channel communication, and include 18aGA (Figure 1.10), 18pGA and 
carbenoxolone. 18aGA has been used to inhibit gap-junctional communication at 
50jiM  (Taylor et al., 2001) and 18pGA at 5jiM (Allen et al., 2002). The mechanism 
and specificity by which glycyrrhetinic acids inhibit connexin communication is not 
fully understood but it has been suggested that changes in phosphorylation status 
could be involved as Cx43 is dephosphorylated by 18aGA in HeLa cells (Clarke et 
al., 2006).
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Figure 1.10
The Chemical structures of a) the gap junction inhibitor 18-a-glycyrrhetinic acid
(18aGA) and b) the cardiac glycoside ouabain.
The cardiac glycoside group of compounds (digoxin or digitoxin, ouabain and 
strophanthidin) act by inhibiting the action o f the Na+/K+-ATPase exchanger, which 
causes an increase in intracellular Ca2+. In an early study, ouabain decreased 
conduction velocity in bovine heart (Weingart 1977), while strophanthidin and 
ouabain caused cellular uncoupling in guinea pig ventricle (De Mello 1976; Weingart 
& Maurer 1987). More recent investigations have shown that ouabain exerts a 
biphasic effect, where initially gap-junctional communication is decreased followed 
by a reduced connexin expression (Martin et al., 2004). It is likely that these 
uncoupling events contribute to the antiarrhythmic action o f the cardiac glycosides.
Connexin mimetic peptides are short peptides corresponding to extracellular loop 
sequences o f connexins, initially Cx32, that delayed the onset o f synchronous beating 
o f isolated cells aggregating into contracting myo-balls (Warner et al., 1995). These 
peptides were later modified to correspond to extracellular loop sequences in Cx43 
and were shown to block the gap junctions connecting vascular smooth muscle cells 
and endothelial cells (Chaytor et al., 1997; 1998). Gap 26 is a short peptide sequence
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targeted against the first extracellular loop o f Cx43 (VCYDKSFPISHVR). A similar 
connexin mimetic peptide, GAP 27 (SRPTEKTIFII) corresponds to the second extra 
cellular loop, and has been extensively used and has been shown to be equally as 
effective (Chaytor et al., 1999). The peptides have also been modified to act on Cx40 
channels.
A number of other agents can be used to regulate the closure o f gap junction channels 
by activating protein kinases and thereby altering the phosphorylation state o f the 
connexins in the channel. Such agents are listed in table 1.2 and include 
noradrenaline, angiotensin II, phorbal esters such as TPA.
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Agents that 
close gap 
junctions
Agents that 
enhance gap 
junction activ ity
Class Agents Proposed tnochtcism
tors H*. Na*. Ca*, Mg*’ direct cffacts?
LipophiSc agents heptacol, octanol arachtdoctc acid. iocorporaioc?
and fany a ils oleic acid, paimiiolcic add. 
deoaenoie add, oayriaoiec add
Gfycyirhizic acid 18 <r-g ly cyrrbetinic acid. pfeosphoryhtbn?.
metabolites 18-fi-glycyTrbetirac acid, 
earbeaoxolcne
aggregation of Cx-subunits?
Roccpcr ligands carbachol (M-cbolinoocptoc). cGMP.PKG. PKC, PKCe.
notadrceatinc (o'adrcnoccptor). 
FGF-2, angiotensin-0 (ATI receptor). 
Atrial natriuretic factor AKF. VEGF
PKC?. eGMPPKG, ERK
DcphoshoryUting 2,3 buundiooc monoxinve unknown mechanism
agents
Narcotics halothaec. ethranc, isoftuorx incorporation?
Pborbol esters 12-O-ttnidecanoypborboJ-
13-acetate, (TPA)
activation of PKC*. .Ca**?
PKC infc fetors staunKporine inhibition of PKC*
Metabolites ATP-dccrcasc. Diacyiglyociol/ depbospbotylsion, unknown
l-olooyl-2-«cctyl-.»t-glyccrol rocdacisradi&turbapcc of 
tire lipid bi layer?
Ecosanoids Il.l2'«poxyeioosairiei»k: add 
(late effect) thromboxane A2
ERK 1/2, unknown mechanism
Fenamates mcdofenamic acid, mflumic acid, 
ftifcnamk acid
unknown mechanism
IPj-recqstor Mocker 2-aminocthoxydi phenyl borate unknown mechanism
Weak organic adds acetic add. propionic acid H*
Caenabinoids A*-tetjfcydrccanaabi&ol ERK 1/2
Cardiac glycosides strophanthidin, ouabain elevation of [Ca1*];
cAMP-cnhaneing. cAMP, fotskolic. PKA
drags iroprcnaiine
Antiarrbythmic Tedisamil PKA
drugs
Antiarrfeytfcmic, AAPnat. AAPIO, PKOa.
peptides cAAPlORG. 
HPP-S, ZPI23
?PKC
Ekosaooids 11,12-epoxydcosatricnok 
acid, (early effect)
PKA
Fbodol ester TPA PKC
Unsa turned cioosapcniacnoic acid inhfeitioa of
fatty adds tyTodne, kinase, 
(only after 
hypoxia),
Receptor ligands 5-hydroxyrrypurninc unknown
rocchacitra
PDF inhfeitor iso butyrylmcthy Ixacthioc cAMPPKA
* Probably depending oo fee tsofonn o f PKC.
Table 1.2
Agents that act upon cardiovascular gap junctions. Table modified from Dhein, 2004.
1.4.2 Pharmacological manipulation of cardiovascular gap junctions
There are far fewer substances that act on connexin channels thereby enhancing their 
function than those decreasing their activity, and these are summarised in table 1.2. 
However, great interest has been shown in agents that enhance cell coupling as this 
could be advantageous in situations such as in ischaemia-reperfiision, where agents
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could act antiarrhythmically. Agents such as forskolin and isoprenaline have been 
shown to activate PKA, which can lead to increased coupling between cardiac 
myocytes (De Mello 1991), or they may have no effect on coupling (Kwak & 
Jongsma 1996), as explained in 1.3.1.
A naturally occurring antiarrhythmic peptide was identified in bovine atria that 
improved the synchronous contraction o f cultured myocardial cell clusters (Aonuma 
et al., 1980). The hexapeptide, designated AAPnat, has a sequence o f tfeN-Gly-Pro- 
4Hyp-Gly-Ala-Gly-COOH (Aonuma et al., 1982). AAPnat was detected in heart, 
kidney and blood o f rats at concentrations o f 203pmol/g, 165pmol/g-l and 
3.8pmol/ml respectively (Kohama et al., 1985). Using mouse models, arrhythmias 
induced by CaCb (Kohama et al., 1987), aconitine (Aonuma et al., 1983) and ouabain 
were all reduced upon addition of AAPnat, but epinephrine-induced arrhythmias were 
unaffected . Derivatives of AAPnat such as HPP-5 (N-3-(4-hydroxyphenyl) propionyl- 
Pro-Hyp-Gly-Ala-Gly) (Aonuma et al., 1980) and the synthetic derivative AAP10 
(H2N-Gly-Ala-Gly-Hyp-Pro-Tyr-CONH2) (Muller et al., 1997) have also shown 
antiarrhythmic actions. AAP10 is semicyclic in structure and binds to a membrane 
protein/receptor (Grover & Dhein 2001). All AAPs have been shown to activate PKC 
(Dhein et al., 2003). The action of AAP10 was inhibited by GDP-p-S, PKC inhibitors 
and a specific inhibitor of PKCa (CGP54345), which indicates that AAP10 acts via a 
G-protein which activates PKCa causing Cx43 phosphorylation and thereby improves 
gap-junctional conductance (Muller et al., 1997; Weng et al., 2002).
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1.5 Diseases caused by gap junction abnormalities
Gap junctions are present in all nucleated cells, with the exception of adult striated 
muscle and sperm, and it is no surprise that abnormalities of connexins cause a wide 
range o f diseases in many tissues and organs throughout the body (Evans & Martin 
2002). The majority o f diseases described to date relate to single gene defects, which 
indicates that disease processes could involve polygenic abnormalities affecting 
structure, expression or trafficking o f the gap junction forming proteins, the 
connexins. A summary of human diseases associated with connexin gene 
abnormalities and for comparison phenotypic abnormalities identified in mice with 
connexin abnormalities is shown in Table 1.3.
Mouse Cefi and tissues with major Phenotype(s) of Cx- Human
connexin expression levels defident mice Human heredttary dsease(s) connexin
as. as. as. hCx2S
mCx26 breast, skin, cochlea, liver, 
placenta
lethal on ED 11 sensorineural hearing loss, 
patmopiantar hyperkeratosis
hCx26
mCx29 myelinated ceKs as. as. hCx30.2
mCx30 skin, brain, cochlea hearing impairment nonsyndromic hearing loss, 
hydrobc ectodermal dysplasia 
hair loss, nafl defects and often 
mental deficiency
hCx30
mCx30.2 as. n.8. as. hCx31.9
mCx30.3 skin n.s. erythrokeratoderma variabiHs hCx303
mCx31 skin, cochlea uterus, transient placental hearing Impairment, hCx31
placenta dysmorphogenesis erythrokeratoderma variabWs
mCx31.1 skin as. as. hCx31.1
mCx32 liver, Schwann ceils. decreased glycogen CMTX, {one of the heredttary hCx32
oligodendrocytes degradation, increased fiver 
carcinogenesis
peripheral neuropathies)
mCx33 testis as.
mCx36 neurons retina visual deficits as. hCx36
mCx37 endoftefium, ovaries female sterility, intensive 
bleeding
as. hCx37
mCx39 as. as. as. hCx40.1
mCx40 heart, endothelium atrial arrhythmia as. hCx40
mCx43 many ceA types and tissues heart malformation and 
ventricular arrhythmia
visceroatriai heteroataxia? hCx43
mCx45 heart endothefla, neurons lethal on ED 10.5 as. hCx45
mCx46 lens zonular nudear cataract congenital cataract hCx46
mCx47 brain, spinal cord as. as. hCx47
mCx50 lens microphthalmia, zonular 
putveruiant and congenital 
cataract
zonular pulverulant cataract hCxSO
n.s. n s. n.s. hCx59
mCx57 ovaries n.s. as. hCx62
n.s. not studied. ED, embryonic days.
Table 1.3
Tissue expressing various mouse connexins and the phenotypes in connexin-deficient 
(knock-out) mice. Inherited human diseases that are associated with various connexin 
mutations are also shown. Table taken from Evans and Martin, 2002.
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1.5.1 Cx43 mutations linked to oculodentodigital dysplasia (ODDD)
Relatively few loss o f function mutations o f Cx43 have been described in the heart. 
However in ODDD, 28 Cx43 mutations have been identified (Paznekas et al., 2003). 
ODDD is a pleiotropic development disorder that causes craniofacial abnormalities, 
lens and comeal defects, abnormalities o f the hair, nails and teeth, syndactyly and 
occasionally heart and neurological problems (Loddenkemper et al., 2002). Although 
rare, most patients live long lives in relatively good health. A mouse model o f ODDD 
has been developed and genetic analysis has revealed that a G60S mutation 
(Flenniken et al., 2005) in the first extracellular loop is very similar to a P59H 
mutation recently discovered in humans (Vasconcellos et al., 2005), thus showing the 
importance o f this model as a tool for studying ODDD and Cx43 mutations in humans 
(Laird 2006).
1.5.2 Genetic abnormalities in Cx26 associated with non-syndromal deafness
Over 30 mutations o f Cx26 have been identified, o f which approximately half account 
for inherited non-syndromal deafness. This has led to the first practical genetic 
marker o f inherited hearing loss (Steel & Kros 2001). The most common mutation in 
Cx26 causing deafness is 35delG, which results in protein translation terminating 
prematurely at amino acid 13 (Estivill et al., 1998; Kelsell et al., 1997). A different 
mutation that produces similar effects is the 167delT mutation resulting in truncation 
o f the protein product at amino acid 56 (Zelante et al., 1997). These two mutations 
produce immature Cx26 that cannot form functional channels. However, other 
mutations cause defective Cx26 trafficking, such as the Trp77Arg and Met34Thr 
mutations, which fail to oligomerise correctly into hexameric complexes and thus no 
functional channels can form (Martin et al., 1999). For example, a Trp44Cys
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mutation results in Cx26 that trafficked to the plasma membrane and oligomerised 
into hexameric channels, but was unable to form functional gap junctions transferring 
Lucifer yellow (Martin et al., 1999), indicating that poorly functioning or inactive 
gap junctions are produced by this mutation. Studies in Xenopus oocytes expression 
systems revealed that some mutations of Cx26 are unable to form electrically active 
channels (White et al., 1998).
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Figure 1.11: Schematic diagrams of Cx26 and Cx43 mutations
Cx26 mutations causing deafness and skin diseases are illustrated (a) with mutations 
associated with deafness shown in purple and mutations associated with both deafness 
and skin diseases shown in orange. Cx43 mutations causing ODDD are shown (b) 
with the locations of 28 mutations shown in red, all linked to ODDD. Reproduced 
from Laird 2006.
1.5.3 Cx32 mutations cause Charcot-Marie-Tooth X-linked disease (CMT-X)
Charcot-Marie-Tooth X-linked disease, a peripheral neuropathy, is a progressive 
atrophy of distal muscles and reduced axonal conduction by Schwann cells (Bergoffen 
et al., 1993), with patients revealing over 200 mutations in Cx32 (Nelis et al., 1999). 
The Cx32 mutations are quite varied but evenly distributed throughout the DNA,
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affecting most connexin domains (Nelis et al., 1999). Truncation or a single amino 
acid substitution in Cx32 leads to dysfunctional channels (Abrams et al., 2001). The 
channel pore size can be reduced by the Ser26Leu mutation and channel opening 
probability is reduced by a Met34Thr mutation (Oh et al., 1997). Further Cx32 
mutations modify intracellular trafficking and assembly thereby impairing Cx32 gap 
junctions to function normally (Martin et al., 2000). Also, Cx32 knockout mice 
developed decreased nerve conduction with age and demonstrated similar morphology 
to CMT-X in humans (Willecke et al., 1999).
Node of Ranvier Schwann cell
Axon
Schwann cell nucleus
Schwann cell plasma membrane
Axon
Incisures of Schmidt-Lanterman
Cx32 channel
Nerve fiber (axon)
Schwann cell cytoplasm
Figure 1.12: Myelin structure and location of connexin32 gap junction channels.
The structure of peripheral myelin is shown at the top. The cytoplasm of a Schwann cell 
wraps several times around a nerve fibre (axon) forming the myelin sheath; Cx32 containing 
gap junction channels are formed between adjacent plasma membranes of the enwrapping 
layers that originate from the same Schwann cell connect the incisures of Schmidt- 
Lanterman. Reproduced from Saez et al, 2003.
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1.5.4 Cataract
In the lens, Cx46 and Cx50 mutations are linked to cataract abnormalities (Pal et al.,
2000). The eye lens is an avascular organ consisting of an epithelial layer covering 
the anterior surface o f  the organ and a large mass o f fibre cells which form the bulk of 
the organ (Saez et al., 2003). In the lens, the anterior epithelial monolayer interfaces 
with the aqueous humour and contains high densities o f ion channels and transporters. 
The epithelial monolayer where Cx43 is expressed controls cellular homeostasis for 
the entire lens via a network of intercellular channels (Goodenough et al., 1980). An 
unusual property o f Cx46 expressed by fibre cells is that it forms CxHcs that are 
predominantly in the open state when expressed and assembled in Xenopus oocytes 
(Pfahnl & Dahl 1999). The role o f the Cx46Hcs in the lens is to provide conduits for 
the passage o f nutrients to the inner avascular parts o f the lens that are remote from 
the aqueous humour (Pfahnl & Dahl 1999). It is apparent that this is the sole 
mechanism for supplying the lens with nutrients and therefore it is likely that 
malfunction o f these channels may result in cataract (Pfahnl & Dahl 1999). Indeed, 
mice with abnormal Cx46 developed cataracts (White & Paul 1999). Reliance by 
organs on a single biological system is unusual and indicates the importance here of 
channels constructed o f  connexins.
1.6 Gap junctions in the heart and cardiovascular system
The principal function o f gap junction channels in the heart is to allow propagation of 
the action potential from cell to cell. The distribution of the gap junction channels, 
mainly confined to intercalated disks at the cell poles with only small proportion 
located at the lateral borders o f the cell ensure normal propagation of the activation 
wave front. The cardiac action potential is propagated along the fibre by activating a
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sodium current, which is mainly dependent on sodium channel availability. At the 
cell pole, the action potential is transferred via gap junction channels to the next cell. 
Gap junctions located along the lateral border of the cell are likely to be responsible 
for a small transverse component o f action potential propagation, causing propagation 
velocity (V) along the fibre axis to be transmitted much faster in the myocardium than 
transversely through it (anisotropy) (reviewed by (Bernstein & Morley 2006). An 
additional function o f cardiac gap junctions is to metabolically couple myocardial 
cells, allowing the passage of small molecules between cells and transmission o f 
chemical signals that can determine the fate of the cells, which may enable slow 
calcium wave spreading, transfer o f “ death”  signals (Kanno et al., 2003) or of 
“ survival”  signals (Yasui et al., 2000).
1.6.1 Connexin distribution and physiology within the heart
Gap junction channels have an established role within the healthy heart since they 
provide the cell to cell pathways for the coordinated spread o f current flow and the 
synchronous contraction o f cardiomyocytes. The major connexin o f the heart, Cx43, 
is found in abundance in ventricular and atrial cardiac myocytes of all mammalian 
species (Severs 2000). Cx40 and/or Cx45 may also be expressed in cardiac myocyte 
subtypes and specific regions o f the heart (Gourdie et al., 1993; Vozzi et al., 1999). 
Co-expression o f two or all three connexins occurs, subject to cardiac myocyte type 
and location. The various types o f cardiac myocyte found in different regions o f the 
heart are characterized by distinctive connexin expression profiles as well as 
differences in overall size and distribution (Severs et al., 2001).
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The cardiac myocytes o f functional ventricles are elongated, branching cells that are 
extensively interconnected by clusters o f Cx43 gap junctions organized in intercalated 
disks (Figure 1.4.1). Present in the intercalated disks are two further types o f 
anchoring junction, the fascia adherens and the desmosome. Respectively, these 
structures are responsible for the cell-cell linkage o f the contractile filaments and 
cytoskeletal intermediate filaments (Gourdie et al., 1991). These anchoring junctions 
function in combination with gap junctions to integrate the electro-mechanical 
function o f cardiac myocytes. In ventricular myocardium, gap junctions occupy 
laterally-facing segments o f membrane (Figure 1.4.1), with large gap junctions 
enclosing the disk periphery (Gourdie et al., 1991).
40
Figure 1.13: The intercalated disk of the cardiac myocyte
(a) illustrates localization o f Cx43 in a dissociated ventricular myocyte, viewed by 
Cx43 immuno-staining using confocal microscopy. The intercalated disks are 
indicated by the bright staining of Cx43 gap junctions (x 650).
(b) shows the appearance o f the intercalated disk between two cardiomyocytes in a 
thin-section electron micrograph. Fasciae adherentes junctions (FA) occupy the 
vertical segments of membrane, with the lateral segments o f membrane dominated by 
gap junctions (GJ) and desmosomes (D) both regions. (GJ* indicates a gap junction 
that has been tangentially sectioned) (x 16,000). From (Severs 2001).
Atrial cardiac myocytes are slender cells compared with their ventricular counterparts. 
Intercalated disks are readily identified in atrial myocytes, but gap junctions are also 
located along the lateral borders. Ventricular cardiac myocytes usually lack Cx40, but 
this connexin is abundant in atrial myocytes, and is arranged with Cx43 in the same 
junctional plaques (Severs et al., 2001). In both ventricular and atrial working 
myocardium, Cx45 is present in very low quantities, in both ventricular and atrial
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myocardium, with slightly higher levels identified in the atria (Coppen et al., 1998; 
Vozzi et al., 1999).
The impulse generation and conduction system are comprised o f further subtypes o f 
cardiac myocyte with distinctive morphologies (Severs 2001). The myocytes o f the 
sino-atrial and atrioventricular nodes are typically small, with randomly orientated 
and poorly developed contractile elements, and dispersed gap junctions containing 
Cx45 (Coppen et al., 1999; Honjo et al., 2002), which forms low conductance 
channels in vitro (Moreno et al., 1995). The features o f these gap junction are 
consistent with poor intercellular coupling which, in the sinoatrial node, may 
contribute to the ability to control atrial tissue without being prone to 
hyperpolarisation and, in the atrioventricular node, to the slowing o f conduction 
which ensures sequential contraction o f atria and ventricles (Severs 2001).
Cardiac myocytes o f  the His-Purkinje conduction system express Cx40 and Cx45 
(Coppen et al., 1998; Gourdie et al., 1993). The bundle branches and Purkinje fibre 
system have large and abundant gap junctions containing high levels of Cx40 (Bastide 
et al., 1993; Gros et al., 1994), a connexin associated with high conductance channels 
(Bukauskas et al., 1995). This allows the system to distribute the impulse rapidly 
throughout the working ventricular myocardium. Cx45 shows overlapping expression 
with Cx40 in the bundle branches and Purkinje fibers but is also distributed 
throughout the entire conduction system (Coppen et al., 1999). In Cx40 knockout 
mice, there is reduced velocity through the conduction system and right bundle branch 
block (Tamaddon et al., 2000; van Rijen et al., 2001). Continued conduction with
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these abnormal characteristics is attributed to the presence o f connexin45 (Coppen et 
al., 1999).
1.6.2 Gap junctions in blood vessels
In the vasculature the main connexins are Cx37, Cx40 and Cx43 where they provide 
intercellular coupling between endothelial cells, between smooth muscle cells and 
myoendothelial cell to cell coupling. In general, most o f the cell types that line the 
walls o f blood vessels express gap junctions in varying patterns o f distributions and 
are responsible for facilitating interactions between these cells (Nishii et al., 2001; 
Severs et al., 2001), in particular the spread o f vasomotor signals (Segal & Duling 
1989). All types of vessel wall cells have been shown to express Cx43, but Cx40 has 
been demonstrated as the main gap junction protein in adult endothelium (van 
Kempen & Jongsma 1999), although there are differences between different species. 
However Cx40 does exhibit heterogeneous expression along the vasculature (Hwan & 
Beyer 2000). Cx37 expression appears to be limited to endothelial cells (Reed et al., 
1993), with exception to the ovary and certain lung cell types. The disparity in Cx37 
and Cx43 distribution could indicate involvement in more dynamic processes than 
Cx40, but their expression patterns along vessel walls are poorly understood. Cx37 
and Cx40 expression was observed to be uniformly distributed, but Cx43 was 
distributed to sites o f turbulent flow in rat aortic endothelium (Gabriels & Paul 1998). 
In arterial smooth muscle cells, Cx43 is the major connexin but low amounts o f Cx40 
and Cx45 are also present (Hill et al., 2002; Ko et al., 2001; Little et al., 1995). 
Connexin expression patterns in endothelial and smooth muscle cells can be 
modulated by pathological conditions, such as early human coronary atherosclerosis
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or arterial wall injury (Blackburn et al., 1995; Haefliger & Meda 2000; Kwak et al., 
2002).
1.7 Pathophysiological roles of gap junctions in the heart
In diseased ventricular myocardium, gap junctions usually undergo two main changes; 
reduced expression o f the main connexin, Cx43, and alterations to the distribution of 
gap junctions.
1.7.1 Reduced Cx43 expression in diseased ventricles
The most consistently observed alteration in ventricular connexin expression involves 
down-regulation o f Cx43, seen in a number o f cardiomyopathies (Dupont et al., 2001; 
Kaprielian et al., 1998; Kostin et al., 2003; Lin et al., 2005). Northern and Western 
blot analysis have demonstrated a considerable decrease in Cx43 transcription and 
protein expression in the left ventricles o f transplant patients with end-stage 
congestive heart failure (Dupont et al., 2001). This reduction o f connexin expression 
is observed regardless o f the underlying cause o f heart failure (Kostin et al., 2003). 
The reduced expression o f ventricular Cx43 was shown to develop long before 
terminal heart failure (Peters et al., 1993). Consistent with this finding, a transgenic 
mouse model o f juvenile dilated cardiomyopathy has demonstrated reduced Cx43 
expression levels and conduction defects at 4 weeks postpartum, with contractile 
dysfunction and heart failure occurring at 12 weeks (Hall et al., 2000). A transient 
reduction o f Cx43 expression can also occur after very brief episodes o f ischaemia 
and reperfusion (ischaemic preconditioning) (Daleau et al., 2001).
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The studies discussed so far have dealt with total Cx43 levels as indicators for 
potential signalling between cells, but do not provide relative information regarding 
the functionality o f the channels. Computer modelling studies have shown that a 40% 
decrease in gap junctions would not significantly impact on conduction velocity 
(Jongsma & Wilders 2000). On this basis, a decrease in Cx43 expression in the 
diseased ventricle is unlikely to be o f major functional relevance. However, the 
diversity o f structural and functional alterations in the diseased heart and the complex 
relationship between passive and active membrane properties (Rudy & Shaw 1997; 
Shaw & Rudy 1997), added to the assumptions inherent in computer modelling, make 
continuing in vivo experimentation vital for gaining further insight.
Observations in foetal Cx43 knockout mice indicated that conduction velocity is 
slowed in these mice (Vaidya et al., 2001) but postnatal studies have been limited by 
the perinatal death o f the mice (Reaume et al., 1995). In another transgenic mouse 
model, with restricted cardiac knockout of Cx43, a decrease o f approximately 86- 
95% protein expression was observed causing sudden death due to spontaneous 
ventricular arrhythmia (Gutstein et al., 2001). However, in transgenic mice expressing 
half the normal level o f  Cx43 (Cx43+/-), acute ischemia induced in isolated perfused 
hearts resulted in a marked increase in incidence, frequency and duration o f 
ventricular tachycardias (Lemer et al., 2000) despite possibly only a modest reduction 
in conduction velocities (Guerrero et al., 1997). There is often substantial variation in 
the degree of reduction o f Cx43 expression, both between and within failing human 
hearts, with some areas o f diseased hearts reducing to > 90% of control amounts of 
Cx43 protein expression (Dupont et al., 2001). A further mouse study o f spatial 
heterogeneity of cardiac Cx43 expression demonstrated both abnormal conduction
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and contractile dysfunction (Gutstein et al., 2001), a result fitting earlier predictions 
made in human studies (Dupont et al., 2001; Kaprielian et al., 1998). This suggests 
the possibility that spatial differences in Cx43 reduction is a major factor predisposing 
the heart to arrhythmia.
2.0 3.01.0
5 weeks old
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Figure 1.14: Electrocardiograms from Cx43 knockout mice.
The recordings show initially that sinus rhythm is normal, followed by ventricular 
tachycardia. The arrhythmias quickly degenerated into ventricular fibrillation. 
Reproduced from Gutstein et al., 2001.
1.7.2 Changes in gap junction distribution in diseased ventricles
In addition to the disturbances in gap junction expression, alteration to the normal 
ordered distribution o f Cx43 gap junctions was first described in the myocardial zone 
bordering infarct scar tissue in the ventricles o f patients with end-stage ischaemic 
heart disease (Smith et al., 1991). Immuno-detection o f Cx43 in myocytes of the 
infarct border zone demonstrated a scattered and disordered distribution, with Cx43 
present on the lateral surfaces o f the cells rather than in the polar, intercalated disk 
arrays characteristic o f normal myocardium (Green & Severs 1993). Using a canine
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infarct model, 3-10 weeks postinfarction in the ventricle, remodelling featured 
reduction in the size and the number of gap junctions in the intercalated disk, and 
fewer lateral (side-to-side) connections between myocytes (with relative preservation 
o f end-to-end contacts), disturbances that could increase transverse axial resistance 
(Luke & Saffitz 1991).
In studies using a rat model o f hypertrophy o f the right and left ventricle, it was 
observed that Cx43 was distributed over the entire cell surface (Emdad et al., 2001; 
Uzzaman et al., 2000) and hypertrophy induced in the right ventricle caused reduced 
longitudinal conduction velocity (Uzzaman et al., 2000). This trait is not usually 
evident in ventricular hypertrophy that is associated with coronary heart disease in 
patients undergoing by-pass surgery. However, disorganised localisation of Cx43 was 
observed in the explanted ventricles o f heart transplant patients (Kostin et al., 2003). 
Hypertrophic cardiomyopathy in humans is characterised by extensive and chaotic 
arrangements o f ventricular gap junctions and consequently is the most frequent cause 
o f sudden cardiac death due to arrhythmia in young adults (Sepp et al., 1996).
‘Hibernating myocardium’ is a condition in which coronary artery disease patients 
have a region of myocardium with impaired contractility that retains the ability to 
recover contractile function after coronary artery by-pass surgery (Heusch 1998). 
Cx43 gap junctions found at the edge o f the intercalated disk were smaller in size and 
overall Cx43 detected in the intercalated disk was decreased when compared with 
normally perfused region of the same heart (Kaprielian et al., 1998). These 
observations suggest a possible link between Cx43 gap junction alterations and 
impaired ventricular contraction in human heart disease, a link that has been
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confirmed in a transgenic mouse model o f heart-specific Cx43 conditional knockout 
(Danik et al., 2004).
1.7.3 Ischaemia and Cx43 knockout (+/-) mice
Mice with homozygous knockout o f Cx43 (-/-) die shortly after birth (Guerrero et al., 
1997). In contrast, mice with heterozygous knockout o f Cx43 (+/-) have a normal life 
expectancy and development, but only have 50% of Cx43 expression and no up- 
regulation o f other connexins (Reaume et al., 1995). On exposure to ischemia, these 
mice develop ventricular arrhythmia more frequently and earlier in the ischaemic 
insult than wild-type mice (Lemer et al., 2000); therefore, a Cx43 deficiency would 
appear to be a disadvantage during ischemia. However, several investigators have 
correlated smaller areas o f myocardial infarction with reduced numbers o f Cx43 gap 
junction and inhibition gap-junctional communication (Garcia-Dorado et al., 1997; 
Kanno et al., 2003). This may be due to the prevention o f hypercontractures caused 
by elevated Ca2+ that is transmitted through gap junctions and inhibition of this by 
heptanol stops the spread o f necrosis from cell to cell (Ruiz-Meana et al., 1999). 
During ischaemia, gap junction communication persisted resulting in the lasting 
cardiac muscle rigor, despite acidosis and increased intracellular Ca2+, which would 
normally attenuate gap junction communication (Ruiz-Meana et al., 2001). It has 
also been observed that Cx43 deficient mice do not benefit from the effects of 
ischaemic preconditioning (Schwanke et al., 2002). The authors concluded that Cx43 
is involved in ischaemic preconditioning and postulated that PKCe-Cx43 complexes 
are essential for ischaemic preconditioning to occur. However, 50% of the 
functioning gap junctions and hemichannels remain, so the absence o f any ischaemic 
preconditioning at all is surprising and there is no evidence showing that PKCe-Cx43
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complexes are either present in the wild-type mice or absent in the Cx43 deficient
mice.
1.7.4 Gap junction remodelling in atrial fibrillation
Atrial fibrillation is a phenomenon in which waves o f electrical activity propagate in 
many directions, causing disorganized depolarization and ineffective atrial contraction 
(Zipes 1997). The condition is associated with progressive remodelling of electrical, 
contractile and structural elements, including altered cell size and mitochondrial shape 
(Allessie et al., 2002). Once atrial fibrillation is established it tends to endure due to 
the remodelling changes (Wijffels et al., 1995). Studies monitoring changes in Cx40 
expression in human atrial samples from chronic atrial fibrillation patients have 
provided inconsistent reports, with some observing a decrease in expression (Kostin et 
al., 2002; Nao et al., 2003) and others an increase (Polontchouk et al., 2001). Cx40 
also appeared to be redistributed towards the edges o f the myocytes (Kostin et al., 
2002; Polontchouk et al., 2001). In addition, other associated junction proteins such 
as desmoplakin and N-cadherin showed similar changes in distribution to those of 
Cx40 (Kostin et al., 2002). This could indicate a spatial association between gap 
junctions and other adhesive junctions during remodelling at the cell surface, a feature 
that has also been observed in the ageing heart (Angst et al., 1997; Peters et al., 1994).
In a goat model o f persistent atrial fibrillation there were noticeable differences in 
Cx40 distribution (van der Velden et al., 1998) and reduction in the Cx40/Cx43 ratio 
(van der Velden et al., 2000). However, there was no apparent redistribution o f Cx40 
to the myocyte borders, as seen in the human studies. These differences observed are
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probably due to differences between species, age or manner o f induction o f  atrial 
fibrillation.
In a considerable number o f patients, it appears that atrial fibrillation is initiated in the 
proximal portions o f the thoracic veins, which have an area of myocardium 
continuous with that o f the atria (Haissaguerre et al., 1998; Jalife 2003). In a study o f 
this myocardial area in canine superior vena cava, gap junctions were principally 
located at intercalated disks, with Cx43, Cx40 and Cx45 co-localized (Yeh et al., 
2001). Areas o f unusual expression patterns have been identified in which Cx43 gap 
junctions are spread across a cluster o f myocytes which are in turn surrounded by 
myocytes expressing small Cx40 gap junctions (Yeh et al., 2001). This variation in 
gap junction distribution and structural heterogeneity structure could potentially form 
an area more liable to cell coupling difficulties and thus the development o f 
arrhythmias.
1.8 The neonatal cardiac myocyte cellular model
Within this thesis, neonatal cardiac myocytes have been used to analyse cellular 
aspects o f processes within the heart. Neonatal cardiac myocytes retain many cardio- 
specific properties such as the ability to synchronously contract. In a study by 
Poindexter et al. (2001) neonatal cardiac myocytes were compared to adult cardiac 
myocytes. It was found that when cultured, both neonatal and adult cardiac myocytes 
rely heavily on the IP3 pathway in the control of intracellular calcium concentrations 
and the control o f their contractile function. Freshly isolated adult myocytes use 
sarcoplasmic reticulum calcium stores for the initiation o f contractile function. In 
addition, the method o f isolation for adult myocytes is more complex than for neonatal
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cells and does not hold any significant advantage as a cellular model (Poindexter et 
al., 2001). With this in mind and a method for isolating neonatal cardiac already in 
place, it was decided that rat neonatal cardiac myocytes were sufficient for my studies 
contained within this thesis.
Another model that is often used to study aspects o f heart physiology and pathology is 
the Langendorff system (Beardslee et al., 1998) and involves perfusion of the isolated 
mammalian heart by carrying fluid under pressure into the sectioned aorta, and thus 
into the coronary system. This model can look at the heart as a whole organ as well as 
limited aspects at a cellular level. However, these models can never completely 
predict the events in the human heart due to the differences between species and the 
physiology o f the cells, but in combination with the cellular model described in this 
thesis they provide a detailed insight into processes in cardiac system during health 
and disease.
1.8.1 Cardiac ischaemia model
Cardiac ischemia occurs when blood flow to the myocardium is obstructed by a partial 
or complete blockage o f a coronary artery. A sudden, severe blockage may lead to 
myocardial infarction. It is usually a result of a coronary thrombosis owing to rupture 
of an atherosclerotic plaque, resulting from a previous history o f coronary heart 
disease. Cardiac ischemia is often associated with serious arrhythmia, which can 
cause sudden death.
In this thesis, it is planned to develop a cellular model o f cardiac ischaemia using rat 
neonatal cardiac myocytes. Ischaemia is a complex metabolic insult consisting o f two
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main components; hypoxia (no oxygen) and substrate depletion (no energy (glucose)). 
The synchronously beating myocytes will be placed in a specially designed hypoxic 
chamber (Ruskinn Invivo2 400 Hypoxic workstation with Ruskinn gas mixer) and 
cultured in a low-glucose cell culture medium. The ischaemic model system is 
explained in more detail in chapter 2.
1.8.2 Thesis aims
The aims o f this thesis were:
a) Develop a model of simulated ischemia in a beating cardiac myocyte cell 
culture system and to study relationships between Cx43 phosphorylation and 
myocyte beating
b) To investigate the effects and therapeutic potential of antiarrhythmic peptides 
on Cx43 behaviour during ischaemic and normoxic conditions.
c) To determine whether simulated ischaemia can activate connexin 
hemichannels and thereby examine any substances released across them, 
especially ATP, and their susceptibility to reagents that influence Cx function.
d) To explore the development and use o f Cx-fluorescent probes in a cardiac 
myocyte model system.
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Chapter 2
General materials and methods
2.1 General materials
2.1.1 Animals
Neonatal Wistar rats were used in the preparation of primary cultures of neonatal 
cardiac ventricular myocytes. Rats were obtained from breeding stocks from the 
animal house facility, UWCM and were housed in the same facility.
2.1.2 General laboratory reagents and chemicals
All reagents and chemicals were AnalaR grade and were obtained from Sigma (UK) 
or Fisons (UK) unless otherwise stated. All reagents and equipment for protein and 
DNA gel electrophoresis were from Biorad (UK) unless stated.
2.1.3 Composition of general buffers and solutions
• PBS: NaCl (137mM), Na2HP04 (lOmM), KC1 (2.7mM);
pH 7.4.
• Tris-HCl: Molar stocks of Tris-HCl at pH 7.4, 8.0 and 8.5 were
prepared and stored at room temperature.
2.1.4 Myocyte culture solutions
• CBFHH: NaCl (137mM), KC1 (5mM), MgS04 (0.8mM),
KH2P 0 4 (0.4mM), Na2HP04 (0.3mM), HEPES 
(18mM), Glucose (5mM), pH 7.4
• Trypsin stock solution: 1:250 trypsin (lg) dissolved in 10ml CBFHH at 4°C
• DNase stock solution: Deoxyribonuclease II from bovine spleen (30000
units, sigma) dissolved in 16ml 0.15M NaCl
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Trypsin working solution:
DNase working solution:
Cardiac myocyte cDMEM:
Trypsin stock solution (1.5ml),
DNase stock solution (0.7ml), P/S (100 mgml'1) 
(0.5ml), volume adjusted to 50ml with CBFHH 
at4°C
DNase stock solution (0.7ml), P/S (100 mgml'1) 
(0.5ml), FCS (1ml), volume adjusted to 50ml 
with CBFHH at 4°C 
Dulbecco’s modified essential medium 
(DMEM), foetal calf serum (FCS) (5% (v/v)), 
penicillin/streptomycin (P/S) (100 mgml*1)
2.1.5 Protein biochemistry reagents
• ATP-assay neutralisation buffer: HEPES (50mM), MgS04 (4mM), pH 7.4;
in PBS
• Cell permeabilisation buffer: Triton X-100 (0.1% v/v), lysine (0.1M);
in PBS.
• Blocking solution: TBS-T containing Marvel fat-free milk
(5% (w/v))
• Lysis buffer: SDS (1% w/v), DTT ImM, NaV04 300mM,
PMSF lOOmM, protease inhibitor cocktail, 
PBS
• Nitrocellulose stripping buffer: lOOmM p-mercaptoethanol, SDS (2% (w/v)),
Tris-HCl (62.5mM), pH 6.7.
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• Protease inhibitor cocktail (lOOx):
• SDS-PAGE running buffer (1 Ox):
• Separating gel buffer (SDS-PAGE):
• Stacking gel buffer (SDS-PAGE):
• SDS-PAGE sample buffer (4x):
• TBS-T(IOX):
• Transfer buffer:
• Molecular weight markers:
Leupeptin (5mg), chymostatin (5mg), 
antipain (5mg), aprotonin (5mg), 
pepstatin A (0.5mg); volume adjusted to 
10ml with dH20.
Glycine (0.5M), Tris (250mM),
SDS (l%(w/v));
Tris (1.5M), SDS (0.4% (w/v)); pH 8.8. 
Tris (0.5M), SDS (0.4% (w/v)); pH 6.8. 
Stacking gel buffer (25% (v/v)), glycerol 
(40% (w/v)), p-mercaptoethanol (10% 
(v/v)), SDS (4% (w/v)), bromophenol 
blue; volume adjusted to 10ml with 
dH20 .
NaCl (1.5M), Tris (0.2M), Tween-20 
(1% (v/v)); pH 7.5.
Na2C 03 (20mM).
Prestained SDS-PAGE standards 
(Precision plus protein standards, range 
10-250kD; Kaleidoscope prestained 
standards, range 7-22 lkD, both Biorad, 
UK)
2.1.6 Molecular biology reagents and buffers
• Agarose gel loading: TAE buffer (IX), glycerol (50% (v/v)),
Buffer orange G; pH 8.0.
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• LB-Agar: Bacto-tryptone (2% (w/v)), yeast extract (0.5% (w/v)),
NaCl (lOmM), Agar (1% (w/v))
• LB medium: Bacto-tryptone (2% (w/v)), yeast extract (0.5% (w/v)),
NaCl (lOmM)
• SOC medium: Bacto-tryptone (2% (w/v)), yeast extract (0.5% (w/v)),
NaCl (lOmM), KC1 (2.5mM), MgCl2 (lOmM),
MgS04 (lOmM), glucose (20mM); pH 7.0
• TAE (50X Stock): EDTA (50mM), Tris (20mM), acetic acid (ImM).
• TE: Tris (lOmM), EDTA (ImM); pH 8.0. Sterile filtered.
• Restriction enzymes: All restriction enzymes and appropriate buffers were
obtained from Promega, UK unless stated otherwise.
Enzyme Restriction site recognised Assay temperature
Eco RI 5’-G|AATTC-3’ 37°C
Xba I 5’-T|CTAGA-3’ 37°C
Not I 5 ’-GC|GGCCGC-3 ’ 37°C
• Molecular weight markers: lkB DNA ladder was obtained from Invitrogen, UK.
• Bacterial cell culture
All growth media were obtained from Sigma (UK), antibiotics from Promega (UK) 
and sterile plastic cultureware from Bibby Sterilin (UK). All glassware was washed in 
detergent free water and autoclaved (135°C, 90mins) before use. Growth media (LB, 
L-agar) were autoclaved under the same conditions prior to the addition of antibiotics 
(Promega UK). All bottles and containers were ‘flamed’ upon opening. Surfaces were 
swabbed with 70% (v/v) ethanol before and after use.
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2.1.7 Cell culture reagents
All reagents and media and were obtained Gibco Life Technologies (UK) unless 
stated otherwise. Cell culture plasticware was obtained by Greiner bio-one 
(Germany). Media were free from mycoplasma contamination and were sterile 
filtered prior to use by passage through a 0.2pm filter. Sterile syringes and needles 
were obtained from WHRI Store (UWCM). All cell culture hoods were wiped with 
70% (v/v) ethanol before and after use and fumigated regularly with vaporised 
formaldehyde.
2.1.8 Computer software and data analysis
Numerical data were stored in spread sheets (Excel, Microsoft) and were plotted in 
graphical form either using GraphPad Prism (GraphPad software inc., USA). All data 
are expressed as means ± standard deviation (SD) or as means ± standard error (SE). 
SD = V(nXx2 -  (Zx)2) / n(n-l) and SE = SD/ V (n-1) where n = number of variables 
and x = mean.
2.1.9 Health and safety
All reagents were handled and stored as recommended by manufacturer’s safety 
sheets. All experiments were carried out in accordance with COSHH regulations and 
local college regulations. All genetic manipulation was registered and carried out 
following GMAG (genetically modified application guidelines). All mammalian and 
bacterial culture medium was disinfected with chloros (2% (v/v)); Philip Harris, UK 
and plastic culture wares were sterilised by autoclaving (135°C, 90mins) prior to 
disposal.
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2.2 General methods
2.2.1 Preparation of primary cultures of neonatal rat cardiac myocytes
i) Preparatory work
On the day prior to the cell preparation, calcium and bicarbonate-free Hanks with 
Hepes buffer (CBFHH) was prepared and sterilised by filtration. In addition, trypsin 
solution was prepared and stored at 4°C overnight. Instruments for the cell 
preparation were sterilised by autoclave. The instruments consisted of large and small 
forceps, large scissors, small curved sprung scissors and a tissue culture sieve.
ii) Preparation of neonatal rat hearts
Approximately 50 -  60 Wistar rats aged 1 - 5  days were killed by cervical dislocation 
according to Schedule 1 of the Animals (Scientific Procedures) Act 1986 followed by 
removal of the head. The skin was sprayed with 70% ethanol, and the thorax opened
on the left and right sides of the sternum by two separate incisions. The heart was
removed and placed immediately in ice-cold CBFHH in a 100mm sterile tissue 
culture dish. During the procedure the instruments were sprayed frequently with 70% 
ethanol to maintain a high level of sterility. The animal carcases were then disposed 
of according to local regulations.
In a tissue culture hood, a second 100mm dish of cold CBFHH was prepared. Using 
small forceps, the hearts were removed one at a time from the first 100mm dish, 
extra-cardiac tissue (aorta, pulmonary artery and pericardium) removed using small 
curved scissors and the hearts cut in half and placed in the second 100mm dish of 
CBFHH. Hearts were washed repeatedly in CBFHH to remove red cells and any 
remaining fragments of non-cardiac tissue, using a 10ml wide-tip pipette. A small
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volume of CBFHH was added to the heart fragments. Then, using small sprung 
scissors, heart fragments were minced into tiny pieces of no more than 0.3mm 
diameter. The minced hearts were suspended in cold CBFHH and transferred to a 
50ml Falcon tube, marked “cells”, using a 10ml wide-tip pipette. Once the minced 
hearts sedimented to the bottom of the tube, the supernatant was removed and 
discarded. The minced hearts were then washed further until the supernatant was 
clear of red cell contamination.
iii) Dissociation of tissue into cardiac myocytes
After removal of CBFHH, 10ml trypsin solution was added to the minced hearts in 
the “cells” tube. The “cells” tube was then placed on a rotary shaker set at a medium 
rate and left for 20mins. DNase solution (7ml) was then added to the “cells” tube, 
and, using a 10ml wide-tip pipette, the minced hearts were triturated to break up the 
DNA and release the dissociated cells. This trituration step usually required about 
5mins. Following trituration, the minced heart fragments were allowed to settle and 
the supernatant was collected in a Falcon tube, marked “collection”, containing 2ml of 
foetal calf serum (FCS). A further 10ml trypsin solution was added and the “cells” 
tube was placed on the rotary shaker for 5mins. A further 7ml of the DNase solution 
was added and the trituration step repeated. The minced heart fragments were again 
allowed to settle and the supernatant was transferred to the “collection” tube. This 
process was repeated for approximately 3-5hrs, which allowed most of the myocytes 
to be dissociated and left white fibrous tissue in the “cells” tube. A total of 4 
collection tubes were usually necessary. Once each collection tube was full it was 
stored on ice until the next stage of the procedure.
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iv) Centrifugation stage
The four collection tubes were centrifuged at 1200rpm for 6mins to loosely pellet the 
cells. The supernatants from the collection tubes were transferred to four 50ml Falcon 
tubes labelled “respin” and recentrifuged at 1200rpm for 6mins. The four pellets in 
the collection tubes were resuspended in DMEM supplemented with 5% FCS and 1% 
P/S (cDMEM) (2ml per pellet) and combined in a 50ml Falcon tube labelled “pooled 
cells”. The supernatants from the “respin” tubes were discarded. The four pellets in 
the “respin” tubes were resuspended in cDMEM and added to the “pooled cells” tube. 
Stock DNase (400pl) was added to the “pooled cells” tube and the cell suspension 
was triturated using a wide-tip pipette. The “pooled cells” tube was centrifuged at 
1200rpm for 6mins. The supernatant was discarded and the pellet was resuspended in 
32ml cDMEM
v) Pre-plating stage
Four 100mm diameter dishes were used for pre-plating to remove fibroblasts. A 
sterile tissue culture sieve was prepared by passing 3ml cDMEM through it into the 
first dish. The cell suspension (8ml) was then added to each dish through the sieve. 
Finally, 3 ml cDMEM was passed through the sieve into the final plate to wash off any 
cells trapped in the sieve. The four dishes were then incubated at 37°C, 80% 
humidity and 5% CO2 for lhr.
vi) Harvesting of cardiac myocytes
The medium from the 4 pre-plating dishes was harvested into a new 50ml Falcon 
tube, labelled “myocytes”. The plates were then washed with cDMEM 3 - 4  times
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and the medium transferred to the “myocytes” tube. The volume of the “myocytes” 
tube was adjusting to 50ml with cDMEM.
vii) Cell counting and plating
The cell suspension (10pl) from the “myocytes” tube was applied to a 
haemocytometer and cells were counted using the standard method. Cells were plated 
out in 60mm dishes at 5 x 106 cells per dish in a volume of 4ml per dish in cDMEM, 
supplemented with bromodeoxyuridine (BrDu) (0.1 mM), added to suppress cell 
division in non-myocyte cells such as fibroblasts. Cells were then incubated at 37°C, 
80% humidity and 5% CO2. Typically each cell preparation yielded between 160-180 
million cells, generating 40-50 60mm dishes if plated at the stated density. The 
resultant cultures of cardiac myocytes (>95%) (Clarke et al., 2006; Webster et al., 
1999) contracted synchronously at >100 beats min'1 (bpm).
2.2.2 Maintenance of ra t neonatal cardiac myocytes
On the day after the preparation, care was taken not to disturb the cells. Thereafter, 
the medium was changed every day with cDMEM with BrDu (0.1 mM). The cardiac 
myocytes usually began to synchronously beat on day two after the cell preparation. 
Thereafter, the beating rate was monitored daily on a light microscope (Nikon). On 
day four after cell preparation, the type of medium was changed to serum-free 
medium. This consisted of DMEM with P/S (lOOpgml'1), BrDu (O.lmM), insulin 
(20pgmr*) and vitamin B12 (1.5jiM). All experiments were performed on days 5,6 or 
7 after cell preparation.
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2.3 Ischaemia and hypoxia
2.3.1 The hypoxic workstation
Cells were made hypoxic within a specially designed chamber (Ruskinn Invivo2 400 
Hypoxic Workstation with Ruskinn gas mixer), essentially a tissue culture incubator 
that was hermetically sealed, enabling precise control of the internal atmosphere. 
Humidity was maintained at 80% and the temperature at 37°C. Within the chamber 
an oxygen electrode measured the internal oxygen level and automatically flushed the 
chamber with nitrogen if the oxygen level increased, thus maintaining the internal gas 
composition at 0.5% oxygen, 5% CO2 and the balance of the gas being nitrogen. The 
pressure in the chamber was maintained slightly above ambient so that any minor leak 
would cause egress of hypoxic gasses rather than ingress of atmospheric oxygen, 
further safeguarding the hypoxic environment.
Cells, instruments and solutions were placed in the chamber using a gas-tight air-lock. 
Items were placed inside the air-lock and the external door closed. Nitrogen was then 
pumped into the lock to remove any oxygen. The internal door could then be opened. 
Manipulation of cells inside the chamber was achieved using gas-tight sleeves. 
Rubber cuffs made a seal around the upper arms, air was removed by a vacuum pump 
and nitrogen was pumped in. The vacuum/flush cycle (operated by foot pedals) was 
repeated three times to ensure no oxygen remained in the sleeves. Small circular 
doors then allowed entry into the chamber.
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Figure 2.1: In Vivo400 hypoxia cabinet
Manufacture’s image of the In Vivo 400 cabinet (Ruskinn, UK). The main ports are 
open with the gas-tight sleeves removed. Within the chamber 60mm cell culture 
dishes are visible. On the right of the cabinet is the air-lock door which allows 
cells and equipment to enter the chamber without introducing oxygen. Reproduced 
from Ruskinn brochure, UK.
2.3.2 Monitoring myocytes beating rates
Myocyte beating rates were monitored during ischaemic and hypoxic experiments 
using a Nikon light microscope with camera linked up to a video monitor and 
computer. During ischaemia or hypoxia, myocyte beating rates were recorded by 
viewing and counting the cells by eye. Occasionally, to monitor these results taken 
manually the cells were video captured using the computer and software used to work 
out the beating rate of the cells. The results from the video capture showed that 
beating rates taken manually were very accurate, with differences only being on 
average <2 bpm.
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2.3.3 Harvesting of cells during hypoxia
Since brief periods of reoxygenation may activate kinase pathways within the cells, 
great attention was paid to ensure that cells in the chamber remained ischaemic or 
hypoxic. Small volumes of ice-cold PBS and appropriate lysis buffer were made 
hypoxic by placing them in the air-lock on ice at least 30mins prior to harvesting. 
This allowed any oxygen dissolved in the PBS or lysis buffer to diffuse out of the 
liquid prior to its coming into contact with any cells. Once deoxygenated, the hypoxic 
PBS and lysis buffer were positioned in the chamber. Cells were washed twice with 
the deoxygenated PBS and excess removed completely. Cells were then scraped 
within the chamber in a suitable volume of hypoxic lysis buffer. The cell lysate was 
then collected in an Eppendorf tube that was kept on ice and immediately snap frozen 
on dry-ice once removed from the chamber. Cell lysate were then stored at -80°C for 
later analysis.
2.3.4 Anoxic experiments
i) Ischaemic experiments
In order to simulate ischaemic conditions, cells were placed in serum-free low glucose 
medium prior to hypoxic incubation. The medium consisted of glucose-free DMEM 
with P/S (lOOpgmf1), BrDu (O.lmM), insulin (lO pgm l1), vitamin B12 (1.5pM) and 
glucose (0.2mgml_1). The time spent in ischaemia began as soon as the cells entered 
the hypoxic chamber and varied between experiments from l-10hrs. The ischaemic 
cells were then harvested within the hypoxic chamber as described above. Control 
cells were also placed in the low glucose medium for the duration of the experiment.
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ii) Hypoxic experiments
Hypoxia treated cells were placed in serum-free cDMEM (described in section 2.2.2)
prior to hypoxic incubation. The time spent in hypoxia began as soon as the cells
entered the hypoxic chamber and varied between experiments from l-10hrs. The 
hypoxic cells were then harvested within the hypoxic chamber as described above.
2.3.5 Reoxygenated cells
Ischaemic or hypoxic treated cells were removed from the chamber and placed in 
fresh serum-free cDMEM. These cells were then incubated at 37°C, 80% humidity 
and 5% C 02 for lhr following ischaemic/hypoxic incubation. Cells were then washed 
twice with ice-cold PBS and then scraped in a suitable volume of the appropriate lysis 
buffer. The cell lysate was then snap frozen in dry-ice and then stored at -80°C for 
later analysis.
2.4 Characterisation of connexin proteins in cardiac myocytes
2.4.1 Extraction of protein from myocytes
The lysis buffer was prepared on ice by adding protease inhibitor cocktail and PMSF, 
both at a dilution factor of 1:100. The cell culture medium was removed and the cells 
were washed twice in PBS. All liquid was completely removed and 200pl of lysis 
buffer was added. The cells were then scraped using a cell-scraper (Greiner, UK), 
then the lysate was transferred to an Eppendorf, snap frozen then stored at -80°C for 
later Western analysis. Before further analysis, the cell lysates were thawed and 
sonicated individually with 2 bursts of lOsecs, using a sonicator probe to break down 
any residual DNA and to disperse the aggregated membranes.
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2.4.2 Measurement of protein concentration using a colourmetric assay
The Biorad DC protein assay (Biorad, UK) was used as a colourmetric assay for the 
estimation of protein concentrations in the range of 100-500pgmr’. The assay, based 
on the Lowry assay (Lowry et al., 1951), measures the reaction of proteins with 
alkaline copper tartarate and Folin reagent. Briefly, 5 pi of protein sample was mixed 
with 25 pi of reagent A (contains NaOH (1-5% (w/v), sodium tartatrate (<1% (w/v)) 
and copper sulphate (<0.1% (w/v) in a well of a microtitre plate. Following this, 
200pl of reagent B (which is dilute Folin’s reagent) was added and gently agitated to 
mix the reagents. Colour was allowed to develop for 15mins and absorbance read in a 
plate reader (Denley, UK) at 695nm (A695). Protein concentration was calculated from 
the linear regression graph generated using the A695 of known concentration solutions 
of BSA (10-1500 pg/ml) prepared in the same buffer used in the extraction of protein.
2.4.3 Protein separation by SDS-polyacrylamide gel electrophoresis (PAGE)
Protein samples were separated mainly on the basis of size using discontinuous 
polyacrylamide gel electrophoresis and denaturing conditions as described by 
Laemmli (1970). Protein samples (lOOpg) extracted from treated cells were mixed by 
vortexing with a volume of SDS-PAGE (4X) sample buffer and agitated for 30mins at 
room temperature prior to loading the gel for electrophoresis. Discontinuous SDS- 
PAGE involved protein concentrating (stacking phase) and separating components. 
The separating gel mixture was mixed by swirling and was immediately transferred 
into a gel casting system (Biorad, UK). The gel was overlaid with dFLO and allowed 
to set for lhr at room temperature. After this time, the gel surface was washed with 
dFLO and dried. The stacking gel was applied on top of the separating gel phase and 
an appropriate sample-well comb was inserted.
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Reagents Separating gel Stacking gel
(10% (v/v)) (ml) (5.0% (v/v)) (ml)
Stock acrylamide (40% (w/v) 7.2 0.9
Buffer 7.6 (separating) 1.8 (stacking)
Ammonium persulphate (10% (w/v)) 0.448 0.060
TEMED 0.02 0.006
dH20 14.72 3.1
Final volume 30.0 5.9
The stacking gel was allowed to set for 30mins, the comb removed and sample wells 
were rinsed with (IH2O. Protein samples were loaded on to the gel and were separated 
by electrophoresis in SDS-PAGE running buffer at 40mA until the samples had run 
out from the sample wells. The current was then adjusted to 15mA and run overnight 
at room temperature until the dye front (bromophenol blue) diffused into the running 
buffer. Apparent size of proteins was deduced by reference to known molecular 
weight standards (Precision plus protein standards, range 10-250kD; and 
Kaleidoscope prestained standards, range 7-22 lkD, both Biorad, UK) separated under 
the same conditions.
2.4.4 Detection of connexin proteins by Western blotting
i) Transfer of proteins to nitrocellulose membranes
Proteins from acrylamide gels were transferred to a nitrocellulose membrane 
(Hybond-ECL, Amersham-Pharmacia Biotech, UK) for immuno-labelling analysis. 
The separating phase of the gel was overlaid with nitrocellulose membrane pre-wetted 
in transfer buffer and sandwiched between filter paper. The g e l: membrane filter was
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loaded into the transfer apparatus (Biorad, UK) with the membrane placed between 
the gel and the positive electrode. The proteins were transferred onto the membrane 
by electrophoresis in transfer buffer for 3hrs at room temperature and at 300V. Protein 
transfer was determined by staining the membrane (protein-side up) with Ponceau S 
solution (Ponceau S 0.1% (w/v)), acetic acid (5% (v/v); Sigma, UK).
ii) Immuno-labelling of protein on nitrocellulose membranes
Ponceau S stain on the nitrocellulose membrane was removed by washing the 
membrane several times in dKhO and then with TBS-T for lhr, changing the solution 
regularly. To prevent non-specific antibody binding, the membrane was blocked, by 
incubation in blocking solution at room temperature for lhr. Membranes were then 
incubated with antibodies specific to the proteins, (normally at a dilution of 1:2000 in 
blocking solution as determined by previous titration of antibody against antigen) at 
4°C for 12-15hrs. Primary antibodies used were Zymed rabbit anti Cx43 (Cambridge 
UK) (specific for phosphorylated and non-phosphorylated forms of Cx43) and Zymed 
mouse monoclonal anti Cx43 (specific for the non-phosphorylated form of Cx43). 
After this time, the membranes were thoroughly washed (~lhr) in TBS-T changing 
the solution frequently. Membranes were blocked at room temperature for a further 
lhr in blocking solution as above. Membranes were then incubated in secondary 
antibody (goat anti rabbit or goat anti mouse conjugated to horse-radish peroxidase) 
(Biorad, UK) used at a dilution of usually 1:2000 in TBS-T at room temperature for 
lhr. Membranes were extensively washed in TBS-T, changing the solution often and 
finally with PBS.
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iii) Detection of immuno-labelled protein
Detection of immuno-labelled protein was carried out using enhanced 
chemiluminescence (ECL) (Super-Signal; Pierce, UK). A stable peroxide solution 
was mixed with an equal volume of luminol containing buffer and the membrane was 
overlaid with sufficient solution (5ml) to allow complete coverage for lmin. ECL 
solution was removed, the membrane placed on a thin transparent sheet and then 
covered with saran wrap. Air bubbles were removed using a roller. The membrane 
was transferred to a photographic cassette and exposed to X-ray film (Hyper Film, 
Amersham-Pharmacia Biotech, UK) for periods ranging from 15secs-2mins 
depending on the intensity of the chemiluminescence signal. The film was developed 
and dried at 50°C for 15mins.
iv) Densitometric analysis of protein blots
Developed films were scanned at 400-750nm using a densitometer (300dpi, GS-700, 
Biorad, UK). Bands corresponding to proteins were highlighted using Colour Scan 
software (Biorad, UK) and were compared by density analysis. All measurements
were calibrated against an area of the blots containing no protein.
2.5 ATP measurements
ATP was measured using a luciferase-luciferin based bioluminescence assay (Sigma, 
USA). Briefly, ATP is consumed and light is emitted when firefly luciferase
catalyzes the oxidation of D-luciferin:
Frefly Ludfertao ^
ATP + Luciferin Adenyl-luciferin + PPj^ Mg5
Adenyl-luciferin + 0 2 ---------------► Oxyluciferin + AMP + C02 + light
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The first reaction is reversible and the equilibrium lies far to the right, but the second 
reaction is essentially irreversible. When ATP is the limiting reagent, the light 
emitted is proportional to the ATP present. All ATP measurements were expressed as 
a percentage of the control.
i) Extracellular ATP measurements
Cell culture medium (250pl) was removed from the cell monolayer by sterile pipette 
tips at specific time points, then snap frozen and stored at -80°C. Extracellular 
samples were then centrifuged at 250g for 4mins at 4°C and analysed for ATP content 
using the ATP assay outlined below.
ii) Intracellular ATP measurements
Intracellular ATP measurements were made as previously described (Turner et al., 
2004). Cells were washed twice with ice-cold PBS then 500pl 5% trichloroacetic 
acid (TCA) was added and the cells were scraped. The lysate and the pink coloured 
precipitate were collected in an Eppendorf tube, which was snap frozen and stored at 
-80°C for later analysis of ATP content. Intracellular samples were then thawed on 
ice, and then centrifuged at 12000rpm for lOmins at 4°C.
2.5.1 ATP Assay
ATP standards were made up to known concentrations in the range 0.5-10pM for 
intracellular samples or l-100nM for extracellular samples, from a stock of 0.1 M ATP 
stored at -80°C. For intracellular samples, luminometer cuvettes were with 200pL of 
ATP-assay neutralisation buffer in each and left at room temperature for 30mins. The 
ATP assay mix (Sigma, FL-AAM) was then prepared, at a dilution of 1:25 for
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intracellular samples or 1:10 for extracellular samples, in ATP-Assay Mix Dilution 
buffer, and stored on ice. For extracellular samples, 50jil of ATP-assay mix working 
dilution was added to a luminometer cuvette followed by 50|xl of sample, briefly 
mixed, and then measured for luminescence (Turner Designs 20/20 luminometer) 
three times for lOsecs with the mean being recorded. For intracellular samples, 50pl 
of ATP-assay mix working dilution was added to the ATP-assay neutralisation buffer 
in the cuvette and 30 seconds allowed to elapse to ensure mixing. 5 pi of standards or 
sample was added to the cuvette, briefly mixed, and then measured for luminescence 
three times for lOsecs with the average being recorded.
2.5.2 ATP sample protein analysis
The protein concentration was calculated as a control for number of cells on each 
plate. The excess supernatant was removed and the TCA was neutralised with 500pL 
of 1M NaOH. The samples were left at room temperature and agitated for 30mins to 
allow the protein to dissolve. Protein concentration was then calculated using a 
Biorad DC protein assay kit as described in section 2.4.1. Intracellular ATP values 
were then normalised for protein concentration and expressed as ATP per unit of 
protein.
2.6 Immunofluorescence
2.6.1 Preparation of cells for immunostaining
Cardiac myocytes were prepared on two well glass coverchambers (Nunc) at a density 
of lxlO6 per well, or on 16mm diameter circular glass coverslips at a density of 5xl05 
per coverslip. Following exposure to the experimental conditions cells were washed 
twice in ice-cold PBS and were fixed in 3.7% paraformaldehyde in PBS for lOmins or
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-20°C methanol for 5mins. They were then washed twice with PBS and stored at 4°C 
in PBS.
2.6.2 Immunohistochemistry
Cells were permeabilised with PBS containing 0.1% Triton for 30 minutes and 
blocked with PBS containing 1% BSA for 30mins. Then 200pl of primary antibody 
to the samples incubated for 2hrs at 37°C in the dark. The primary antibody was then 
removed and samples were washed several times with ice-cold PBS. The secondary 
antibody was then added and incubated in a dark environment for 45mins at 37°C. 
The secondary antibody was then removed and the samples then washed thoroughly 
with PBS for lhr, changing the solution regularly.
The samples in coverchambers were then stored in PBS at 4°C in the dark until 
analysis. The samples on coverslips were mounted on glass slides using FluorSave™ 
Reagent (Calbiochem, Germany) and stored in the dark at 4°C until analysis.
2.6.3 Antibodies
The main primary antibodies used for immunostaining Cx43 were the polyclonal 
antibody against Cx43 (raised in rabbit) (Zymed, Cambridge UK), or the monoclonal 
antibody against non-phosphorylated Cx43 ((Chemicon, Chandlers Ford, UK) or 
(Zymed, Cambridge, UK)). All were used at a dilution of 1:250 in PBS. The 
secondary antibodies used were a selection of either goat anti rabbit or goat anti 
mouse antibodies that were conjugated to either Alexa-488 or Alexa-546 fluorescent 
dyes.
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2.7 Microinjection into cells
Microinjection into cells was used to assess direct cell-cell communication and to 
transfect cardiac myocytes with cDNA. Intracytoplasmic microinjection of dye or 
cDNA was achieved using an Eppendorf Femtojet 5247 device.
2.7.1 Monitoring direct cell-cell communication
Direct cell-cell communication was studied by monitoring the transfer of small 
fluorescent dyes between the cells in the monolayer. The dyes used were Lucifer 
yellow (charge -2, MW 457Da), Alexa-488 (charge -1 , MW 570Da) or Alexa-594 
(charge -1 MW 758Da). All dyes were from Molecular Probes (Leiden, The 
Netherlands). To ensure success, experiments were repeated in triplicate with >30 
cells injected per experiment. Five minutes after injection cells were fixed in 4%w/v 
paraformaldehyde for 5mins and washed in PBS. The percentage of injections 
resulting in dye transfer to different numbers of neighbouring cells was assessed on an 
Zeiss Axiovert 200 fluorescence microscope using appropriate filter sets (Zeiss, UK) 
(Martin et al., 2004).
2.8 General molecular biology methods
2.8.1 DNA amplification by polymerase chain reaction (PCR)
PCR is an in vitro method of nucleic acid amplification involving repeated thermal 
cycles that cause DNA denaturation, primer annealing and DNA extension (Saiki et 
al., 1988). Briefly, substrate DNA is denatured at high temperature to give single 
stranded templates, followed by the annealing of oligonucleotide primers to specific, 
nucleotide sequences defined regions of the template at a lower temperature (Topt). 
The primers are then extended enzymatically by a thermal stable DNA polymerase,
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such as Taq polymerase. The resulting product is an additional double stranded DNA 
copy of the original template. The amplification process is exponential; therefore 
large quantities of DNA (pg) are generated from very small amount of template (ng). 
Bio-x-act Taq DNA polymerase (Bioline, UK) was used for all PCRs unless stated. 
Bio-x-act uses a complex of temperature-stable DNA polymerases possess 3’-5’ 
exonuclease (proof-reading) activity. The optimum temperature of dNTP (Pharmacia, 
UK) incorporation using Bio-x-act is 68°C.
Optimal conditions for the DNA polymerase used in the reactions were achieved 
using buffers provided by the manufacturers. Reactions were set up in the thin walled 
tubes on ice with all reagents added to the dH20  and mixed by brief vortexing. 
Negative controls were setup in all experiments which contained no DNA templates. 
The protocols for the reaction mixture and cycling conditions are shown below:
Reagents Per Reaction (pi)
MgCl2 (50nM) 2.2
lOx Buffer 5
dNTPs (25mM) 0.5
Forward Primer 1
Reverse Primer 1
DNA Taq polymerase 0.5
DNA Template X*
Ultrapure H20 38.8-X
Final volume 50
♦Amount of DNA Template varied (3-60ng/pl)
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Sample reactions were subjected to the following cycling conditions
• Hot start 94°C, 2mins
• 94°C, 2mins; 55°C, lmin; 68°C, 2 mins; (10 cycles)
• 94°C, 2mins; 55°C, lmin; 68°C, 2 mins + 20secs extension/cycle; (25 cycles)
• 68°C, lOmins
Following completion of cycling, reactions were kept at 4°C until analysis. All 
amplifications were carried out using a PCR Sprint Thermal Cycler (Thermo Electron, 
USA)
2.8.2 Analysis of DNA products by agarose gel electrophoresis
Double stranded DNA fragments were separated according to size and concentration 
by agarose gel electrophoresis. Agarose gels (1% (w/v)) were made by adding ultra- 
pure agarose (Biorad, UK) to TAE (lx) and heated for several minutes in a 
microwave (800W, Sanyo, UK) until completely dissolved. The gel solution was 
cooled and lpl ethidium bromide added. The gel was then poured and a comb 
inserted into a gel tray (Mini Sub-DNA cell, Biorad, UK). DNA samples (5pi) were 
mixed with an equal volume of DNA loading buffer and loaded into the gel. DNA 
molecular size markers (5 pi; Invitrogen, UK) were also loaded. Electrophoresis was 
carried out at 90V until the dye front migrated approximately two-thirds through the 
gel (orange G co-migrates with DNA ~200bp). The gel was visualised and 
photographed using a UV transilluminator lamp (302nm) integrated into a 
ChemiDoc™ (Biorad, UK) apparatus. Known amounts of DNA were run on an 
agarose gel and used as a comparison in order to estimate amounts of DNA produced 
by PCR.
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2.8.3 DNA purification and modification
i) Purification of PCR products
PCR products were purified using the Qiagen PCR purification system (Qiagen, UK). 
Briefly, the PCR sample was mixed with 5 volumes of buffer containing 50mM KC1, 
lOmM Tris, 1.5mM MgCl2, Triton X-100 (0.1% (v/v)); pH 8.8, vortexed and applied 
to a spin column membrane (column retains fragments lOObp-lOkb). The column was 
centrifuged at 12,000g for 30secs. The flow through was discarded and washed twice 
in buffer PE (Qiagen, UK) containing 80% ethanol (0.75ml) and recentrifuged. To 
elute the DNA dH20 (30|il) was added to the column and incubated for lmin at room 
temperature then centrifuged at 12,000g for a further minute.
ii) DNA extraction and purification of from agarose gels
PCR products analysed on agarose gels were then extracted and purified using the 
Qiagen gel extraction system (Qiagen, UK). Briefly, the desired DNA fragments 
were excised from the agarose gel with a clean scalpel, weighed, and incubated with 3 
gel volumes of buffer QG (Qiagen, UK) at 50°C for 10-15mins. Once completely 
dissolved, one gel volume of isopropanol was added, vortexed and the solution 
applied to a spin column. The column was centrifuged at 12,000g for 30secs and the 
flow through discarded. Column washing and elution of DNA was as described 
above.
iii) Klenow modification
PCR products used for cloning or in vitro expression were modified using the Klenow 
fragment, a proteolytic cleavage fragment of DNA polymerase I (Klenow & 
Henningsen 1970) (Promega, UK) to fill in incomplete DNA chains and to remove
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excess 3’A residues. Purified PCR fragments were incubated with Klenow fragment 
(lfil; 5U/pl), dNTPs (lfxl; 20mM) and appropriate buffer at 25°C for 30mins.
2.8.4 Subcloning of PCR products
i) Ligation of PCR products
PCR products were ligated into plasmid vectors by a number of similar methods 
including TA cloning and TOPO cloning as described in chapter 6.2. Once ligated 
into the vector, plasmids were amplified in the competent bacteria DH5a.
ii) Transformation and culture of competent bacteria
Transformation of competent bacteria with plasmid DNA is a procedure that enables 
rapid and large scale replication of the plasmid DNA, which can be used for 
subsequent use and analysis. Plasmid DNA was introduced into competent DH5a E. 
coli (Invitrogen, UK) (50pl) by adding lOng plasmid DNA to the cells and mixing by 
pipetting. Cells were incubated on ice for 30mins and then subjected to ‘heat-shock’ 
at 37°C for 20secs, and then returned to the ice for a further 2mins. Following the 
incubation on ice, 700pl of pre-warmed SOC medium (Invitrogen, UK) without 
antibiotics was added to the cells and incubated at 37°C in an orbital incubator 
(~150rpm) for 60mins. After this time, transformed E. coli (200pl) were plated out 
on duplicate LB-agar plates containing the necessary antibiotics: 50pg/ml ampicillin 
for pGEM-T, 50pg/ml carbenicillin and kanamycin for pCR3. The remaining cells 
were concentrated and plated out as necessary. The LB-agar plates were inverted and 
incubated at 37°C for 15-24hrs and stored at 4°C.
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iii) Harvesting recombinant plasmids
Bacterial colonies should contain only transformed cells as antibiotic resistance is 
conferred by the recombinant plasmid. However, it is important to determine whether 
the cells contain plasmid only or plasmid plus insert DNA and whether the insert, if 
present, is in the correct orientation for expression.
Cells were harvested for DNA analysis using a QIAprep miniprep kit (Qiagen, UK), 
which uses the principle of alkaline lysis of bacterial cells followed by adsorption of 
DNA onto silica membranes in the presence of high salt. Colonies of cells were 
picked from L-agar plates using a sterile pipette tip and added to 3ml of pre-warmed 
LB containing the appropriate antibiotics into microfuge tubes. The cells were then 
propagated on an orbital shaker at 37°C for 12-15hrs. The cells were centrifuged at 
6000rpm, the supernatant removed and then resuspended in buffer PI (50 mM Tris- 
Cl, pH 8.0; 10 mM EDTA; lOOpg/ml RNase A). A lysis buffer (200 mM NaOH, 1% 
SDS (w/v)) was then added and the tubes carefully inverted several times. The 
lysates were neutalised by adding a buffer containing 3M potassium acetate, pH 5.5 
and mixed by inverting the tubes immediately, and a white precipitate formed. The 
precipitates were then centrifuged at 6000rpm for lOmins forming a compact white 
pellet. The resulting supernatants were applied to a QIAprep spin column and 
centrifuged for lmin to ensure that the DNA binds to the silica membrane in the 
column. The columns containing the bound DNA is then centrifuged twice in the 
presence of a wash buffer (1.0 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol 
(v/v)). The columns were re-centrifuged to ensure any residual buffer was eliminated, 
and then the DNA was eluted in dh20 by centrifuging the column.
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iv) Analysis of recombinant plasmids
The resultant plasmid DNA samples were digested with appropriate restriction 
endonucleases to analyse whether they contained the inserted DNA fragment and 
determine its orientation. The endonucleases were selected as their recognition sites 
were close to 5’ or 3’ termini of the DNA insert and in the MCS of the plasmid, 
resulting in a recognised diagnostic pattern when visualised on an agarose gel. A 
typical example of a restriction digest setup is shown below and was carried out at the 
respective recommended temperature and length of time (usually 37°C and 2-3hrs). 
Plasmid DNA lpg
Restriction enzyme (5U/pl) 1 pi
1 OX Buffer* 1 jul
H2O to 10pl
* Buffer appropriate to restriction enzyme used.
v) Preparation of large quantities of DNA
If large quantities of DNA were required, the bacterial culture (1.5ml) transformed 
with recombinant plasmid was transferred into LB medium (250ml) containing the 
appropriate antibiotic and incubated at 37°C in an orbital shaker for 15hrs at 150rpm. 
The plasmid DNA was isolated and purified according to the Qiagen maxi-prep 
protocols check. Briefly, bacterial culture (250ml) was transferred to a 300ml 
centrifuge tube (Sorvall instruments, UK) and cells were pelleted by centrifugation at 
6,000g for 30mins at 4°C. Pellets were resuspended, lysed and proteins precipitated 
by using resuspension buffer, lysis solution and neutralisation buffer (10ml each, 
Qiagen, UK), as described in the previous section. Samples were centrifuged at 
30,000g for 30mins at 4°C. Supernatants were filtered through gauze onto a Qiagen
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ion-exchange column (Tip 500) pre-equilibrated with equilibration buffer (10ml) 
(containing NaCl (750mM), MOPS (50mM), ethanol (15% (v/v)), Triton X-100 
(0.15% (v/v)); pH 7.0). A wash buffer (NaCl (1M), MOPS (50mM), isopropanol 
(15% (v/v)) pH 7.0; 2 x 30ml) was passed twice through the columns and DNA was 
eluted with 15ml elution buffer (NaCl (1.25M), Tris-Cl (50mM), isopropanol (15% 
(v/v)); pH 8.5). DNA was precipitated from solutions using isopropanol (75% (v/v), 
10.5ml) and centrifuged at llOOOrpm for 30mins at 4°C After the supernatant was 
removed ethanol (70% (v/v), 15ml) was added and the DNA was centrifuged at 
llOOOrpm for 15mins at 4°C. The supernatant was removed and dried before being 
resuspended in 300(il dH20. The concentrations and purity of the DNA were 
determined, and stock solutions (1 mg/ml) were stored at -20°C.
2.8.5 DNA Sequencing
i) Sequencing reactions
Automated sequencing was carried out using the BigDye® Terminator v3.1 cycle 
sequencing kit (Applied Biosystems, USA) on an ABI Prism 377 sequencer (Applied 
Biosystems, USA). The standard protocol is shown below:
Terminator ready reaction mix * 4. Opl
DNA Template 250-500ng
Primer (3.2pmole/|il) 3.2pmol(lpl)
dH20  to lOpl
*Terminator ready mix includes fluorescently labelled dye terminators dNTPs (dCTP,
Rox (Red); dTTP, Tamra (Yellow); dATP, R6G (Green); dGTP, R110 (Blue)), Tris-
HC1, pH 9.0, MgCl2, thermal stable pyrophosphate and AmpliTaq DNA polymerase,
FS.
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Samples were subjected to cycling conditions as follows using a PCR Sprint Thermal 
Cycler (Thermo Electron, USA).
• Hot start 96°C
• 96°C, lOsecs; 50°C, 5secs; 60°C, 4mins; (25cycles)
Samples were incubated on held at 4°C until ready to use.
ii) Sample preparation
Following cycle sequencing, the DNA extension products were precipitated. Tubes 
were briefly centrifuged and isopropanol (75% (v/v), 80pl) was added, vortexed, and 
incubated at room temperature for 20mins. The precipitated DNA was then 
centrifuged at 14,000g for 45mins at 4°C and the DNA pellet was washed with 75% 
(v/v) isopropanol by centrifugation at 14,000g for lOmins and air dried for lOmins. 
Sequencing results were obtained by Core Molecular Biology Facility, Heath 
Hospital, Cardiff.
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Chapter 3
Effects of simulated ischaemia, reoxygenation and  connexin 
mimetic peptides on ra t neonatal cardiac myocytes
3.1 Introduction
Coronary or ischaemic heart disease (CHD) is the leading cause o f death in the Western 
world (30% of male, 23% of female deaths). In CHD, the blood supply to the 
myocardium is insufficient for its needs and leads to ischaemia. Ischaemia is a complex 
metabolic insult comprising hypoxia, substrate depletion, acidosis and a build up o f toxic 
metabolites. Cardiac ischaemia is frequently accompanied by lethal arrhythmias, likely 
caused by electrical conduction abnormalities possibly resulting from changes in the 
extent o f phosphorylation of Cx43 that may, in turn be linked to reduced electrical 
coupling of myocytes via gap junctions (Saffitz 2000). Cx43 dephosphorylation is 
associated with electrical uncoupling of cardiac myocytes during global ischaemia 
induced with the Langendorff model (Beardslee et al., 2000). However, the cessation of 
mechanical function (beating) occurs much earlier than the dephosphorylation o f Cx43 
(Beardslee et al., 2000).
Cardiac ischaemia causes a number of possible clinical presentations. Acute myocardial 
infarction occurs when an epicardial coronary artery is occluded, usually by thrombosis 
within a diseased vessel (Fuster et al., 1992). Subsequently, an area o f myocardium is 
deprived of blood flow and causes a short-lived period of angina pectoris. Patients 
usually develop ventricular arrhythmia (ventricular fibrillation or ventricular 
tachycardia). As ischemia continues, the affected area of myocardium stops contracting, 
but is susceptible to a second period of ventricular arrhythmia. Ventricular damage can 
be minimised if  sufficient blood flow is restored quickly (Simes et al., 1995). Thus, the 
therapeutic approach to myocardial infarction is to re-open the artery and restore blood
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flow (reperfiision). This is usually achieved with thrombolytic drugs (such as warfarin or 
heparin) or percutaneous transluminal coronary angioplasty (PTCA) usually in 
combination with implantation of an intra-coronary stent (Braunwald et al., 2000; Keeley 
et al., 2003). However, reperfusion can cause “reperfiision arrhythmia” and oxidative 
stress in the myocytes (Yellon & Baxter 1999).
In studies using rabbit hearts, ischemia was shown to induce two phases of ventricular 
arrhythmia, the first o f which occurred between 5-7mins after arrest of perfusion and was 
associated with membrane depolarization and mild acidification (Cascio et al., 2005). A 
second phase of ventricular arrhythmia occurs later between 20-30mins after stopping 
perfusion and was associated with a rapid increase of tissue impedance, thought to be due 
to conductance properties of the gap junctions accounting for cell-to-cell coupling. An 
important property that is modulated by ischemia is intercellular resistance and is 
determined primarily by gap junctional conductance. During ischemia, conduction 
slowing accounts for changes of cellular excitability and during the first 10 minutes of 
ischemia, 70% of the decrease of conduction velocity is owing to the change in active 
membrane properties (i.e. gap junctions and membrane channels) (Cascio et al., 2005).
3*1.1 Ischaemia and Cx43 Phosphorylation
Cx43 phosphorylation occurs primarily on multiple serine residues located on the 
carboxyl tail and is mediated by several known and unknown protein kinases, for 
example, PKC and MAP kinase (Chapter 1, Figure 1.9). The carboxyl tail o f Cx43
85
contains 21 serine residues and the amino tail contains two. Phosphorylation o f Cx43 by 
PKC has been shown to have variable effects on gap junction channel conductance. In 
rat neonatal cardiac myocytes, activation o f PKC is variously reported to cause an 
increase in conductance (Kwak et al., 1995), a decrease in conductance (Munster & 
Weingart 1993) or no change in conductance (Spray & Burt 1990). Clearly, 
phosphorylation of gap junction proteins is a complex process and its functional role 
remains controversial.
Global ischemia in a rat Langendorff model results in dephosphorylation o f Cx43 in the 
intact heart (Beardslee et al., 2000). The reversibility o f this dephosphorylation event 
upon reperfusion has not been definitively demonstrated with data being inconsistent. 
Beardslee et al. (2000) reported a degree of rephosphorylation in some hearts, with others 
showing continued dephosphorylation. It has been observed that infarct size was reduced 
upon application o f the gap junction blocker heptanol at the time of reperfiision (Garcia- 
Dorado et al., 1997), which suggests that gap junctions may have a cardiotoxic effect 
during or after reperfiision, i.e. communication across gap junctions exacerbates damage 
following infarction. Therefore, it is important to determine the regulatory processes 
involving Cx43 during ischaemia/reperfiision, in order to explore any therapeutic 
potential for gap junction modifying drugs.
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3.1.2 Intrinsic responses in the myocardium
Following the onset o f ischaemia, intrinsic responses protect the cell. ATP and pH levels 
fall causing the cell to change to glycolytic metabolism. The increase in intracellular 
Ca2+ is initially buffered by uptake into mitochondria, but phospholipids and free-fatty 
acid levels also rise as mitochondrial respiration stops. As membrane integrity fails, 
damage to the cell becomes irreversible (Williams & Benjamin 2000). Reperfiision puts 
the cell under significant stress, and as blood flow is restored reactive oxygen species 
activate apoptotic signalling cascades (Hernandez et al., 2000). Apoptosis can also be 
induced by mitochondrial damage (Bialik et al., 1999) and hypercontractive necrosis can 
occur due to Ca2+ overload of the mitochondria (Wang & Ashraf 1999).
Hypoxia inducible factor 1 (HIF-1) is a transcriptional activator that functions as the 
main regulator o f oxygen homeostasis (Semenza 2001). HIF-1 is a heterodimer 
composed of HIF-1 a  and HIF-1 p subunits. During normoxia, the HIF-1 a  subunit is 
ubiquitinated and subjected to rapid proteasomal degradation whereas in hypoxia the 
amount of HIF-1 a  that is ubiquitinated is dramatically reduced, causing the protein to 
accumulate (Kallio et al., 1999; Sutter et al., 2000). The two subunits o f HIF-1 then form 
the active heterodimer and can now activate a number o f oxygen responsive genes.
Hypoxia/ischaemia has dramatically stimulatory effects on vascularization o f the 
coronary vasculature in foetal and juvenile animals. However, in aged animals, 
angiogenesis is impaired due to inhibition of vascular endothelial growth factor (VEGF)
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production by HIF-1 activity (Rivard et al., 2000). During hypoxia it was also shown that 
HIF-1 was essential for the regulation of iNOS gene expression in cardiac myocytes 
(Jung et al., 2000).
Previous models of hypoxia have used metabolic poisons such as potassium cyanide and 
iodoacetic acid (Li & Nagy 2000), which have additional effects to the induction of 
hypoxia especially the chemical inhibition of essential metabolic processes that 
ultimately kill the cell. In our approach described in this chapter, we have devised an 
ischaemia model that simulates more accurately the events that occur in infarction. 
Primary rat neonatal cardiac myocytes were utilised and ischaemia was simulated by 
combining hypoxia, induced precisely using a hypoxic chamber, with substrate depletion, 
achieved by using a low glucose cell culture medium.
3.1.3 Chapter aims
The investigations in this chapter were to study the effects o f hypoxia and simulated 
ischaemia on Cx43 phosphorylation status and cell beating rates in our cardiac ischaemia 
cellular model system of rat neonatal cardiac myocytes. The effects o f two connexin 
mimetic peptides on the cardiac myocytes were examined.
3.2 Methods
3.2.1 Materials
Calf intestinal phosphatase was from Promega (Southampton, UK) and Alexa-488 was 
obtained from Molecular Probes (Leiden, The Netherlands). GAP 26 and GAP 27 were 
synthesised by Fmoc (9-fluorenylmethyl carbamate) - polyamide solid-phase chemistry 
and assessed for purity by MALDI-TOF mass spectrometry and reversed phase HPLC 
(Sigma-Genosys, Cambridge, UK). All other reagents were obtained from Sigma (Poole, 
U.K).
3.2.2 Cell culture
Rat neonatal cardiac myocytes were prepared and plated as described in chapter 2 (Clarke 
et al., 2006; Turner et al., 2004). Cells were maintained cDMEM with BrDu (O.lmM) for 
the first 3 days and thereafter in serum-free medium as described in 2.2.2.
3.2.3 Hypoxia and ischaemia
Cardiac myocytes were made hypoxic in a gas tight humidified 37°C anaerobic chamber, 
with an internal environment of 0.5% oxygen and 5% carbon dioxide, as described in 
chapter 2. Cardiac myocytes were manipulated inside the hypoxic chamber to maintain a 
hypoxic environment at all times, as described in 2.3. Cell beating rate was monitored 
using a Nikon light microscope located within the hypoxic chamber. Control cells were 
incubated in a tissue culture incubator (Heraeus® HERAcell® 150) at 37°C and an 
environment of 21% oxygen and 5% carbon dioxide. For ischaemic treatment, cells were 
placed in low glucose (0.2gL_1) serum free medium for the duration of the experiment
89
and for hypoxic and control treatments, cells remained in the serum-free medium (3gL_I 
glucose), as described in 2.3.4.
3.2.4 Dye transfer across gap junctions
Rat neonatal cardiac myocytes were seeded at a density of 4x l06 cells/60mm dish. Direct 
cell-cell communication was assessed before and after treatment of the cells with the 
connexin mimetic peptides GAP26 and GAP 27, by studying transfer of Alexa-488 
(charge -1 , MW 570Da) following intracytoplasmic microinjection o f dye using an 
Eppendorf Femtojet 5247 device. Experiments were repeated in triplicate with >30 cells 
injected per experiment. Five minutes after injection cells were fixed in 4%w/v 
paraformaldehyde for 5mins and washed in PBS prior to the percentage of injections 
resulting in dye transfer to different numbers o f neighbouring cells being assessed on an 
Zeiss Axiovert 200 fluorescence microscope using appropriate filter sets (Zeiss, UK) 
(Martin et al., 2004).
3.2.5 Western blot analysis
Rat neonatal cardiac myocytes on 60mm dishes (4xl06), were treated and then harvested 
as described 2.4.1. Equal amounts o f protein (lOOpg rat neonatal cardiac myocyte 
lysates; 50pg HeLa cell lysates) were analysed by SDS-PAGE (10% w/v) (described in 
2.4.3) and transferred to nitrocellulose membrane for immuno-detection of Cx43 as 
described in 2.4.4. Membranes were probed with a polyclonal antibody to Cx43 (Zymed, 
USA) (1:4000 dilution) that recognises multiple phosphorylated/nonphosphorylated 
isoforms o f Cx43 and a secondary goat anti rabbit horseradish peroxidase antibody
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(1:2000 dilution). To standardise protein expression, blots were also probed with a 
monoclonal antibody to a-tubulin (1:10000 dilution) and a secondary goat anti mouse 
horseradish peroxidase antibody (1:2000 dilution). Blots were developed by enhanced 
chemiluminescene (ECL) and quantified using a Biorad GS-700 densitometer as 
described in 2.4.4.
3.2.6 Connexin 43 phosphorylation assays
Protein extracts (30pg) were digested with 60 units of calf intestinal phosphatase for lh r 
at 37°C and analysed by SDS-PAGE and Western blotting as described above. In some 
experiments cells were treated with lOOng/ml TP A, a protein kinase C activator, for 
30mins prior to harvesting the cells to serve as a positive control when analysing serine 
368 phosphorylation o f Cx43.
3.2.7 Statistical analysis
Cell beating rate data was analysed by unpaired t-test and ANOVA (analysis of variance) 
followed by Dunnett’s multiple comparison test, with P<0.05 being considered 
significant.
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3.3 Results
3.3.1 Immunoblot analysis of Cx43
Immunoblot analysis o f rat neonatal cardiac myocytes showed that Cx43 separated into 
two phosphorylated forms (PI and P2 bands) that migrated at 43 -  45 kDa and a minor 
band at 41 kDa, which represents the non-phosphorylated form. Occasionally, an 
additional phosphorylated band (P3) migrated at 46 -  48 kDa. These observations are 
shown in Figure 3.1a. Removal o f the phosphorylated bands occurred after alkaline 
phosphatase treatment, confirming that the 41 kDa band was the non-phosphorylated form 
of Cx43 (Figure 3.1b). These results concur with previous reports regarding the 
phosphorylation state o f Cx43 in cardiac myocytes (Beardslee et al., 2000).
3.3.2 The effects of simulated ischaemia on cardiac myocyte beating and Cx43 
phosphorylation
Cultured rat neonatal cardiac myocytes maintained in serum-free low glucose (0.2g/L) 
medium contracted synchronously at an average rate o f 160bpm. Incubation of cardiac 
myocytes in hypoxia (0.5% O2), in combination with the substrate-depleted cell culture 
medium (see above) caused cessation of beating within 3-4hrs, as shown in Figure 3.2. 
The beating rate then gradually decreased during the first 2hrs of ischaemic incubation, 
and it was also observed that cessation of beating after this time was mainly due to a 
gradual loss of amplitude (Figure 3.2).
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Figure 3.1: Analysis of Cx43 in rat neonatal cardiac myocytes
Confluent monolayers of rat neonatal cardiac myocytes were harvested for protein 
analysis and the cell lysates analyzed by standard SDS-PAGE and Western blotting 
with an antibody targeted to Cx43. a) shows typical state of Cx43 in the cardiac 
myocyte in normoxia, and b) after alkaline phosphatase (alk phos.) treatment of 
cardiac myocyte cell lysates illustrating the elimination of the phosphorylated isoforms 
ofCx43.
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Figure 3.2: The effect of ischaemia on the beating rates of rat neonatal cardiac 
myocytes
Confluent monolayers of rat neonatal cardiac myocytes were exposed to ischaemia and 
cell beating rates were recorded. Cells were viewed under a light microscope within 
the hypoxic chamber. Data analysed by unpaired t-test. *** P<0.001 (n=4).
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During ischaemia, the phosphorylated component of Cx43 was maintained up to 4hrs 
(Figure 3.3), but after 5hrs of ischaemia, the phosphorylated component o f Cx43 
decreased from 51.4% to 23.3% of total Cx43. The phosphorylation state o f Cx43 then 
remained stable for further periods o f 6 and 7hrs o f ischaemic insult. However, Cx43 
expression levels were decreased by approximately half after 7hrs o f ischaemia (Figure 
3.4).
In some experiments involving ischaemic incubations, Cx43 phosphorylation was not 
always completely abolished. However, the levels of phosphorylated Cx43 always 
decreased from control levels with expression levels remaining fairly constant. 
Variations in the quality o f the cardiac myocytes from each preparation and insufficient 
length o f hypoxic incubations may account for these variations.
3.3.3 The effects of simulated ischaemia and reoxygenation on cardiac myocyte 
beating and Cx43 phosphorylation
Incubation of cardiac myocytes in ischaemic conditions caused cessation of synchronous 
beating after 3-4hrs. After 5-7hrs of ischaemia, the cells were reoxygenated and resumed 
their synchronous beating, with cells recovering to 76.1% and 59.5% of the starting 
beating rate, for reoxygenation after 6hrs and 8hrs respectively (Figure 3.5a).
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Figure 3.3: The effect of ischaemia on the phosphorylation status of Cx43
a) A typical (representative) Western blot of confluent monolayers of rat neonatal 
cardiac myocytes were subjected to ischaemia for l-4hrs and the cell lysates analyzed 
by standard SDS-PAGE and Western blotting with an antibody targeted to Cx43. (b) 
Rat neonatal cardiac myocytes were treated as mentioned above. The graph shows the 
combined densitometric analysis of 2 Western blots.
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Figure 3.4: The effect of prolonged ischaemia on the phosphorylation status of 
Cx43
a) Confluent monolayers of rat neonatal cardiac myocytes were subjected to 
ischaemia for 5-7hrs and the cell lysates analyzed by standard SDS-PAGE and 
Western blotting with an antibody targeted to Cx43. (b) Rat neonatal cardiac myocytes 
were treated as mentioned above. The graph shows the combined densitometric 
analysis of 2 Western blots.
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As shown in Figure 3.4, ischaemic incubation for greater than 5hrs abolished the 
phosphorylated component of Cx43. Reoxygenation of ischaemic cardiac myocytes after 
5hrs o f insult resulted in the recovery to control levels o f the phosphorylated component 
of Cx43 (Figure 3.6). Cx43 rephosphorylation also occurred after more prolonged 
periods of ischaemia o f 6 and 7hrs (Figure 3.6).
Reoxygenation of ischaemic cardiac myocytes resulted in a recovery of Cx43 
phosphorylation and beating function. To assess the dynamics of the recovery, cardiac 
myocytes were subjected to ischaemic insult for 6hrs and then reoxygenated. Upon 
reoxygenation, cells began to beat after lOmins o f reoxygenation, with synchronous 
beating restored after 20mins (Figure 3.5b). This suggests that gap-junctional 
communication is restored rapidly.
Ischaemic incubation (6hrs) of cardiac myocytes resulted in a reduction in Cx43 
phosphorylation levels (Figure 3.7). Reoxygenation of ischaemic myocytes for 2 minutes 
had little effect on Cx43 phosphorylation, but after 5mins reoxygenation Cx43 
phosphorylation had recovered to approximately control levels and was maintained 
thereafter (Figure 3.7). Importantly, recovery o f phosphorylation occurred before the 
recovery of synchronous beating.
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Figure 3.5: The effect of ischaemia/reoxygenation on the beating rates of rat 
neonatal cardiac myocytes
Confluent monolayers of rat neonatal cardiac myocytes were exposed to ischaemia for 
either 6hrs or 8hrs and then reoxygenated a) cell beating rates were recorded after 
30mins or b) cell beating rate was recorded at specific time points. Cells were viewed 
under a light microscope within the hypoxic chamber. Data analysed using one-way 
ANOVA followed by Dunnett’s Multiple Comparison Test. *** P 0 .0 0 1  (n=4).
99
a)
Cx43
Control
Ischaemia
Reoxygenated
5hrs 6hrs 7hrs 5hrs
+
6hrs 7hrs 
+ +
b)
1 DO­
SS c
o <o
°  $  o C
£  X  50- co o
Control 5hrs 6hrs 7hrs 5hrs 6hrs 7hrs
Ischaem ia Ischaem ia +
re oxygenation
! = )  Non phosphorylated Cx43 
■ ■  Phosphorylated Cx43
Figure 3.6: The effect of ischaemia/reoxygenation on the phosphorylation status 
of Cx43
a) Confluent monolayers rat neonatal cardiac myocytes were subjected to normoxia, 
ischaemic insult for 5hrs, 6hrs or 7hrs, or reoxygenation after 5hrs, 6hrs or 7hrs of 
ischaemic insult. Cell lysates analyzed by standard SDS-PAGE and Western blotting 
with an antibody targeted to Cx43 and a-tubulin. Lane 1 - Control; Lane 2 - 5hrs 
ischaemia; Lane 3 - 6hrs ischaemia; Lane 4 - 7hrs ischaemia; Lane 5 - 5hrs ischaemia 
followed by lhr reoxygenation; Lane 6 - 6hrs ischaemia followed by lhr 
reoxygenation; Lane 7 - 7hrs ischaemia followed by lhr reoxygenation, (b) Rat 
neonatal cardiac myocytes were treated as mentioned above. The graph shows the 
combined densitometric analysis of 2 Western blots.
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Figure 3.7: The effect of reoxygenation on the phosphorylation status of Cx43 in 
ischaemic rat neonatal cardiac myocytes
a) Confluent monolayers rat neonatal cardiac myocytes were treated with 6hrs of 
ischaemic insult, then subjected to reoxygenation and harvested for protein analysis at 
specific time points. Cell lysates analyzed by standard SDS-PAGE and Western 
blotting with an antibody targeted to Cx43. Lane 1 - Control; Lane 2 - 6hrs ischaemia; 
Lane 3 - 6hrs ischaemia + 2 minutes reoxygenation; Lane 4 - 6hrs ischaemia + 5 
minutes reoxygenation; Lane 5 - 6hrs ischaemia + 10 minutes reoxygenation; Lane 6 - 
6hrs ischaemia + 20 minutes reoxygenation; Lane 7 - 6hrs ischaemia + 30 minutes 
reoxygenation; Lane 8 - 6hrs ischaemia + 60 minutes reoxygenation; Lane 9 - 6hrs 
ischaemia + 90 minutes reoxygenation, (b) Rat neonatal cardiac myocytes were treated 
as mentioned above. The graph shows the combined densitometric analysis of 2 
Western blots.
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3.3.4 Effects of connexin mimetic peptides on gap-junctional communication in rat 
neonatal cardiac myocytes
To demonstrate that intercellular transfer of dye occurred across gap junctions, cardiac 
myocytes were treated with the connexin mimetic peptides GAP 26 (300pM) and GAP 
27 (300pM) 30mins prior to microinjection (Figure 3.8). Dye transfer was dramatically 
reduced by both peptides with GAP 26 causing 10% and 35% of cells to transfer dye to 
no cells or 1-4 cells respectively (Figure 3.9a). GAP 27 reduced dye transfer, with 25% 
and 55% of cells transferring dye to no cell or 1-4 cells respectively (Figure 3.9b). 
Previous reports showed GAP 27 decreased dye transfer but to a lesser extent (Chaytor et 
al., 1999), likely due to the use o f COS-7 cells which do not communicate as efficiently 
by gap junctions as cardiac myocytes. Both peptides reversibly reduced dye transfer and 
after washout, transfer was restored with 55% and 75% of cells transferring dye to >11 
cells after GAP 26 and GAP 27 treatment respectively (Figure 3.8iv,vi and 3.9). In 
combination with a reduction in intercellular communication the connexin mimetic 
peptides caused a reduction in cardiac myocyte beating rate (Figure 3.10). The beating 
rate decreased by approximately 45% after treatment with GAP 26 for lhr. After 2hrs o f 
treatment the beating rate was further reduced to approximately 25% of the control rate 
(Figure 3.10a). Importantly, the synchronicity of the cardiac myocyte beating was not 
affected by the connexin mimetic peptides.
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Figure 3.8: The effect of the connexin mimetic peptides GAP 26 and GAP 27 on 
Alexa-488 transfer in rat neonatal cardiac myocytes
Confluent monolayers of rat neonatal cardiac myocytes were viewed under a 
fluorescent microscope immediately after microinjection of Alexa-488. (i) Control 
cells; (ii) Control cells phase view; (iii) Following 30mins treatment with 300pM GAP 
26; (iv) Following washout after 30mins treatment with 300pM GAP 26; (v) 
Following 30mins treatment with 300pM GAP 27; (vi) Following washout after 30 
minutes treatment with 300|aM GAP 27. *Injected cell. Bar = 50pm.
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Figure 3.9: The effect of the connexin mimetic peptides GAP 26 and GAP 27 on 
Alexa-488 transfer in rat neonatal cardiac myocytes
a) Confluent monolayers of rat neonatal cardiac myocytes were viewed under a 
fluorescent microscope immediately after microinjection of Alexa-488 under control 
conditions or following 30mins treatment with 300pM GAP 26 and following washout 
after 30mins treatment with 300pM GAP 26. b) Confluent monolayers o f rat neonatal 
cardiac myocytes were viewed under a fluorescent microscope immediately after 
microinjection of Alexa-488 under control conditions or following 30mins treatment 
with 300pM GAP 27 and following washout after 30mins treatment with 300pM GAP 
27. The extent of dye spread was monitored. Approximately 30 cells were injected per 
set o f experiments.
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Figure 3.10: The effect of the connexin mimetic peptides GAP 26 and GAP 27 on 
the synchronous beating rate of rat neonatal cardiac myocytes
a) Confluent monolayers of rat neonatal cardiac myocytes were treated with 300pM 
GAP 26 and viewed under a light microscope to record cell beating rates at specific 
time points, b) Confluent monolayers o f rat neonatal cardiac myocytes were viewed 
under a light microscope and cell beating rates were recorded under control conditions 
or following treatment with 300juM GAP 26 or GAP 27 and following washout after 
30mins treatment with 300pM GAP 26 or GAP 27.
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3.4 Discussion
A neonatal cardiomyocyte model was developed to study the effects o f ischaemic insult 
on the heart at the cellular level. Gap junctions, constructed primarily o f Cx43, are 
widely regarded as an essential component in maintaining the synchrony o f beating 
between cardiomyocytes in the heart (Saffitz & Yamada 1998; Severs 2000). Onset o f 
ischaemia often results in heart arrhythmias, presumably due to the uncoupling o f gap 
junction mediated communication. Our ischaemic model system uses a hypoxic chamber 
and nutrient-free media. An advantage of using a specially designed chamber to induce 
hypoxia is that the cellular responses are a consequence o f a hypoxic environment 
whereas in chemical hypoxia, the chemicals presumably reduce oxidative metabolism 
and damage cells, making the relevance o f the results questionable.
The present studies indicate that this model is robust and reliable. The cells beat 
synchronously and protein analysis o f Cx43 extracted from cardiac myocytes consistently 
produced two phosphorylated components, that were abolished by alkaline phosphatase 
treatment, and a third non-phosphorylated component. In healthy, synchronously beating 
cardiomyocytes, Cx43 is mainly in the phosphorylated state.
Ischaemia caused cessation of beating after 2-3 hours and this was followed by 
dephosphorylation o f Cx43 after 4-5 hours. In comparison, whole organ Langendorf 
ischaemia (no perfusion) studies report that gap junction uncoupling occurs after 22 
minutes and Cx43 dephosphorylation after 15-30 minutes (Beardslee et al., 2000). This 
is a more rapid response to ischaemia, probably due to the differences in behaviour in
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whole heart organ studies where there are more cell types involved, for example 
fibroblasts. The time taken for synchronous beating to cease (2-3 hours) corresponds 
with the half-life o f Cx43 but there was no difference detected in total Cx43. This 
indicates that newly synthesised Cx43 loses the ability to form functional gap junctions 
or may not reach the plasma membrane. Gap junction uncoupling caused cardiac 
myocytes to cease beating. Under control conditions, when Cx43 is phosphorylated, 
cardiac myocytes beat rapidly and synchronously. Ischaemia-induced cessation of 
beating is followed by dephosphorylation of Cx43. However, following reoxygenation, 
my studies showed that synchronous beating only recovered after Cx43 phosphorylation 
was restored, suggesting a possible association between synchronous beating and Cx43 
phosphorylation. This recovery phenomenon occurred within minutes, suggesting that 
newly synthesised Cx43 is not involved and pre-existing dephosphorylated Cx43 is 
rephosphorylated. Immunofluorescent studies before and after ischaemic insult showed 
that gap junctions probably constructed of Cx43 were internalised during hypoxia 
(Turner et al., 2001). The recovery o f Cx43 phosphorylation could be due to attachment 
of already synthesised connexins and CxHcs to gap junction plaques or less likely 
reinsertion o f internalised Cx43 into the plasma membrane and not newly synthesised 
Cx43. This is supported by studies using the protein synthesis inhibitor cycloheximide 
that showed that the recovery of Cx43 phosphorylation was very robust and not affected 
by inhibition of protein synthesis (Turner et al., 2004). Further, immunofluorescent 
studies would have helped to confirm this possibility. The identity o f the protein kinase 
responsible for the robust recovery of Cx43 phosphorylation after ischaemia and 
reoxygenation is unknown (Turner et al., 2004). Indeed, it is likely that many protein
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kinases are involved as Cx43 recovers both phosphorylation components (PI and P2), 
likely to be at different phosphorylation sites on the carboxyl tail. The involvement of 
the MAP kinases, PKA and PKG has been shown to be limited as the inhibitors o f these 
protein kinases had no effect on the recovery of phosphorylation after hypoxia and 
reoxygenation (Turner et al., unpublished results). However, Cx43 phosphorylation 
failed to recover after reoxygenation of hypoxic treated cells in the presence o f a non­
isoform specific PKC inhibitor has indicated that PKC could be involved (Turner et al., 
unpublished results).
In summary, the present results illustrated that ischaemia induced the cessation o f 
synchronous beating in neonatal cardiac myocytes and was followed later by complete 
dephosphorylation o f Cx43. In addition, upon reoxygenation restoration o f synchronous 
contraction in cardiac myocytes occurred once Cx43 phosphorylation was restored. 
These step-wise sequences indicate that Cx43 phosphorylation state and synchronous 
contraction of neonatal rat myocytes are closely related.
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Chapter 4
The effects of an antiarrhythmic peptide rotigaptide (ZP123) on 
communication across gap junctions and connexin properties
4.1 Introduction
Direct communication across gap junctions facilitates the functional coordination of cell 
networks (Loewenstein 1981). Modifying the extent of cell to cell signalling across gap 
junction channels is likely to disrupt the synchronisation of individual activities of 
constituent cells in tissues and organs. Remodelling of gap junctions and changes in 
intercellular communication believed to occur across these channels are associated with 
a number of pathophysiological conditions including ischaemia, cardiac arrhythmia as 
well as endothelial and epithelial wound healing events (Saez et al., 2003; Severs et al., 
2004). Connexins are increasingly identified as therapeutic targets functioning in 
cellular co-ordination (Dhein 2004).
4.1.1 Rotigaptide (ZP123)
In the heart, gap junctions located primarily at the intercalated discs couple myocytes 
electrically and mechanically ensuring intercellular propagation of action potentials that 
trigger Ca2+ transients, communication processes that underpin synchronous contraction 
at the cellular and organ level (Kleber & Rudy 2004). During acute myocardial 
infarction the blood supply to areas of the heart is interrupted and gap junctions close 
(Beardslee et al., 2000), stopping the electrical communication between the myocytes, a 
process often leading to fatal arrhythmia. To address cardiac arrhythmia, hexa-peptides 
such as AAP10 derived from bovine atria and its stable analogue ZP123 have been 
developed to modify gap-junctional channel properties and intercellular communication 
(Dhein et al., 2003; Muller et al., 1997). ZP123 was developed by the Danish
pharmaceutical company Zealand Pharma (Glostrup, Denmark) and has since been 
renamed rotigaptide. Rotigaptide is believed to be the first specific gap junction 
modifying product to be developed for a specific indication, being designed to
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normalize cardiac arrhythmias. Rotigaptide promoted electrical coupling between 
ventricular myocytes without changing membrane conductance (Xing et al., 2003). The 
peptide attenuated gap junction closure during acidosis, preserved intercellular coupling 
and improved synchronisation of beating of clusters of heart cells (Eloff et al., 2003; 
Haugan et al., 2005; Kjolbye et al., 2003; Xing et al., 2003). Most importantly, 
rotigaptide reduced the inducibility of re-entry ventricular tachycardia during acute 
ischaemia in dogs (Xing et al., 2003). These properties suggest that rotigaptide could be 
a prototype of a new class of antiarrhythmic drug. Indeed, rotigaptide successfully 
underwent three phase I clinical trials during 2005. These were safety and tolerability 
trials involving healthy volunteers and drug interaction trials with digoxin. Rotigaptide 
has now entered Phase II with the primary objective being to determine whether 
rotigaptide administration decreases the occurrence of ventricular arrhythmia in patients 
with chronic heart failure and acute myocardial infarction.
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Figure 4.1: The chemical structure of the hexa-peptide rotigaptide. Rotigaptide is 
an antiarrhythmic peptide currently in phase II clinical trials.
4.1.2 Permeability of connexin channels
Channels constructed from each connexin subtype have slightly different permeability 
properties. For example, Cx43 channels are generally accepted to have broad range 
permeability to most molecules less than lkDa in size. By contrast, Cx26 channels are 
more selective and are permeable to small dyes such as Lucifer yellow (MW 457D) and
111
Alexa 488 (MW 570D) but impermeable to larger marker dyes such as Alexa594 (MW 
780D) (Nicholson et al., 2000). Differences in the permeabilities of Cx26, Cx32 and 
Cx43 channels to secondary messengers that include cAMP, adenosine and IP3 have 
also been reported (Goldberg et al., 2002; Harris 2001; Niessen et al., 2000).
Cells in most tissues often express different combinations of connexins. Connexin 43 is 
the most widely expressed connexin in mammals and is the dominant connexin 
expressed in heart. It is also highly expressed in skin but Cx26 and up to ten other 
connexins are also differentially expressed in the dermal cell layers (Di et al., 2001; 
Willecke et al., 2002). Cx32 is found in several tissues including the nervous system 
and liver (Willecke et al., 2002). The distinctive permeability properties observed with 
different connexins are believed to reflect specific physiological requirements of 
different tissues. The dynamic role that connexin channels play in various physiological 
and pathophysiological conditions makes agents that target gap-junctional 
communication potentially useful therapeutic tools.
4.1.3 HL-1 cells
There have been many attempts to create a cardiac muscle cell line that proliferates in 
culture, with limited success so far (Claycomb et al., 1998). HL-1 cells are an 
immortalized cardiac muscle cell line derived from the AT-1 mouse atrial cardiac 
myocyte cells with a tumour lineage (Claycomb et al., 1998; Delcarpio et al., 1991). 
HL-1 cells can be passaged indefinitely in culture, yet they maintain an ability to 
contract. They retain differentiated cardiac morphological, biochemical and 
electrophysiological properties (Claycomb et al., 1998). However, while Hl-1 cells 
have the ability to beat, the cells are inconsistent with respect to this function.
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Nevertheless, they remain a useful tool for cardiac specific studies, but they are still not 
a completely successful replacement for primary ventricular cardiac myocytes.
4.1.4 Chapter Aims
The investigations described in this chapter are concerned with the effects of rotigaptide 
on the cell communication properties and protein expression profiles of Cx43 in three 
cell model systems: rat neonatal cardiac myocytes, HL-1 cells (Claycomb et al., 1998) 
and HeLa cells transfected and selected to express different connexins. The effect of 
rotigaptide on the permeability of Cx32 and Cx26 gap junctions in HeLa cell model 
systems allowed the connexin specificity of rotigaptide action to be examined.
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4.2 Methods 
4.2.1 Materials
G418-sulphate and Calf Intestinal Phosphatase were purchased from Promega 
(Southampton UK). Lucifer yellow, Alexa-488, Alexa-594 and goat anti-rabbit and 
mouse Alexa-488 and Alexa-594 secondary antibodies were obtained from Molecular 
Probes (Leiden, The Netherlands). The Cx43 monoclonal and P368 antibodies were 
obtained from Chemicon (Chandlers Ford, UK). Rotigaptide was supplied by Zealand 
Pharma (Glostrop, Denmark) and dissolved in water to give a 50pM stock and 18aGA 
was dissolved in DMSO to give a 25mM stock. GAP 26 was obtained from Sigma- 
Genosys (Cambridge, UK). All other reagents were obtained from Sigma (Poole, U.K).
4.2.2 Cell culture
Rat neonatal cardiac myocytes were prepared and plated as described in chapter 2 
(Clarke et al., 2006; Turner et al., 2004). HL-1 cardiomyocytes were maintained in 
Claycomb medium, supplemented with 10% foetal calf serum, P/S (lOOpg/ml), 
epinephrine (0.1 mM) and L-glutamine (2mM) as previously described (Claycomb et al., 
1998). HeLa cells selected to express Cx43-GFP, Cx32-GFP or Cx26-GFP were 
prepared as described (Paemeleire et al., 2000) and maintained in DMEM, 
supplemented with 10% foetal calf serum, P/S (100pg/ml), amphotericin (100|ig/ml), L- 
glutamine (2mM) and geneticin sulphate (G-418-sulphate 4mg/ml). HeLa cells 
expressing wild type Cx26 or Cx43 were maintained in cDMEM supplemented with 
0.5pg/ml puromycin (Elfgang et al., 1995).
4.2.3 Dye transfer across gap junctions
Rat neonatal cardiac myocytes and HeLa cells were seeded at a density of 4xl06 
cells/60mm dish and lxlO6 cells/60mm dish respectively. Cx-GFP protein expression in
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HeLa cells was enhanced by addition of 5mM sodium butyrate to the medium 18hrs 
prior to the experiments (George et al., 1998). Direct cell-cell communication was 
assessed before and after treatment of the cells with rotigaptide by studying transfer of 
Lucifer yellow (charge -2, MW 457Da), Alexa-488 (charge -1, MW 570Da) or Alexa- 
594 (charge -1 MW 758Da) following intracytoplasmic microinjection of dye using an 
Eppendorf Femtojet 5247 device. Experiments were carried out in triplicate with >30 
cells injected per experiment. Five minutes after injection cells were fixed in 4%w/v 
paraformaldehyde for 5mins and washed in PBS prior to the percentage of injections 
resulting in dye transfer to different numbers of neighbouring cells being assessed on an 
Zeiss Axiovert 200 fluorescence microscope using appropriate filter sets (Zeiss, UK) 
(Martin et al., 2004).
4.2.4 Hypoxia and ischaemia
Cardiac myocytes were made hypoxic in a gas-tight humidified 37°C anaerobic 
chamber, with an internal environment of 0.5% oxygen and 5% carbon dioxide, as 
described in chapter 2. Cardiac myocytes were manipulated inside the hypoxic chamber 
to maintain a hypoxic environment at all times, as described in 2.3. Cell beating rate 
was monitored using a Nikon light microscope within the hypoxic chamber. Control 
cells were incubated in a tissue culture incubator (Heraeus® HERAcell® 150) at 37°C 
and an environment of 21% oxygen and 5% carbon dioxide. For ischaemic treatment, 
cells were placed in a low glucose (0.2gL_1) serum free medium for the duration of the 
experiment and for hypoxic and control treatments, cells remained in the serum-free 
medium (3gL'1), as described in 2.3.4.
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4.2.5 Cell Cytometric analysis
HeLa cells expressing Cx43-GFP were plated onto 6 well dishes (lxlO5 cells) and were 
exposed to 50nM or 250nM rotigaptide for periods of 1 or 5hrs. Cells were harvested by 
trypsinisation, washed in PBS and resuspended to a final concentration of lx l0 6/ml. 
Cells (lxlO5) were added to 500pi of FACS sheath fluid (Becton Dickson) and subject 
to fluorescent activated cell sorting (FACS) analysis after excitation at 488nm. Data was 
exported to a Microsoft Excel spreadsheet and analysed. Experiments were carried out 3 
times and data presented as mean ± sem.
4.2.6 Protein localisation and image analysis
HeLa cells expressing wild type Cx43 (3x105 cells) were seeded onto 16mm2 coverslips 
and allowed to settle as monolayers. Following treatment with rotigaptide at 
concentrations of 50nM, lOOnM and 250nM for 5hrs respectively cells were fixed and 
processed for immunocytochemical staining (described 2.6.2) with a monoclonal 
antibody targeted to the carboxyl tail of Cx43 (1:250 dilution). The secondary antibody 
was goat anti-mouse conjugated to Alexa-488 (Martin et al., 2004). Slides were viewed 
under an Axiovert 200 microscope linked up to a Zeiss confocal laser scanning system. 
Images were acquired under identical conditions and magnification. In parallel 
experiments, HeLa cells expressing Cx43-GFP (5xl05 cells) were seeded onto 24mm2 
cover-chambers (LabTek) and cells were viewed before and after treatment of the cells 
with rotigaptide as described above.
4.2.7 Western blot analysis
Cells grown on 60mm dishes (4xl06 rat neonatal cardiac myocytes; lxlO6 HeLa cells) 
were treated for periods of 1 to 5hrs with 50nM, lOOnM or 250nM rotigaptide, or 25pM
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18a-glycyrrhetinic acid (18aGA) prior to harvesting as described 2.4.1. Equal amounts 
of protein (lOOpg rat neonatal cardiac myocyte lysates; 50jig HeLa cell lysates) were 
analysed by SDS-PAGE (10% w/v) (described 2.4.3) and transferred to nitrocellulose 
membrane for immuno-detection of Cx43 as described in 2.4.4. Membranes were 
probed with a polyclonal antibody to Cx43 (Zymed, USA; 1:4000 dilution) that 
recognises multiple phosphorylated/nonphosphorylated isoforms of Cx43 and a 
secondary goat anti rabbit horseradish peroxidase antibody (1:2000 dilution). In some 
experiments, blots were also probed with a polyclonal antibody that recognises site- 
specific phosphorylation of serine 368 on the carboxyl tail of Cx43 (1:1000 dilution). To 
standardise protein expression, blots were also probed with a monoclonal antibody to a- 
tubulin (1:10000 dilution) and a secondary goat anti mouse horseradish peroxidase 
antibody (1:2000 dilution). Blots were developed by enhanced chemiluminescene (ECL) 
and quantified using a Biorad GS-700 densitometer as described in chapter 2 (Martin et 
al., 2004).
4.2.8 Connexin 43 phosphorylation assays
Protein extracts (30pg) were digested with 60 Units of calf intestinal phosphatase for 
lhr at 37°C and analysed by SDS-PAGE and Western blotting as described above. In 
some experiments cells were treated with lOOng/ml TPA, a protein kinase C activator, 
for 30mins prior to harvesting the cells to serve as a positive control when analysing 
serine 368 phosphorylation of Cx43.
4.2.9 Statistical analysis
Data were evaluated by ANOVA followed by Dunnett’s multiple comparison test, with 
P<0.05 being considered significant.
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4.3 Results
43.1 Rotigaptide increases gap-junctional communication in rat neonatal cardiac 
myocytes.
Rat neonatal cardiac myocytes were efficiently coupled with 20.9% of cells transferring 
dye to >11 neighbouring cells. Rotigaptide treatment at 50nM, lOOnM or 250nM for 1 
hour had no significant effect on dye transfer (Figure 4.3a). Exposure of the cells to 
50nM rotigaptide for 5hrs increased dye spread approximately 4 fold, with 75.6 ± 9.7% 
of cells transferring dye to > 11 cells (Figure 4.2 and 4.3b). Treatment of the cells for 
5hrs with lOOnM and 250nM rotigaptide also significantly increased intercellular 
coupling (Figure 4.2 and 4.3b). There was no further modification of dye spread at these 
increased doses, suggesting that 50nM is the optimal concentration at which rotigaptide 
operates in this system and that any further enhancement is not readily distinguished by 
monitoring spread of dye.
To demonstrate that intercellular transfer of dye occurred across gap junctions, cells 
were treated with 18aGA for lhr prior to microinjection and following exposure to 
rotigaptide for 5hrs (Figure 4.2). Dye transfer was totally blocked under both 
conditions (Table 4.1). These results suggest that rotigaptide does not offset the effects 
of 18aGA, a known gap junction uncoupler (Davidson & Baumgarten 1988). Despite 
the increase in intercellular coupling elicited by rotigaptide, the peptide had no 
significant effect on beating rates and their synchronicity in cardiac myocytes, which 
was maintained at approximately 150bpm during each of the drug treatments (Figure 
4.4).
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Figure 4.2: The effect of rotigaptide (ZP123) and 18aGA on Alexa-488 transfer 
in rat neonatal cardiac myocytes
Confluent monolayers of rat neonatal cardiac myocytes were viewed under a 
fluorescent microscope immediately after microinjection of Alexa-488. (i) Control 
cells; (ii) Control cells following lhr pre-treatment with 25mM 18aGA; (iii) 
Following 5hrs treatment with 50nM rotigaptide; (iv) Following 5hrs treatment with 
lOOnM rotigaptide; (v) Following 5hrs treatment with 250nM rotigaptide; (vi) 5hrs 
treatment with 50nM rotigaptide followed by lhr 25mM 18aGA. * Injected cell. 
Bar = 50pm.
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Figure 4.3: The effect of rotigaptide (ZP123) on Alexa-488 transfer in rat 
neonatal cardiac myocytes
Confluent monolayers of rat neonatal cardiac myocytes were microinjected with 
Alexa-488 under control conditions or following treatment with 50nM, lOOnM or 
250nM ZP123 a) for lhr and b) 5hrs. The extent of dye spread was monitored. 
Approximately 30 cells were injected per set of experiments, which were repeated in 
triplicate. **P<0.01.
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Figure 4.4: The effect of rotigaptide (ZP123) on the beating rate of rat neonatal 
cardiac myocytes
Confluent monolayers of rat neonatal cardiac myocytes were viewed under a light 
microscope and cell beating rates were recorded under control conditions or 
following treatment with 50nM, lOOnM or 250nM ZP123 for 5hrs (n=12).
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4.3.2 Rotigaptide increases gap-junctional communication in HL-1 cells.
HL-1 cells displayed a lower degree of dye coupling than cardiac myocytes with 61.7 ± 
9.3% of cells transferring dye to 5-10 neighbouring cells and 1.7% of cells transferring 
dye to >11 cells. Treatment of HL-1 cells with rotigaptide at 50nM, lOOnM or 250nM 
for 5hrs significantly increased transfer of dye to >11 cells to 38.3 ± 4%, 32.5 ± 4.9% 
and 57.5 ± 8.1% respectively (Table 4.1, Figure 4.5).
4.3.3 The connexin specificity of rotigaptide action.
Untransfected HeLa cells are communication incompetent and do not transfer dyes to 
neighbouring cells (Elfgang et al., 1995; George et al., 1998). Therefore, HeLa cells 
were made communication competent by transfection and selection of variants 
expressing Cx43-GFP, Cx32-GFP or Cx26-GFP, or wild type Cx43 or Cx26. Following 
induction of Cx43-GFP expression with sodium butyrate, 37.9 ± 8.2% of the transfected 
cells transferred dye to >5 neighbours confirming previous results (Martin et al., 2001) 
(Figure 4.6). Time course experiments, pursued to analyse the effects of rotigaptide 
(50nM) on the efficiency of gap-junctional coupling, showed that 2-3hrs incubation 
with the peptide was without significant effect on the intercellular spread of Lucifer 
yellow (Figure 4.6a). However, as with HL-1 cells, after 5-6hrs incubation with 
rotigaptide, increased dye transfer was observed with 69.1 ± 7.1% of cells transferring 
dye to >5 cells, although overnight incubation did not result in further dye spread. Dye 
transfer was significantly reduced following pre-incubation of the cells with 18aGA for 
lhr prior to microinjection of dye under control conditions and following 5hrs 
rotigaptide (50nM) treatment; a similar result was obtained with cardiac myocytes 
(Figure 4.2).
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The effect of rotigaptide on dye transfer properties of different cells and connexins
j  Cell and Cx subtype expressed Treatment; Dose! Time j Dye % coupling ± sem ;
Control | - 0 hr Alexa-488; 20.90 ± 4 .8 2
Rotigaptide j 50nM 1 hr Alexa-488; 31.93 ± 18 .64
Rotigaptide lOOnM lh r  Alexa-488; 24.68 ±  10.46 j
‘Rat neonatal cardiac myocytes 
expressing Cx43 (transferring to 11 or 
more cells)
Rotigaptide 250nM lh r Alexa-488; 30.33 ± 16.33
Rotigaptide j  50nM 5hrs Alexa-488; 75.60 ± 9 .7 9 * *
Rotigaptide j  lOOnM 5hrs Alexa-488 34.09 ± 3.70
Rotigaptide 250nM 5hrs Alexa-488 44.10 ± 8 .7 0 * *
18aGA 50pM 30mins Alexa-488 0**
Control - 0 hr Alexa-488 1.667 ± 1 .667
'HL-1 cardiomyocytes expressing 
1 Cx43 (transferring to 11 or more cells)
Rotigaptide j 50nM ! 5hrs Alexa-488 38.33 ± 4 .0 1 * *
Rotigaptide lOOnM 5hrs Alexa-488 32.50 ± 4 .9 6 *
Rotigaptide 250nM 5hrs Alexa-488; 57.50 ± 8 .1 4 * *
18aGA 50pM 30mins Alexa-488 0**
HeLa cells expressing wild type Cx26 
(transferring to 11 or more cells)
Control - Ohr Alexa 488 
Rotigaptide 50nM 5hrs Alexa 488
15.5 ± 3 .9  
18.9 ± 3 .2
Control - 0 hr LY 37.91 ± 8.2
Rotigaptide j 50nM 2-3hrs: LY 35.6 ± 5 .9 7
2HeLa cells expressing Cx43-GFP 
(transferring to 5 or more cells)
Rotigaptide j 50nM ; 5-6hrs LY 
Rotigaptide j 50nM ! o/n j LY
69.1 ± 7 .1 2 * *  
56.7 ±  6.84 *
Control - O hr Alexa-594 9.06 ± 1 .2 4
Rotigaptide j 50nM 5-6hrs Alexa-594 54.8 ± 9 .16*
Control - 0 hr LY 37.73 ± 3 .38
3HeLa cells expressing Cx32-GFP Rotigaptide ; 50nM 5-6hrs LY 42.12 ± 4 .57
(transferring to 3 or more cells) Rotigaptide lOOnM 5-6hrs LY 27.13 ± 2 .62
Rotigaptide 250nM 5-6hrs LY 46.27 ± 6 .12
Control - 0 hr LY 45.20 ± 6 .13
3HeLa cells expressing Cx26-GFP 
(transferring to 3 or more cells)
Rotigaptide ; 50nM 5-6hrs LY 
Rotigaptide lOOnM 5-6hrs LY
29.31 ± 5 .28  
27.75 ± 0.25
Rotigaptide 250nM 5-6hrs LY 28.50 ±  7.90
Table 4.1: Confluent monolayers o f  rat neonatal cardiac myocytes, HL-1 cardiomyocytes and HeLa cells 
expressing Cx43-GFP, Cx32-GFP or Cx26-GFP were microinjected with Alexa-488, Lucifer yellow o r 
Alexa-594 following treatment with Rotigaptide at various concentrations and times as indicated in the; 
table. The extent o f dye transfer was recorded and the data here represented as % o f cells transferring: 
dye to >11 neighbouring cells for 'rat neonatal cardiac myocytes and HL-1 cardiomyocytes, to >5 
neighbouring cells for 2HeLa cells expressing Cx43-GFP and to >3 neighbouring cells for 3HeLa cells 
expressing Cx32-GFP and Cx26-GFP. * P<0.05, ** P<0.01 compared with non treated cells.
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Figure 4.5: The effect of rotigaptide (ZP123) on Alexa-488 transfer in HL-1 
cardiomyocytes
Confluent monolayers of HL-1 cardiomyocytes were microinjected with Alexa-488 
under control conditions or following treatment with 50nM, lOOnM or 250nM 
ZP123 for 5hrs. The extent of dye spread was monitored. Approximately 30 cells 
were iniected per set of experiments, which were repeated in triplicate. **P<0.01.
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Figure 4.6: The effect of rotigaptide (ZP123) on dye transfer in HeLa cells 
expressing Cx43-GFP
Confluent monolayers of HeLa cells expressing Cx43-GFP were microinjected with: 
a) Lucifer yellow under control conditions or following treatment with 50nM ZP123 
for 2-3hrs, 5-6hrs or overnight or b) Lucifer yellow or Alexa-594 under control 
conditions or following treatment with 50nM ZP123 for 5hrs. In all experiments the 
extent of dye spread was monitored and approximately 30 cells were injected per set 
of experiments, which were repeated in triplicate. *P<0.05, **P<0.001 in a. In b 
*P<0.05 between control cells and ZP123 treated cells was determined by student t 
test, for Lucifer yellow and Alexa-594 transfer respectively.
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To investigate the effect of rotigaptide on the intercellular spread of various dyes, the 
spread of Lucifer yellow and Alexa-594 was compared in HeLa cells expressing Cx43- 
GFP. Lucifer yellow was found to diffuse more efficiently through Cx43-GFP gap 
junctions than Alexa-594, with 37.9% of cells transferring Lucifer yellow whereas only 
9% of cells transferred Alexa-594 to >5 neighbouring cells respectively. Transfer of 
both dyes increased significantly after 5hrs treatment with rotigaptide (50nM) (Figure 
4.6b). In general, Cx43-GFP channels transferred Lucifer yellow to a greater number of 
cells than Alexa-594.
HeLa cells expressing Cx32-GFP and Cx26-GFP exhibited lower dye coupling 
efficiency than Cx43-GFP transfected HeLa cells, with 37.3 ± 3.4% of Cx32-GFP 
expressing cells transferring Lucifer yellow to >3 neighbouring cells (Figure 4.7a). 
Incubation with 50nM rotigaptide for 5hrs had no significant effect on the extent of 
Lucifer yellow transfer. Furthermore, incubation of these cells for 5hrs with lOOnM or 
250nM rotigaptide caused no significant change in dye transfer. Similar results were 
obtained with Cx26-GFP expressing cells (Figure 4.7b). Rotigaptide caused no 
significant difference in the extent of transfer of Alexa 488 (charge -1, MW 570) 
between Cx26 expressing HeLa cells that under control conditions were extensively 
coupled with 15.5 ± 3.9% transferred the dye to >11 cells. Following five hours of 
preincubation with 50nM rotigaptide, 18.9 ± 3.2% of cells transferred dye (P<0.5%).
4.3.4 The effects of rotigaptide on cardiac myocytes during ischaemia
Cardiac myocytes were exposed to ischaemia resulting in the cessation of synchronous 
beating after approximately 3hrs of the insult. Upon reoxygenation, after 6hrs of 
ischaemia, the synchronous contraction of cardiac myocytes was restored as shown in
126
Figure 4.8a. The dynamics of these events mimicked those seen in control (non- 
rotigaptide treated) cardiac myocytes. Therefore, it appears that rotigaptide has no 
apparent effects on cardiac myocyte beating rates under ischaemic or reoxygenated 
conditions.
Cardiac myocytes treated with rotigaptide (50nM) were subjected to prolonged 
ischaemia, leading to complete dephosphorylation of Cx43 after 6hrs of ischaemia 
(Figure 4.9). Similar results were seen with non-rotigaptide treated cardiac myocytes 
when exposed to ischaemia (chapter 3, figure 3.6). Reoxygenation of rotigaptide treated 
cells after 5 and 6hrs of ischaemia resulted in recovery of phosphorylated Cx43. After 
7hrs of ischaemic incubation, Cx43 phosphorylation recovered only slightly and 
synchronous beating was not resumed, following reoxygenation, as shown in Figure 4.9.
Since 50nM rotigaptide had no significant effects on beating rate or Cx43 
phosphorylation, a dose response experiment was performed, the results being displayed 
in Figures 4.8b and 4.10. The doses of rotigaptide used were lOOnM, 500nM and lfiM. 
At all doses, rotigaptide had no significant effect on cardiac myocyte beating rates, 
when compared with non-rotigaptide treated cells, as shown in Figure 4.8b. The lOOnM 
rotigaptide treated cells had reduced beating rates at the start and after reoxygenation. 
However, observations revealed that these cells were beating irregularly, i.e. not 
synchronously. Treatment of control cells with rotigaptide at the two higher 
concentrations resulted approximately in a 3-fold increase in total Cx43 expression 
(Figure 4.10). Rotigaptide treatment had no effect on Cx43 phosphorylation during 
ischaemia and reoxygenation. Any changes in Cx43 expression and phosphorylation
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during ischaemia/reoxygenation were shown to be insignificant and could not be 
reproduced consistently.
4.3.5 Effects of rotigaptide on connexin43 expression profiles in rat neonatal 
cardiac myocytes.
Immunoblot analysis of rat neonatal cardiac myocytes confirmed that Cx43 migrated 
electrophoretically as two phosphorylated forms (PI and P2 bands; 43 - 45kD), with a 
minor band at 41 kDa as shown in chapter 3 (Figure 3.1). Cx43 in rat neonatal cardiac 
myocytes also showed a 41 kDa band that was likely to be a non-phosphorylated form of 
Cx43 (Chapter 3, Figure 3.1), consistent with previous reports (Beardslee et al., 2000).
Rat neonatal cardiac myocytes treated with 50nM, lOOnM and 250nM rotigaptide for 1 
or 5hrs showed little change in Cx43 phosphorylation status using an antibody that 
recognises multiple phosphorylated isoforms of Cx43 (Beardslee et al., 2000) (Figure 
4.11a). Densitometric analysis of the gels confirmed that there was no significant 
difference between the phosphorylation status of Cx43 under control conditions or 
rotigaptide treatment detected by this antibody (Figure 4.1 lb).
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Figure 4.7: The effect of rotigaptide (ZP123) on dye transfer in HeLa cells 
expressing Cx32-GFP and Cx26-GFP
a) Confluent monolayers of HeLa cells expressing Cx32-GFP were microinjected 
with Lucifer yellow under control conditions or following treatment with 50nM, 
lOOnM or 250nM rotigaptide for 5hrs. b) Confluent monolayers of HeLa cells 
expressing Cx26-GFP were microinjected with Lucifer yellow under control 
conditions or following treatment with 50nM, lOOnM or 250nM rotigaptide for 5hrs. 
In all experiments the extent of dye spread was monitored and approximately 30 cells 
were injected per set of experiments, which were repeated in triplicate.
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Figure 4.8: The effect of rotigaptide (ZP123) on the beating rate of rat neonatal 
cardiac myocytes during ischaemia/reoxygenation
Confluent monolayers of rat neonatal cardiac myocytes were viewed under a light 
microscope and cell beating rates were recorded a) after 50nM rotigaptide treatment 
in normoxia, during ischaemia or following treatment reoxygenation after 6hr 
ischaemic insult, or b) after treatment with lOOnM, 500nM or lpM  rotigaptide in 
normoxia, during ischaemia or following treatment reoxygenation after 6hrs 
ischaemic insult (n=3).
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Figure 4.9: The effect of rotigaptide (ZP123) on the phosphorylation status of 
Cx43 during ischaemia/reoxygenation
a) Confluent monolayers rat neonatal cardiac myocytes were treated with 50nM 
rotigaptide. Cells were then subjected to normoxia, ischaemic insult for 5hrs, 6hrs or 
7hrs, or reoxygenation after 5hrs, 6hrs or 7hrs of ischaemic insult. Cell lysates 
analyzed by standard SDS-PAGE and Western blotting with an antibody targeted to 
Cx43 and a-tubulin. Lane 1 - Control; Lane 2 - 50nM rotigaptide + 5hrs ischaemia; 
Lane 3 - 50nM rotigaptide + 6hrs ischaemia; Lane 4 - 50nM rotigaptide + 7hrs
ischaemia; Lane 5 - 50nM rotigaptide + 5hrs ischaemia followed by lhr
reoxygenation; Lane 6 - 50nM rotigaptide + 6hrs ischaemia followed by lhr
reoxygenation; Lane 7 - 50nM rotigaptide + 7hrs ischaemia followed by lhr
reoxygenation, (b) Rat neonatal cardiac myocytes were treated as mentioned above. 
The graph shows the combined densitometric analysis of 2 separate Western blots. P 
= Phosphorylated Cx43; NP = non-phosphorylated Cx43.
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Figure 4.10: The effect of rotigaptide (ZP123) on the phosphorylation status of 
Cx43 during ischaemia/reoxygenation
a) Confluent monolayers rat neonatal cardiac myocytes were treated with lOOnM, 
500nM or lOOOpM rotigaptide or had no drug treatment (Control). Cells were then 
subjected to normoxia, ischaemic insult for 6hrs, or reoxygenation after 6hrs o f 
ischaemic insult. Cell lysates analyzed by standard SDS-PAGE and Western 
blotting with an antibody targeted to Cx43 and a-tubulin. Lane 1 -  Control normoxia; 
Lane 2 - lOOnM rotigaptide; Lane 3 - 500nM rotigaptide; Lane 4 - lpM  rotigaptide; 
Lane 5 -  Control 6hrs ischaemia; Lane 6 - lOOnM rotigaptide + 6hrs ischaemia; Lane 
7 - 500nM rotigaptide + 6hrs ischaemia; Lane 8 - lpM  rotigaptide + 6hrs ischaemia; 
Lane9 -  Control 6hrs ischaemia followed by lhr reoxygenation; Lane 10 - lOOnM 
rotigaptide + 6hrs ischaemia followed by lhr reoxygenation; Lane 11 - 500nM 
rotigaptide + 6hrs ischaemia followed by lhr reoxygenation; Lane 12 - lpM  
rotigaptide + 6hrs ischaemia followed by lhr reoxygenation, (b) Rat neonatal cardiac 
myocytes were treated as mentioned above. The graph shows the combined 
densitometric analysis of 2 separate Western blots. P = Phosphorylated Cx43; NP = 
non-phosphorylated Cx43.
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Figure 4.11: The effect of rotigaptide (ZP123) on the phosphorylation status of 
Cx43
a) Confluent monolayers rat neonatal cardiac myocytes were treated with 50, 100 or 
250nM rotigaptide for 1 or 5hrs and cell lysates analyzed by standard SDS-PAGE 
and Western blotting with an antibody targeted to Cx43 and a-tubulin. Lane 1 - 
Control; Lane 2 - 50nM rotigaptide for lhr; Lane 3 - lOOnM rotigaptide for lhr; Lane 
4 - 250nM rotigaptide for lhr; Lane 5 - 50nM rotigaptide for 5hrs; Lane 6 - lOOnM 
rotigaptide for 5hrs; Lane 7 - 250nM rotigaptide for 5hrs. (b) Rat neonatal cardiac 
myocytes were treated with 50, 100 or 250nM rotigaptide for 1 or 5hrs. The graph 
shows the combined densitometric analysis of 4 separate Western blots. P = 
Phosphorylated Cx43; NP = non-phosphorylated Cx43.
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4.3.6 Effects of rotigaptide on connexin43-GFP distribution and expression levels
The inherent autofluorescent properties of Cx43-GFP permitted analysis of the effect of 
rotigaptide on Cx43-GFP expression in live cells by FACS analysis. The results showed 
that exposure of cells to rotigaptide did not change the overall level of Cx43-GFP 
fluorescence (Figure 4.13). Further studies using confocal microscopy determined that 
treatment of the cells with 50nM rotigaptide also had little effect on the cellular 
distribution of Cx43-GFP, with the protein located predominantly at areas of cell-to-cell 
contact probably corresponding to gap junction plaques (Figure 4.12e and f). 
Immunofluorescent analysis of HeLa cells expressing wild type Cx43 before and 
following treatment with 50nM, lOOnM or 250nM rotigaptide illustrated that the 
peptide did not change the distribution of Cx43 within the cell with similar patterns of 
Cx43 gap junction plaques seen at areas of cell-to-cell contact under each treatment 
group (Figure 4.12a-d).
4.3.7 Effects of rotigaptide on connexin43 expression profiles in transfected HeLa 
cells.
Under control conditions, Cx43-GFP migrated at ~70kDa and band intensity increased 
following 18-24hrs treatment with sodium butyrate i.e. at times when dye transfer 
studies were performed (Figure 4.14a). A further band, at ~81kD was confirmed as a 
phosphorylated isoform of Cx43-GFP in these cells (Figure 4.14a) since the chimera 
was dephosphorylated by alkaline phosphatase treatment. Parallel data from HeLa cells 
expressing wild type Cx43 gave similar results.
The effect of rotigaptide on the phosphorylation status and expression of Cx43-GFP in 
HeLa cells was studied. After treatment with rotigaptide (50nM) for l-5hrs in the
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presence or absence of 18aGA (25pM), the phosphorylation status of Cx43-GFP, after 
5hrs treatment of the cells with rotigaptide (50nM) remained unaltered (Figure 4.14c 
and d). However, preincubation of cells with the gap junction inhibitor 18aGA reduced 
the phosphorylation of Cx43-GFP; phosphorylation of Cx43 was similarly reduced 
following incubation with 18aGA in the rotigaptide treated cells (Figure 4.14b).
Rotigaptide is reported to stimulate protein kinase C (Dhein et al., 2003) and it is 
possible that the antibodies used in the current work failed to detect significant changes 
in phosphorylation at specific sites. We therefore investigated the effects of rotigaptide 
on Cx43 expression using an antibody specifically recognising the Ser368 
phosphorylation site that is reported to be phosphorylated by protein kinase C (Lampe et 
al., 2000). Treatment of cells with TP A, a potent activator of protein kinase C (Lampe 
et al., 2000), confirmed that phosphorylation of Cx43 and Cx43-GFP at position ser368 
occurred (Figure 4.15b and c). HeLa cells expressing wild type Cx43 under control 
conditions, following TPA treatment and 5hrs treatment with 50nM rotigaptide were 
also probed with another antibody that detects multiple Cx43 isoforms (Rivedal et al.,
1996). In both cases, there was no indication of alteration in the amount of Cx43 
expressed following rotigaptide treatment, but it was noted that substantial 
phosphorylation occurs following TPA treatment (Figure 4.15a and b).
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Figure 4.12: The effect of rotigaptide (ZP123) on Cx43 spatial localisation
Confluent monolayers of HeLa cells expressing wild type Cx43 were fixed and 
stained with a monoclonal antibody targeted to Cx43 following (a) Control 
conditions, (b) preincubation with 50nM rotigaptide for 5hrs, (c) preincubation with 
lOOnM rotigaptide for 5hrs, (d) preincubation with 250nM rotigaptide for 5hrs. 
Confluent monolayers of HeLa cells expressing Cx43-GFP and its intracellular 
distribution was assessed e) under control conditions and f) following 50nm 
rotigaptide treatment. It also appears that when GFP is tagged to Cx43 there is also 
greater accumulation of Cx43-GFP in the cytoplasm. Nuclei were stained with 
propidium iodide. The white arrows point to Cx43 gap junction plaques. Bar = 20pm 
(a-d) or 10pm (e-f).
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Figure 4.13: The effect of rotigaptide (ZP123) on Cx43-GFP expression.
Cx43-GFP expressing HeLa cells were subject to FACS analysis and the % of cells 
expressing Cx43-GFP recorded following treatment for 1 and 5hrs with 50 and 
250nM ZP123 respectively (n=3).
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Figure 4.14: The effect of rotigaptide and 18aGA on Cx43-GFP expression
a) Confluent monolayers of HeLa cells expressing Cx43-GFP were lysed under 
control conditions or following treatment with 50nM rotigaptide for 5hrs. Cell 
lysates were digested with alkaline phosphatase for lhr at 37°C followed by SDS- 
PAGE and Western blotting with antibodies to Cx43. b) Cx43-GFP HeLa cells were 
treated with 50nM rotigaptide and or 25pM 18aGA. c) Cx43-GFP HeLa cells were 
treated with 50, 100 or 250nM rotigaptide for 5hrs. d) The graph shows the 
combined densitometric analysis of three separate Western blots following treatment 
of Cx43-GFP HeLa cells with 50, 100 or 250nM rotigaptide for 5hrs. PI = 
Phosphorylated Cx43; NP = non-phosphorylated Cx43.
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Figure 4.15: Analysis of Cx43 serine 368 phosphorylation
a) (i) HeLa cells expressing wild type Cx43 were probed with an antibody 
specifically targeted to the carboxyl tail of Cx43 under control conditions, treated 
with lOOng/ml TPA for 30mins or with 50nM rotigaptide for 5hrs prior to harvesting 
and Western blot analysis, (ii) a-tubulin staining, b) (i) Cx43 expressing HeLa cells 
were probed with an antibody specifically targeted to serine 368 on the carboxyl tail 
of Cx43 under control conditions, treated with lOOng/ml TPA for 30mins or with 
50nM rotigaptide for 5hrs prior to harvesting and Western blot analysis, (ii) a-tubulin 
staining, c) (i) HeLa cells expressing Cx43-GFP were probed with an antibody 
specifically targeted to serine 368 on the carboxyl tail of Cx43 under control 
conditions, treated with lOOng/ml TPA for 30mins or with 50nM rotigaptide for 5hrs 
prior to harvesting and Western blot analysis, (ii) a-tubulin staining, (d) 
Densitometric analysis of ser 368 phosphorylation in Cx43-GFP expressing HeLa 
cells. All blots were performed in triplicate.
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4.4 Discussion
The specificity and effects of rotigaptide, an antiarrhythmic peptide, on intercellular 
communication across gap junctions in HeLa cell model systems and in cardiac cells 
was studied. In heart, gap junctions provide low resistance intercellular channels that 
facilitate synchronous contraction of the myocytes (Kleber & Rudy 2004). Since 
disturbed myocardial coupling is implicated in arrhythmogenesis (Severs et al., 2004; 
Xing et al., 2003) it is likely that drugs that modulate the extent of inter-myocyte 
communication via gap junctions may influence synchronisation and rhythmicity of 
contraction in the myocardium. The mechanism of action of such drugs should reveal 
new therapeutic approaches to understanding and correcting arrhythmia.
Rotigaptide is a stable analogue of the antiarrhythmic peptide AAP10 (Muller et al.,
1997). Its increased stability compared to AAP10 results in protracted action since D- 
amino acids are less prone to degradation by proteases than L-amino acids. Rotigaptide 
has an in vitro half-life in human plasma of 14 days compared to 3-4 minutes for 
AAP10 (Kjolbye et al., 2003). Previous studies have shown that AAP10 enhanced 
conductance in adult cardiac myocytes and in HeLa cells expressing Cx43 (Dhein et al., 
2001). Rotigaptide prevented re-entrant ventricular tachycardia during myocardial 
ischaemia in dogs (Xing et al., 2003). Although some effects of rotigaptide on cardiac 
electrophysiology and Cx43 mediated communication have been studied (Dhein et al., 
2003; Eloff et al., 2003) its influence on other functional properties of gap junctions 
were unknown.
The present results show that rotigaptide increased gap-junctional intercellular 
communication in cells expressing Cx43 as monitored by the direct intercellular transfer
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of fluorescent dyes. This increased communication was demonstrated in HeLa cells 
expressing wild type Cx43 and Cx43-GFP, but was not observed in HeLa cells 
expressing wild type Cx26, Cx26-GFP or Cx32-GFP. Although some connexins used in 
the present work were fused to GFP at its carboxyl terminus, HeLa cells expressing 
Cx43-GFP, Cx32-GFP and Cx26-GFP were shown previously to be electrically and dye 
coupled and to propagate intercellular Ca2+ waves to each other via gap junctions 
(Paemeleire et al., 2000) or CxHcs (Bukauskas et al., 2000; Contreras et al., 2002). 
Fluorescent and non-fluorescent wild type Cx43 expressing channels show similar 
functional characteristics in a variety of cell types, although subtle differences in 
channel gating have been reported (Bukauskas et al., 2000; 2002; Paemeleire et al., 
2000). The present studies show that rotigaptide acts on both wild type and chimeric 
Cx43 but not on Cx32 and Cx26 chimeric channels. Increased intercellular dye 
coupling was also observed in beating neonatal cardiac myocytes and a cell line derived 
from cardiac atria that possesses cardio-specific properties (Claycomb et al., 1998). 
Cx43 is the dominant gap junction protein in both cell types but all express low amounts 
of Cx40 (unpublished data from our laboratory). The enhancing effect on Cx43 dye 
coupling via gap junctions occurred after 5 hours exposure to rotigaptide. In contrast, 
the accelerated transmission of electrical signals following rotigaptide treatment was 
observed within 15 minutes using isolated guinea pig ventricular myocytes and rat atrial 
strip preparations (Haugan et al., 2005; Xing et al., 2003). These differences in the 
speed of action suggest that rotigaptide may act rapidly on electrical coupling across 
gap junctions followed later by an increase in the spread of larger molecules/ions across 
the junctions. Despite the enhanced propagation of dye now reported and the increase 
in electrical coupling (Eloff et al., 2003; Haugan et al., 2005), rotigaptide had no effect 
on the overall synchronisation and contraction rate of the cardiac myocytes and the
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spatial localisation of Cx43 in cells was unaltered, in our cardiomyocytes model. 
Furthermore, even after exposure of cells to rotigaptide for 5 hours, the overall 
expression level of Cx43 the HeLa cell model or in neonatal cardiac myocytes was 
unchanged.
The present study has also shown that rotigaptide does not affect ischaemic cardiac 
myocytes. After cells were exposed to prolonged ischaemia (5-7hrs), rotigaptide had no 
apparent effect on the dynamics of the response of cells to this insult (Chapter 3). 
Indeed the beating rate and Cx43 phosphorylation remained similar to that in cells not 
treated with rotigaptide. It is unsurprising, but encouraging, that rotigaptide has little 
effect on cells that are beating normally and in synchrony and that its effects may be 
limited to cells that beat asynchronously.
Exposure of cells for 30 minutes to AAP10 and rotigaptide has been associated with 
enhanced PKC activity in HeLa cells expressing Cx43 (Weng et al., 2002) suggesting 
that rotigaptide influenced phosphorylation of Cx43 via a protein kinase C dependent 
mechanism associated with enhanced electrical communication and these studies 
implicated a 200kDa plasma membrane protein (Weng et al., 2002). Phosphorylation of 
Cx43 may be linked to the control of gap junction mediated communication during 
connexin biogenesis and degradation (Laird 2005) and in the response of cardiac 
myocytes to normoxia and hypoxia (Lampe & Lau 2004; Turner et al., 2004). 
Activation of PKC results in phosphorylation of several serine sites including Ser368 
and Ser 262 located near the carboxyl terminal tail of Cx43 (Lampe & Lau 2004). 
However, no detectable changes in the phosphorylation status or expression levels of 
Cx43 were observed following rotigaptide treatment by Western blot analysis,
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examined using a range of antibodies that detect multiple Cx43 phosphorylated 
isoforms or a specific protein kinase C phosphorylation site (Serine 368) (Lampe et al., 
2000). Control experiments using the phorbol ester TPA, a potent inducer of protein 
kinase C (Lampe et al., 2000), showed that Cx43-GFP is subject to protein kinase C 
dependent phosphorylation at serine 368 further demonstrating that the attached GFP 
reporter protein does not modify normal Cx43 function. To determine ultimately 
whether rotigaptide modulates the phosphorylation status of Cx43 may require other 
techniques such as mass spectrometry to detect whether specific phosphorylation 
modifications occur after treatment with the peptide (Axelsen et al., 2006). It was also 
noteworthy that the Cx26-GFP and Cx32-GFP expressing HeLa cells were unaffected 
by rotigaptide and that these modified connexins were either not phosphorylated or 
were subject to minor phosphorylation (Lampe & Lau 2004).
Intercellular communication across gap junctions in cells expressing various connexins, 
including homotypic Cx43, 32 and 26 have been extensively studied
electrophysiologically (Harris 2001) and by dye coupling (Cao et al., 1998; Elfgang et 
al., 1995). These studies have shown that connexin channels show differential 
permeabilities to a range of dyes, including those currently studied. The present data 
indicate that rotigaptide selectively influences homotypic gap junctions constructed of 
Cx43, but was without effect on gap junctions constructed of Cx26 and 32. However, it 
is noteworthy that any relationship between gap junction permeability and gap junction 
conductance is yet to be elucidated.
The highly specific effect of rotigaptide on gap junction intercellular communication is 
further supported by radioligand binding assays in which rotigaptide displayed only
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weak binding affinity to 80 different receptors and ion channels including K+ ATP 
channels and dopamine (Haugan et al., 2005). Further analysis of the selective action of 
rotigaptide on connexins, to supplement electrophysiological studies in cardiac tissue 
(Eloff et al., 2003) are expected to elucidate the biochemical mechanisms that result in 
the action of rotigaptide occurring at Cx43 gap junctions but not on junctions constructed 
of Cx26 and Cx32.
The emergence of rotigaptide as an enhancer of intercellular communication across gap 
junctions constructed of Cx43 supports the view that it shows promise for further 
development as a therapeutic tool for modulating acute cardiac arrhythmias.
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Chapter 5
Simulated ischaemia induces ATP release from Connexin 
hemichannels in rat neonatal cardiac myocytes
5.1 Introduction
Cardiac tissue and its constituent myocytes exposed to hypoxia undergo a number of 
changes, including remodelling involving changes in Cx43 expression and in 
electrical conduction velocity. A well established metabolic response to hypoxia by 
cardiac myocytes involves an increased release of ATP (Forrester & Williams 1977). 
It is possible that this response to hypoxia and ischaemia could be a fundamental 
property of cardiac myocytes and possibly other cells in various tissues but to a 
different extent. In the heart, ATP release may have an effect on coronary circulation 
and also induce changes in cardiac arrhythmia.
5.1.1 ATP is released across connexin hemichannels (CxHcs)
Cells release ATP by various mechanisms, including the emptying of secretory 
vesicles hitting the plasma membrane, by ABC transporter proteins (Lazarowski et al.,
2003) and a large ATP dependent plasma membrane anion channel (Dutta et al.,
2004). More recently, CxHcs have emerged as a further release pathway for purines 
including ATP, implicating a role in paracrine intercellular signalling (Braet et al., 
2003; Stout et al., 2002). As discussed in chapter 1, CxHcs are high conductance un­
apposed hexameric channels located in the plasma membrane (Martin & Evans 2004; 
Saez et al., 2003). CxHcs are normally maintained in a closed configuration, but have 
been shown to open under stress allowing release from the cell of ATP, NAD+, 
glutamate and prostaglandins (Bennett et al., 2003; Bruzzone et al., 2001; Cherian et 
al., 2005; Ebihara 2003; Goodenough & Paul 2003). CxHcs have been detected in 
isolated primary cardiac myocytes and a range of cell cultures (Evans et al., 2006; 
Kondo et al., 2000). They can be opened by metabolic inhibition and low 
extracellular Ca2+ levels in various cell types (Contreras et al., 2002; Kondo et al.,
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2000), hypo-osmotic challenges (John et al., 2003) and high intracellular Ca2+ levels 
induced by the photoliberation of IP3 (Leybaert et al., 2003).
5.1.2 Purinergic signalling in the cardiovascular system
Extracellular ATP binds to cell surface P2Y and P2X receptor classes; the former are 
seven trans-membrane domain G-protein linked receptors and the latter are 
transmitter-gated cation channels (Bumstock 2006; North 2002). ATP binds to P2Y 
receptors in vascular endothelium and smooth muscle, regulating vascular tone 
(Bumstock 1999). Binding and activation of the P2Y receptor by ATP leads to Ca2+ 
activation of eNOS and the production of nitric oxide, a potent endothelium-derived 
vasodilator (Bumstock 1999). In addition, adenosine, a breakdown product of ATP, 
acts on PI receptors resulting in vasodilation (Bumstock 2002). Adenosine has also 
been shown to have several cardiovascular protective effects, including the promotion 
of endothelial cell proliferation (Bumstock 2006).
5.1.3 Chapter Aims
Investigations described in this chapter were carried out to determine the dynamics of 
cardiac myocyte Cx43Hc opening during a physiological model of ischaemia 
involving profound hypoxia with glucose depletion. Relationships between CxHc 
opening during ischaemia and extracellular and intracellular ATP levels were studied 
and the question addressed as to whether ATP levels can be maintained within 
physiological limits by inhibition/blockage of open CxHcs. The temporal relationship 
between Cx43 dephosphorylation and hemichannel opening during ischaemia was 
also examined. The studies can lead to a better appreciation of the therapeutic value
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of peptides that inhibit or enhance gap junction communication, especially in the 
context of their potential future use as myocardial protective agents following 
ischaemia.
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5.1 Methods
5.2.1 Materials
AAP10 was supplied by Zealand Pharma (Glostrop, Denmark) and dissolved in water 
to give a 50pM stock and 18aGA (Sigma, UK) was dissolved in DMSO to give a 
25mM stock. GAP 26 and GAP 26 scrambled peptide were dissolved in (IH2O and 
was synthesized by Sigma-Genosys (Cambridge, UK). All other reagents were 
obtained from Sigma (Poole, U.K).
5.2.2 Cell culture
Rat neonatal cardiac myocytes were prepared and plated as described in chapter 2 
(Clarke et al., 2006; Turner et al., 2004). Cells were maintained cDMEM with BrDu 
(0.1 mM) for the first 3 days and thereafter in serum-free medium as described in 
section 2.2.2.
5.2.3 Hypoxia and Ischaemia treatments
Cardiac myocytes were rendered hypoxic in a hermetically sealed environmental 
chamber (InVivo2 Hypoxic workstation 400 with Ruskinn gas mixer) with a 
humidified atmosphere at 37°C containing 0.5% O2, 5% CO2 and nitrogen to balance 
as previously described (Turner et al., 2004). Hypoxic cells were maintained in 
serum-free DMEM supplemented as shown above and containing 3gL‘1 glucose. To 
simulate ischaemia, cardiac myocytes were maintained in supplemented serum-free 
DMEM containing 0.2gL_1 glucose and placed within the hypoxic chamber with 0.5% 
O2. Control cells were maintained in ambient (21%) O2 and 5% CO2 conditions at 
37°C in a standard tissue culture incubator (Heraeus® HERAcell® 150).
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5.2.4 Drug treatments
Cells were treated with the following drugs and peptides: 50pM 18a-glycyrrhetinic 
acid; 300pM GAP 26, a connexin mimetic peptide specific to Cx43 that has a 
sequence of VCYDKSFPISHVR; 50nM AAP10, an anti-arrhythmic peptide that has a 
sequence of Gly-Ala-Gly-Hyp-Pro-Tyr; 300pM GAP 26 scrambled peptide, a non­
functional version of GAP 26 with a sequence of CVDISKYRHSVFP. Cells were 
exposed to the agents for the duration of the experiments.
5.2.5 ATP measurements
ATP was measured using a luciferase-luciferin based luminescence assay (Sigma, 
USA) as described in section 2.5. For extracellular ATP measurements, cell culture 
medium was removed at specific time points, centrifuged at 250g for 4mins and 
supernatants analysed for ATP content, as described in 2.5. Intracellular ATP 
measurements were made as described in section 2.5.2.
5.2.6 Lactate dehydrogenase measurements
Lactate dehydrogenase (LDH) content of media used to incubate cells was measured 
using a colourmetric assay (Sigma, USA). NAD reduced to NADH resulted in the 
stoichiometric conversion of a tetrozolium dye, measured colourimetrically. Cell 
culture medium was removed at specific time points, centrifuged at 250g for 4mins 
and analysed for LDH content (Decker & Lohmann-Matthes 1988).
5.2.7 Western blot analysis
Rat neonatal cardiac myocytes grown on 60mm dishes (4xl06) were subjected to 
ischaemia for periods of 1 to 7hrs, or hypoxia for 5 or lOhrs prior to harvesting as
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described in 2.4.1. Equal amounts (lOOfig) of protein were analysed by SDS-PAGE 
(10% w/v) (described section 2.4.3) and transferred to nitrocellulose membrane for 
3hrs at 300mA. The resulting blots were probed with a polyclonal antibody to Cx43 
(Zymed, USA; 1:4000 dilution) that recognises multiple phosphorylated or 
nonphosphorylated isoforms of Cx43 and a secondary goat anti rabbit horseradish 
peroxidase antibody (1:2000 dilution). Blots were developed by enhanced 
chemiluminescene (ECL) and quantified using a Biorad GS-700 densitometer (Martin 
et al., 2004).
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5.3 Results
5.3.1 Ischaemia causes a transient release of extracellular ATP
Extracellular and intracellular ATP levels were stable for 120mins in normoxic 
conditions before cells were subjected to ischaemia or hypoxia (Figure 5.1). After the 
first 60mins of ischaemia, neonatal cardiac myocytes still maintained their ATP 
content with no perceptible change observed in extracellular and intracellular ATP 
levels. However, after approximately 80mins of ischaemia, ATP release increased 
substantially (166% ± 16.9 of pre-ischaemic values) (Figure 5.1a), and then returned 
to ATP levels similar to those prior to this peak of release. These ‘basal’ ATP levels 
were again maintained for a further 240mins of ischaemia until they steadily 
decreased over the following 300mins of ischaemia. Relatively little released ATP 
was detected between 360-600mins.
Intracellular ATP levels measured concurrently also remained approximately constant 
but then decreased steadily after 120mins of ischaemia over the subsequent 8hrs to 
29.0% ± 3.9 of initial levels (Figure 5.1b). However, this ATP loss was largely 
reversed after transfer to a normoxic environment following 6 and 8hrs of ischaemia 
with intracellular ATP levels recovering to 78.5% ± 13.2 and 75.2% ± 13.3 
respectively. When the myocytes were reoxygenated following lOhrs of ischaemia, a 
much smaller recovery of intracellular ATP levels was observed (Figure 5. lb).
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Figure 5.1: The effect of ischaemia and hypoxia on extra- and intra-cellular 
ATP levels in rat neonatal cardiac myocytes.
Confluent monolayers of rat neonatal cardiac myocytes were made either ischaemic 
(Isch) or hypoxic (Hyp) as described in the methods, (a) Extracellular medium was 
sampled at determined time points during treatment and then analysed for ATP 
content; **P<0.01 unpaired T-test. (b) Cells were harvested in 5% TCA at 
determined time points during treatment and then analysed for intracellular ATP 
content; ischaemia (n=7); hypoxia (n=4).
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Figure 5.2: The effect of the gap junction inhibitor GAP 26 on extra- and 
intra-cellular ATP levels in rat neonatal cardiac myocytes during ischaemia.
Confluent monolayers of rat neonatal cardiac myocytes were made ischaemic 
(Isch) as described in the methods and treated with 300}iM GAP 26 or 300pM 
Scrambled (Serb) GAP 26 at the beginning of the timecourse. (a) Extracellular 
medium was sampled at determined time points during treatment and then analysed 
for ATP content, (b) Cells were harvested in 5% TCA at determined time points 
during treatment and then analysed for intracellular ATP content. Ischaemia (n=7) 
**P<0.01 unpaired T-test; Ischaemia + GAP 26 (n=4); Ischaemia + Scramble GAP 
26 (n=4).
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5.3.2 Gap junction channel inhibitors block the transient release of ATP
Exposure of ischaemic myocytes to GAP26, a specific gap junction inhibitor, 
markedly reduced the transient peak of ATP release that occurred after 80mins 
(Figure 5.2a); a scrambled GAP26 peptide used as a control was without effect. 
Furthermore, extracellular ATP levels in myocytes exposed to GAP26 were generally 
much lower than control levels throughout ischaemia (e.g. 21.0% ± 7.9 after 80mins).
A further gap junction inhibitor, 18aGA, produced a similar response by attenuating 
the transient ATP release that was observed consistently at 80mins of ischaemia 
(Figure 5.3a).
Intracellular ATP levels in ischaemic myocytes exposed to GAP26 and 18aGA 
decreased after the first 60mins of ischaemia but then recovered, and after this time 
the level of intracellular ATP was similar to that observed in ischaemia. However, 
ATP loss by the cells then increased after 8hrs (12.9% ± 2.4 GAP26; 23.8% ± 2.9 
18aGA) (Figure 5.2b & 5.3b). The scrambled GAP26 peptide caused a greater 
decrease in intracellular ATP levels after 6 or 8hrs (Figure 5.2b), compared to cardiac 
myocytes treated with ischaemia.
5.3.3 The effect of AAP10 on extra- and intracellular ATP during ischaemia
Treatment of myocytes with AAP10 during ischaemia resulted in a 2-3 fold increase 
in ATP release (313% ± 48.4), and this peak observed at 80mins was followed by a 
less pronounced second peak of ATP release at 180mins (229% ± 55.3) (Figure 5.4a). 
At later time periods, ATP returned to control levels and continued to decrease 
steadily, eventually reaching zero after 6hrs of ischaemia. Ischaemic cardiac
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myocytes treated with AAP10 showed a steady decrease in intracellular ATP levels, 
with slight fluctuations. In comparison, in the absence of the peptide myocytes 
subjected to ischaemia showed a lesser decrease in intracellular ATP levels after 6 or 
8hrs (Figure 5.4b).
5.3.4 Cardiac myocytes remain intact during hypoxia and short periods of 
ischaemia
LDH release from cardiac myocytes remained around basal levels up to 180mins of 
ischaemic treatment but at later times, they increased gradually over 360mins. 
Thereafter, LDH increased sharply especially after 8hrs of ischaemia (Figure 5.5a). 
Lower LDH levels were recorded in hypoxia, and the marked increase seen in 
ischaemia at later times was not observed (Figure 5.5b). The addition of GAP 26 and 
18aGA had no significant effect on LDH release from cardiac myocytes during 
ischaemia and hypoxia.
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Figure 5.3: The effect of the gap junction inhibitor 18«GA on extra- and intra­
cellular ATP levels in rat neonatal cardiac myocytes during ischaemia.
Confluent monolayers of rat neonatal cardiac myocytes were made ischaemic 
(Isch) as described in the methods and treated with 50pM 18aGA at the beginning 
of the timecourse. (a) Extracellular medium was sampled at determined time 
points during treatment and then analysed for ATP content, (b) Cells were 
harvested in 5% TCA at determined time points during treatment and then analysed 
for intracellular ATP content. Ischaemia (n=7) **P<0.01 unpaired T-test; 
Ischaemia + 18aGA (n=6).
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Figure 5.4: The effect of the anti-arrhythmic peptide AAP10 on extra- and 
intra-cellular ATP levels in rat neonatal cardiac myocytes during ischaemia.
Confluent monolayers of rat neonatal cardiac myocytes were made ischaemic 
(Isch) as described in the methods and treated with 50nM AAP10. (a) Extracellular 
medium was sampled at determined time points during treatment and then analysed 
for ATP content, (b) Cells were harvested in 5% TCA at determined time points 
during treatment and then analysed for intracellular ATP content. Ischaemia (n=7) 
**P<0.01 unpaired T-test; Ischaemia + AAP10 (n=4).
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Figure 5.5: The effect of ischaemia and hypoxia on lactic dehydrogenase 
(LDH) leakage from cardiac myocytes.
(a) Extracellular medium from confluent monolayers of ischaemic (Isch) rat 
neonatal cardiac myocytes were treated with prolonged ischaemia alone, 18aGA or 
GAP 26 and then assessed for LDH content, (b) Extracellular medium from 
confluent monolayers of hypoxic (Hyp) rat neonatal cardiac myocytes were treated 
with prolonged hypoxia alone or 18aGA and then assessed for LDH content. (For 
all treatments n=4)
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5.3.5 Ischaemia causes dephosphorylation of Cx43 and cessation of 
synchronous contraction in cardiac myocytes
Exposure of beating cardiac myocytes to ischaemia resulted in the phosphorylated 
component of Cx43 being maintained for up to 4hrs of insult, thus encompassing the 
period when the characteristic peaks of ATP release observed (Chapter 3, Figure 3.3). 
However, after 5 and lOhrs of ischaemia, the phosphorylated component of Cx43 had 
decreased from 69.2% to 30.6% and 18% of initial total Cx43 values respectively 
(Figure 5.6). Rat neonatal cardiac myocytes contracted synchronously at 150-210 
beats per minute, but exposure to ischaemia caused the cell beating rate to steadily 
decrease until after 240mins when beating stopped (Figure 5.7).
5.3.6 Effects of hypoxia on ATP levels, Cx43 expression and myocyte 
contraction
In contrast to the effects of ischaemia, hypoxia had little effect on extracellular ATP 
levels, which remained approximately constant in cardiac myocytes (Figure 5.1a). In 
hypoxic myocytes exposed to 50pM 18aGA, ATP levels fluctuated slightly but 
showed little overall change until about 240mins when they decreased steadily 
(Figure 5.8a), possibly due to the cytotoxic effects of prolonged exposure to 18aGA. 
Intracellular ATP levels in hypoxic myocytes decreased to approximately 15% less 
than the basal level and were maintained for the duration of the 8hrs treatment (Figure 
5.1b), with 50pM 18aGA also having little effect (Figure 5.8b). Exposure to 
prolonged (8hrs) hypoxic insult had little effect the synchronous beating rate that 
remained approximately constant (Figure 5.7). Also, lOhrs hypoxia resulted in little 
change Cx43 phosphorylation status (Figure 5.9).
160
C ontrol 
Ischaem ia 5h rs  10hrs
b) 10CH
® c11 o  »
~ x
Control 5hrs 10hrs
Ischaem ia
Non phosphorylated Cx43 
Phosphorylated Cx43
Figure 5.6: The effect of ischaemia on the phosphorylation status of Cx43
a) Confluent monolayers of rat neonatal cardiac myocytes were subjected to 
ischaemia for 5 and lOhrs and the cell lysates analyzed by standard SDS-PAGE 
and Western blotting with an antibody targeted to Cx43, Lane 1 - Control; Lane 2 - 
5hrs ischaemia; Lane 3 - lOhrs ischaemia. (b) Rat neonatal cardiac myocytes were 
treated as mentioned above. The graph shows the densitometric analysis o f the 
Western blot.
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Figure 5.7: The effect of ischaemia or hypoxia on beating rates of cardiac 
myocytes.
Confluent monolayers of rat neonatal cardiac myocytes were viewed under a light 
microscope and cell beating rates were recorded throughout an ischaemic or 
hypoxic timecourse. Ischaemic cells were reoxygenated at 6, 8 and lOhrs and 
beating rates were recorded after 30mins in normoxia. (n=3)
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Figure 5.8: The effect of 18aGA on extracellular ATP levels in rat neonatal 
cardiac myocytes during hypoxia.
Confluent monolayers of rat neonatal cardiac myocytes were made hypoxic (Hyp) 
as described in the methods. The cells were then treated with 50pM 18aGA at the 
beginning of the timecourse. (a) Extracellular medium was sampled at determined 
time points during treatment and then analysed for ATP content, (b) Cells were 
harvested in 5% TCA at determined time points during treatment and then analysed 
for ATP content. Hypoxia (n=4); Hypoxia + 18aGA (n=4).
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Figure 5.9: The effect of hypoxia on the phosphorylation status of Cx43
a) Confluent monolayers of rat neonatal cardiac myocytes were subjected to 
hypoxia for 5 and lOhrs and the cell lysates analyzed by standard SDS-PAGE and 
Western blotting (equal amounts of protein were run) with an antibody targeted to 
Cx43, Lane 1 - Control; Lane 2 - 5hrs hypoxia; Lane 3 - 6hrs hypoxia, (b) Rat 
neonatal cardiac myocytes were treated as mentioned above. The overall 
expression appears, by eye, to be greater in hypoxia than in normoxia. The graph 
shows the densitometric analysis of the Western blot.
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5.4 Discussion
The results of the present study show that there is low level ATP release by cultured 
cardiac myocytes that increases under conditions of ischaemic stress. The data 
strongly suggests that the general and especially a peak of ATP release at 80 minutes 
of ischaemia occurs through CxHcs, since it was blocked by the connexin mimetic 
peptide GAP 26 and 18aGA. In contrast, the antiarrhythmic peptide, AAP10, 
enhanced ATP release by ischaemic myocytes. The ATP concentration measured in 
media used to incubate neonatal cardiac myocytes in the hypoxic chamber was 
4.78 ± 0.764nM. Values for myocyte intracellular ATP was 9.09 ± 1.298mmol 
ATP/mg of protein. The extracellular ATP level corresponds closely to that 
determined in human airway epithelial cells located close to the plasma membrane 
and using a different method of measurement (Okada et al., 2006).
CxHcs were previously regarded as evanescent precursors of gap junctions, structures 
that are essentially two hemichannels in opposition and providing a direct 
communication channel between cells (Evans et al., 2006; Martin & Evans 2004). 
However, CxHcs are emerging as plasma membrane channels with unitary 
conductances that vary according to Cx subtype (Saez et al., 2005). CxHcs have been 
the subject of intense research, with many mechanisms of channel opening being 
highlighted. The most common strategies for studying the gating of CxHcs involve 
the manipulation of extracellular ion concentrations, especially low extracellular Ca2+ 
(Contreras et al., 2003; Quist et al., 2000), in addition to low concentrations of other 
extracellular ions such as Mg2+ (Contreras et al., 2003), Cl" (Kondo et al., 2000) and 
Na+ (John et al., 1999). Depolarisation is another method utilised along with sheer 
stress (Cherian et al., 2005), point mechanical stimulation (Gomes et al., 2005;
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Romanello et al., 2003), negative pressure (Bao et al., 2004) and osmolarity changes 
(John et al., 2003; Quist et al., 2000).
The present studies allow ischaemic stress to be added to the list of those changes, 
especially environmental, that open CxHcs. Another study (Thompson et al., 2006) 
has also shown that ischaemia opens hemichannels in neuronal cells and although the 
protein nature of the neuronal channels was not investigated, it was proposed that they 
were pannexins and not connexins. The precise mechanisms involved in CxHc 
opening under these conditions are unknown but it is highly likely that changes in 
phosphorylation could be involved (De Vuyst et al., 2006). CxHcs have been shown 
to be inhibited by activation of kinases such as PKC and v-Src (Bao et al., 2004; 
Lampe & Lau 2004), and therefore dephosphorylation could result in increased 
channel opening under these conditions.
In the present study, ischaemia caused ATP (molecular mass 501 Da) but not LDH 
(molecular mass 140kDa) to be released from cardiac myocytes. Extracellular LDH 
increased during ischaemia, as expected, but the increase appeared to be due to a 
steady leakage followed by a vast release as ischaemia continued. This indicates that 
the plasma membrane remains intact and only allows a small leakage until 
approximately 6-7 hours of ischaemia when the plasma membrane’s permeability is 
seriously compromised. ATP release during ischaemia was low until a peak appeared 
at around 80 minutes. This suggests that cells have a mechanism to regulate the loss 
of ATP via CxHcs. The results indicate that there is a basal release of ATP from 
cardiac myocytes during normoxia and ischaemia and this is prevented by GAP26 and
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18aGA, indicating that much of the ATP release from cells is most likely to be 
through CxHcs.
ATP released from cells through CxHcs adds further information to how cardiac cells 
respond to conditions of low oxygen. ATP and its breakdown products are known to 
influence movement of blood through the vasculature by causing blood vessel 
relaxation via purinergic receptors. ATP released from cells dilates blood vessels and 
thus facilitates increased oxygen delivery to the heart. ATP is converted via ecto- 
apyrase (CD39) to AMP, which is then further processed to adenosine by ecto - 5’- 
nucleotidase (CD73), and both metabolites are well characterised modulators of 
cardiac function (Eltzschig et al., 2006). Adenosine is also a biochemical mediator of 
bradyarrhythmias associated with hypoxia and ischaemia (Belardinelli 1987). Indeed, 
in addition to adenosine, ATP and other adenosine nucleotides have been known for a 
long time to cause atrioventricular block (Drury & Szent-Gyorgyi 1929). More 
recently, adenosine was shown to induce cardiac arrhythmia and especially 
ventricular automaticity (Hernandez & Ribeiro 1996).
In the present studies, hypoxia was tolerated better than ischaemia by cardiac 
myocytes; cells continued to beat in hypoxic conditions whereas in ischaemia they 
stopped synchronous beating after 4hrs (Chapter 3). This is perhaps unsurprising, 
since ischaemia puts cells under greater stress than hypoxia, due to the lack of 
metabolic substrates and the disruption of glycolysis. In ischaemia, there was 
continued loss of ATP, which could not be sustained (Turner et al., 2004) and this 
ultimately lead to cell death as reflected by LDH measurements. Ischaemic 
preconditioning involves the phosphorylation of Cx43 and implicates the involvement
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of Cx43Hcs at non-junctional areas in cardiac myocytes (Schulz & Heusch 2004). 
Similar molecular mechanisms involving CxHcs are likely to operate in 
stroke/hypoxia models (de Pina-Benabou et al., 2005; Kirchhoff et al., 2001). 
Overall, these studies suggest that open CxHcs are major participants/contributors in 
cell death. The data shows that the connexin mimetic peptides could be useful 
therapeutic tools for cardio- and neuro-protection in ischaemic injury. Interestingly, 
traditional connexin inhibitors (halothane/octanol), that are far less specific than the 
Cx mimetics used in the present studies, have been shown to reduce Cx43-linked 
brain injury in animal models (de Pina-Benabou et al., 2005).
The data showed that ischaemia but not hypoxia was accompanied by 
dephosphorylation of Cx43. The roles of Cx43 phosphorylation in the functioning of 
gap junctions and CxHcs continue to be debated (Lampe & Lau 2004; Moreno 2005; 
van Veen et al., 2006), with the kinases phosphorylating specific connexins slowly 
being revealed (Ek-Vitorin et al., 2006; Somekawa et al., 2005) and the relevant 
phospho-serines subject to modification in ischaemia identified (Axelsen et al., 2006). 
Many investigations have shown that ATP metabolism is disrupted in 
hypoxic/ischaemic hearts. For example, Beardslee et al. (2000) showed that 
dephosphorylation of Cx43 occurred within 30-40 minutes of induction of ischaemia 
in perfused hearts. Using isolated cardiac myocytes, dephosphorylation occurred 
within 8 hours and was rapidly and robustly reversed within 30 minutes (Turner et al., 
2004). Using cultured neonatal rat ventricular myocytes, Zeevi-Levin et al., (2005) 
showed that total Cx43, including phosphorylated and unphosphorylated forms, 
increased initially before Cx43 dephosphorylation occurred at later times of hypoxia. 
The present results are broadly in agreement with the above, and variations, especially
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in the timings of dephosphorylation, can be ascribed to the efficiency and induction of 
sustained low oxygen tensions.
Connexin mimetic peptides are ll/12mers that corresponded to extracellular loop 
sequences of connexin 32 (Warner et al., 1995). These peptides were modified later 
to mimic extracellular loop sequences in Cx43 and were shown to block the gap 
junctions connecting vascular smooth muscle cells and endothelial cells (Chaytor et 
al., 1997; 1998). The broad action of connexin mimetic peptides is demonstrated by 
the blockage of gap junction communication in cells of the immune system (Oviedo- 
Orta & Evans 2004) as well as in brain endothelial cells (Braet et al., 2003). 
Connexin mimetic peptides have been shown to reduce ATP release in a range of cells 
subjected to various types of stress (Boudreault & Grygorczyk 2004; Braet et al., 
2003; Gomes et al., 2005; Pearson et al., 2005)
The studies obtained with two different short peptides indicate that CxHcs are 
prospective therapeutic targets in addressing cardioprotection in hypoxic/ischaemic 
stress (Murphy 2004; Salameh & Dhein 2005). Indeed, plasma membrane channels 
constructed of connexins as well as their orthologues, the pannexins, are emerging as 
key components in the response of cells to hypoxia/ischaemia in physiologically 
susceptible tissues (Thompson et al., 2006) and their roles in regulating cell death 
especially in nervous tissue (Contreras et al., 2004). With regard to the molecular 
mechanism of action, the connexin mimetic peptides are proposed to bind to CxHcs 
located in unopposed plasma membrane regions thereby limiting the movements of 
ions and metabolites across these channels (Evans et al., 2006). In ischaemia, it is 
possible that CxHcs open and allow increased Ca2+ entry leading to Ca2+ overload,
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adenine nucleotide depletion and oxidative stress ultimately involving mitochondrial 
dysfunction (Halestrap et al., 2004). The present results show that ATP depletion and 
release that is blocked by the connexin mimetic peptide, and increased by AAP10, 
becomes evident after 80-90 minutes, possibly caused by the opening of 
mitochondrial transition pores. The mechanism of action of AAP10 as well as its 
analogue rotigaptide is less clear. Nevertheless, the observation that the peak of ATP 
release evident in ischaemic neonatal cardiomyocytes at 80 minutes is blocked by 
connexin mimetic peptides likely to interact with CxHcs and increased by AAP10 at 
the same time following initiation of ischaemia suggests that both peptides act, with 
opposite outcomes, on CxHc permeability.
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Chapter 6
Approaches to studying trafficking and assembly of gap junctions
in cardiac myocytes
6.1 Introduction
Reporter proteins tagged to connexin proteins have been used extensively to study gap 
junction biogenesis, and this approach has featured the use of connexins tagged at the 
carboxyl terminus with reporter proteins such as aequorin and green fluorescent protein 
(GFP) (George et al., 1998; Jordan et al., 1999; Martin et al., 2001). After transfection 
into cells of the relevant cDNA and expression of the chimeric connexins, they are 
assembled into functionally active gap junctions, allowing intercellular Ca2+ wave 
propagation and transfer of small fluorescent dyes, with similar gating parameters to their 
wild type equivalents (Bukauskas et al., 2000; 2002; Paemeleire et al., 2000). When used 
in conjunction with high-resolution time-lapse microscopy the chimeric fluorescent 
connexins allow imaging of the dynamics of gap junction channel assembly in live cells 
(Laird 2006; Martin et al., 2001). However, GFP and its variants are 25-27kD proteins 
and are often of similar bulk to the protein of interest. They are usually fused to the 
carboxyl tail of connexins which varies in length from about 18 (Cx26) to 275 (Cx57) 
amino acids. Attachment of GFP to the end of the C-terminus, but not to regions nearer 
to the membrane of the C-terminus of Cx32, resulted in the connexin being trafficked 
normally to the plasma membrane and forming functional gap junctions (Martin et al., 
2000).
Cyan (CFP), red (DsRedFP) and yellow (YFP) variants of GFP have enabled analysis of 
co-expressed connexin proteins and protein-protein interactions using advanced imaging 
procedures such as FRET. Fluorescent protein tags are very versatile but due to their 
large size as described above there are some disadvantages despite the fact that most of
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the fluorescently tagged connexins form functional gap junction channels. DsRedFP 
chimera of Cx43 is an example of a non-functional tag since it has difficulties in folding 
and becomes aggregated (Lauf et al., 2001; Martin et al., 2001).
6.1.1 The visual identification of Cx43 in cardiac myocytes
Connexins in the heart are usually detected as large punctate stains at the intercalated disc 
by immuno-labelling, utilising antibodies that specifically detect connexin proteins (or 
more specifically epitopes on the cytoplasmic side of the connexin) followed by labelling 
with a secondary antibody that is fluorescent (Kaba et al., 2001; Severs et al., 2001; 
2004). Immunostaining of connexins is an effective technique for studying protein 
localisation in HeLa, Cos-7 as well as others cultured cells when used in combination 
with live cell imaging (Martin et al., 2001). However, the trafficking pathways of 
connexins during their assembly and delivery to the intercalated discs in the heart have 
not yet been elucidated. A major reason is that it is very difficult to express fluorescently 
labelled connexins in primary rat cardiac myocytes. Indeed, a recent literature search 
revealed that no investigator to my knowledge has successfully transfected primary 
neonatal cardiac myocytes with recombinant connexin genes.
6.1.2 FlAsH fluorescent labelling system
A novel labelling system, FlAsH (Fluorescein Arsenical Hairpin binder), was described 
by Griffin et al. (1998), that allows live cell imaging and ‘pulse-chase’ labelling of a 
continuously expressed protein such as Cx43. Cx43 was labelled with FlAsH (green) and 
later ReAsH (a red label) was added, thereby allowing older and newer copies of Cx43 to
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be identified in a single image (i.e. pulse-labelling), as shown in Figure 6.1 (Evans & 
Martin 2002; Gaietta et al., 2002).
Using recombinant techniques, the carboxyl tail of Cx43 can be labelled with a small 
motif (6 -  20 residues) containing the sequence -  Cys -  Cys -  Xaa -  Xaa -  Cys -  Cys -  
(Gaietta et al., 2002), although the motif -  Cys -  Cys -  Pro -  Gly -  Cys -  Cys -  was 
recommended due to higher affinity and more rapid binding (Adams et al., 2002). Cells 
containing the tagged Cx43 are then exposed to a membrane permeant nonfluorescent 
biarsenical derivative of fluorescein, F1AsH-EDT2 (Panvera (now Invitrogen), USA). 
FlAsH binds with high affinity and specificity to the tetracysteine motif conferring strong 
green fluorescence (Figure 6.2b) (Griffin et al., 1998). The FlAsH molecule is a 
combination of fluorescein with trivalent arsenic substituents on the 4’- and 5’- positions 
(Figure 6.2a). The rigid spacing of the two arsenics in the FlAsH molecule enables it to 
bind with the thiol groups of the tetracysteine motif with high affinity and specificity. 
The simultaneous addition of EDT (1,2-ethanedithiol) minimises possible toxicity and 
non-specific binding to endogenous thiols caused by the trivalent arsenic atoms (Gaietta 
et al., 2002). The tetracysteine motif is clearly much smaller than a fluorescent protein 
tag such as GFP or aequorin and therefore is less likely to influence protein trafficking or 
functions. In addition, red and blue emitting analogues have also been developed known 
as ReAsH-EDT2 and H0XASH-EDT2 respectively (Adams et al., 2002). It was proposed 
by the authors that use of these reagents will enhance the study of the dynamics of protein 
trafficking events, protein interactions and protein-protein interactions in living cells.
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6.1.3 Chapter Aims
The investigations in this chapter aimed to express Cx43 in primary rat neonatal cardiac 
myocytes. Upon successful Cx43-GFP expression in cardiac myocytes, the biogenesis 
and trafficking characteristics in cardiac myocytes and how they are affected by 
ischaemia or hypoxia would then become open to analysis.
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Figure 6.1: FlAsH and ReAsH labeling of Cx43-TC
Two temporally separated pools of Cx43-TC can be labelled with FlAsH and ReAsH 
to allow monitoring of gap junction plaque formation over time. Cx43-TC was stably 
expressed in HeLa cells and stained with FlAsH-EDT2, then incubated over 4 (A,B) or 
8 hours (C,D) at 37°C, and then further stained with ReAsH-EDT2. This illustrates the 
gap junction plaque at varying states of renewal with FlAsH (green) labelling 
representing older and ReAsH (red) labelling representing newer gap junctions. A 3D 
volume projection of Cx43-TC with pulse-chase labelling rotated through different 
angles (E-G) illustrates that newly-synthesised connexins (red) is added to the 
periphery of the existing gap junction plaque (green). To illustrate there is no bias of 
binding between the two dyes the order of the pulse-chase labelling was reversed 
results in a reversal of the pattern of staining (H). Reproduced from Gaietta et al, 
2002 .
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Figure 6.2: FlAsH-EDT2, ReAsH-EDT2 and Cx43-TC construct
a) Diagram showing the chemical structure of FlAsH-EDT2 and ReAsH-EDT2 
ligands and b) Schematic diagram showing the position of the tetracysteine domain 
within the Cx43-TC construct and a connexon hexamer with 6 ReAsH ligands bound 
to the tetracysteine domains. Modified from Gaietta et al, 2002.
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6.2 Methods and Results
6.2.1 Preparation of GFP labelled Cx43 in cardiac myocytes for trafficking studies
A Cx43-GFP chimera had already been developed in our laboratory. Enhanced-GFP 
(eGFP) was attached to the carboxyl terminus of the connexin, and used in HeLa and 
COS-7 cells (Martin et al., 2001; Paemeleire et al., 2000). Briefly, Cx43 cDNA was 
inserted into a vector containing the eGFP sequence (pEGFP-Nl vector, Clontech, USA, 
Figure 6.3b) by cutting with the appropriate restriction enzyme which ensured inframe 
fusion between the Cx43 and the amino terminus of eGFP. The pEGFP-Nl vector 
contains a CMV promoter so it can be expressed immediately in mammalian cells.
As primary cells such as neonatal cardiac myocytes are notoriously difficult to transfect 
and thereby express recombinant proteins different methods of transfection, including 
microinjection of cDNA and lipid-based transfection and an adenovirus expression 
system were carried out as described below.
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Figure 6.3: Plasmid vectors
The vector maps and multiple cloning sites (MCS) of a) the pCR3 vector that contains 
the wild-type Cx43 sequence insert, b) the pEGFP-Nl vector which contains the 
Cx43-GFP sequence insert, and c) the TA cloning vector pGEM-T.
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6.2.1.1 Microinjection of cDNA
The Cx43-GFP in the pEGFP-Nl vector (500mg/ml in 3M Tris, 0.3M EDTA) was 
microinjected into confluent monolayers of beating rat neonatal cardiac myocytes or 
HeLa cells as described by George et al. (1998). Briefly, cDNA solution was injected 
into every cell nucleus within a marked area under low pressure (lOOhPa) and with an 
injection time of 0.2secs (Femtojet 5247, Eppendorf, USA). This resulted in Cx43-GFP 
being expressed by both cell types, although transfection efficiency was poor in cardiac 
myocytes, as illustrated in Figure 6.4. The location Cx43-GFP was mainly along the 
plasma membranes in both cell types. However, the transfection efficiency was low thus 
limiting analysis and therefore an alternative method was sought.
6.2.1.2 Lipid-based transfection of rat neonatal cardiac myocytes
The lipofectamine™2000 transfection reagent (Invitrogen, USA) was used on primary rat 
neonatal cardiac myocytes. Lipofectamine™2000 Transfection Reagent is a proprietary 
cationic lipid formulated to ensure maximum transfection efficiency in a number of cell 
types, including primary rat hepatocytes.
Transfection was carried out on confluent cardiac myocytes plated out in 24mm2 glass 
cover-chambers (Labtek, USA). Cx43-GFP DNA-lipofectamine™ 2000 complexes were 
prepared by mixing 0.25pg of DNA (50pl in DMEM) with 2% (v/v) Lipofectamine™ 
2000 (50|il in DMEM) and incubated for 30mins at room temperature to allow the DNA- 
Lipofectamine™ 2000 complexes to form. The DNA-Lipofectamine™ 2000 complexes 
(lOOpl) were then added to the cardiac myocytes and incubated at 37°C for 48hrs.
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Transfection of primary rat neonatal cardiac myocytes with Lipofectamine™ 2000 
resulted in Cx43-GFP expression observed 48hrs post transfection (Figure 6.5). 
However, the transfection efficiency was low, precluding useful analysis to be performed. 
To increase efficiency, various transfection parameters were altered, with the amount of 
DNA and Lipofectamine™ 2000 reagent being both increased and decreased, but to no 
effect.
6.2.13 Development of an adenoviral expression system
Since the transfection methods described above resulted in poor transfection efficiencies 
and low yields of expressed recombinant proteins, the utility of an adenovirus expression 
system was explored. To ensure neonatal cardiac myocytes were viable for adenovirus 
transfection, a GFP recombinant adenovirus was obtained (Lai group, WHRI, Cardiff). 
Rat neonatal cardiac myocytes were successfully transfected with GFP as shown in 
Figure 6.6. After this positive result the Adeno-X™ Expression System (BD biosciences 
(now Clontech), USA) was selected. The Adeno-X™ Expression System provides a 
method for constructing recombinant adenovirus, by using conventional in vitro ligation 
to incorporate a mammalian expression cassette into a replication-incompetent 
(AE1/AE3) human adenoviral type 5 (Ad5) genome (Mizuguchi & Kay 1998). The 
assembly and production of recombinant adenovirus involves three stages and the 
protocol is outlined in Figure 6.7.
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Figure 6.4: Rat neonatal cardiac myocytes and Hela cells transfected with Cx43- 
GFP by microinjection
Hela cells (A,B) and rat neonatal cardiac myocytes (C,D) were microinjected Cx43- 
GFP. The images were captured 48 hours after the cells were injected. B and D are 
the phase images of A and C respectively.
181
Figure 6.5: (A) Rat neonatal cardiac myocytes transfected with Cx43-GFP by 
lipofectamine 2000. Arrow points to the transfected myocyte. (B) is the phase image of 
(A). The autofluorescence shown is due to cell debris.
The m a m m a lian  expression cassette was constructed by cloning into a shuttle vector 
(pShuttle2) (Figure 6.8) and amplifying it in competent E. coli (described in 2.8.4). The 
second stage involved removal of the mammalian expression cassette containing the 
Cx43-GFP gene from the pShuttle2 vector using the specified restriction endonucleases 
(I-Ceu I, Pl-Sce I). The excised cassette was then ligated into the Adeno-X viral DNA 
(the adenoviral genome). The final stage was to transfect human embryonic kidney 
(HEK) 293 cells with the recombinant Adeno-X vector where it is replicated and 
packaged into infectious adenovirus, and then harvested by lysing transfected cells. HEK 
293 cells stably express the Ad5 El genes that are essential for replication and 
transcription of the adenovirus DNA.
In order to clone Cx43-GFP into the pShuttle2 vector new PCR primers were designed 
incorporating the appropriate restriction endonuclease sites, as shown below:
Forward Cx43 Xbal primer
S’-ACT-ATA-GGG-AGA-TCT-AGA-ATG-GGT-GAC-TGG-AGTr
I i I
Clamp Xbal restriction First 15bp of Cx43
enzyme site
Reverse Cx43-GFP Notl primer
5’-AGT-TCC-CAG-GAT-TGC-GGC-TTA-CTT-GTA-CAG-CTC-3’ !------------------------ ,--------------------------------- ,---------------------
Damp Notl restriction Last 15bp of GFP
enzyme site
The PCR was successful and the DNA was purified (as described in 2.8.1-2.8.3). 
However, the PCR product could not be ligated successfully into the pShuttle2 plasmid 
vector. This was probably due to the failure of the restriction endonucleases (Xba I and
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Not I) to cut the DNA correctly owing to a lack of DNA either side of the restriction 
enzyme site. To overcome this problem, it was decided to clone Cx43-GFP using “Topo 
cloning” (Invitrogen, USA), a method that eliminates the need for restriction digests and 
ligation reactions by allowing direct insertion of the PCR products into the pCR-XL- 
TOPO vector, thereby providing a renewable source of Cx43-GFP for cloning purposes. 
The vector has the ability for TA cloning (explained in section 6.2.3.2) and has 
topoisomerase covalently bound to the plasmid which facilitates the ligation of the PCR 
products as shown in Figure 6.9.
The PCR products containing the Cx43-GFP insert were successfully cloned into the 
pCR-XL-TOPO vector. However, this vector also contains Xba I and Not I sites in its 
MCS so new PCR primers without restriction endonuclease sites would be required and 
therefore the studies were discontinued.
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Figure 6.6: Expression of GFP in rat neonatal cardiac myocytes
GFP was expressed in rat neonatal cardiac myocytes using an adenovirus expression 
system. The virus was used at different moieties of 10 (A,B) and 100 (C,D). Images 
were xlO (A-C) and x40 (D) magnification.
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Figure 6.7:
Protocol for construction of a recombinant adenovirus with the Adeno-X™ Expression 
System. Modified from the BD Adeno-X™ Expression System 1 User Manual
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Figure 6.8: Plasmid vector map and multiple cloning site of pShuttle2.
pShuttle2 allows cloning of the Cx43-GFP gene into a mammalian expression cassette, 
which consists of the human cytomegalovirus immediate early promoter/enhancer 
(PCMV IE), a multiple cloning site (MCS), and the SV40 polyadenylation signal 
(SV40 poly A). The entire cassette is flanked by unique I-Ceu I and Pl-Sce I restriction 
sites so that it can be excised and ligated to BD Adeno-X Viral DNA.
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Figure 6.9: TOPO cloning
Topoisomerase facilitates the insertion of PCR products into the pCR-XL-TOPO 
vector as illustrated (a) and the plasmid vector map is shown in (b).
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6.2.2 Immunostaining of rat neonatal cardiac myocytes
In earlier studies using HeLa cells expressing connexins 26, 32 and 43 it was observed 
that disrupting cytoskeletal elements altered connexin trafficking pathways (Martin et al., 
2001). In primary rat neonatal myocytes, the integrity of microtubules and actin 
filaments was disturbed using nocodazole and cytochalasin D respectively for 5hrs. The 
microtubules were detected by an antibody specific for {3-tubulin followed by a 
fluorescent secondary antibody (Alexa-488, green fluorescence) (Figure 6.10a). 
Treatment of cardiac myocytes with nocodazole (20 mg/ml) resulted in disruption of 13- 
tubulin (Figure 6.10c,e). Actin filaments were stained directly with phalloidin (red 
fluorescence) before and after treatment with cytochalasin D (1 mg/ml) (Figure 
6.10b,d,f). Cardiac myocytes were also treated with brefeldin A which disrupts the Golgi 
apparatus, but could not be analyzed as the anti-ERGIC-53/p58 antibody (Sigma, USA) 
needed to determine the location of ERGIC (Endoplasmic Reticulum Golgi Intermediate 
Compartment) components was unobtainable at the time of the study.
The localisation of Cx43 in primary rat neonatal cardiac myocytes was carried out with a 
Cx43 antibody that detects all Cx43 isoforms (Zymed, USA) and a fluorescent secondary 
antibody containing Alexa-546 (red fluorescence). Cx43 was located intracellularly and 
at the cell borders as shown in Figure 6.11.
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Control
+ Drug
+ Drug 
phase
Figure 6.10: The effect of Nocodazole and Cytochalasin D on microtubules and 
actin filaments.
Confluent monolayers of rat neonatal cardiac myocytes were fixed and stained 
antibodies to b-tubulin under normal conditions (A) and following 5 hours treatment 
with 20 mg/ml nocodazole (C). The structural integrity of actin filaments was 
determined by staining with pholloidin before (B) and after 5 hours treatment with 1 
mg/ml cytochalasin D (D). The phase images of (C) and (D) are shown in (E) and (F) 
respectively.
p-tubulin Actin
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BFigure 6.11: Cx43 immunostaining 
in rat neonatal cardiac myocytes.
Confluent monolayers of rat neonatal 
cardiac myocytes were probed with a 
|Cx43 antibody (Zymed, USA, which 
detects Cx43 (phosphorylated and 
non-phosphorylated)). A fluorescent 
secondary antibody containing Alexa 
546 (red) was used to stain Cx43 
(A,B). The arrows point to gap 
junction plaques and punctate staining 
typical of Cx43. (C) The phase image 
of (B) shows the cell boundaries.
191
6.2.3 Construction of Cx43-TC for FlAsH fluorescent labelling system
The FlAsH labelling system requires the addition of a small tetracysteine (TC) motif to 
the carboxyl terminus of Cx43 achieved by the processes outlined below.
6.2.3.1 Primer Design and PCR
The tetracysteine motif was tagged onto the carboxyl tail of Cx43 by PCR. The 
tetracysteine tag sequence was incorporated into custom designed primers (Invitrogen, 
USA). The designs of the Cx43-TC primers are shown below:
Forward Cx43-TC primer
5*-ACT-ATA-GGG-AGA-GAA-TTC-ATG-CGT-GAC-TGG-AGT-3’
 1 1 1---------------
Gamp EcoRl restriction First 15bp of Cx43
enzyme site
Reverse Cx43-TC primer
S’-CAG-CGA-ATT-CAT-CTA-AAC-AAC-ATC-CTG-GAC-AAC-AAA-TCT-CCA-GGT-CAT-C-S’i | I i
Gamp EcoRl Tetracysteine motif Last 15bp of Cx43
restriction
_________enzyme site__________________________________________________________
Both forward and reverse primers feature EcoRl restriction enzyme sites. The forward 
primer is 33 base pairs (bp) long and features the sequence coding for the first 15bp of 
the Cx43, whereas the reverse primer is 49bp long and incorporates the sequence coding 
for the last 15bp of the Cx43. Wild type rat Cx43 cDNA in the PCR3 vector was 
available from our laboratory and was used as the DNA template for the PCR reaction. 
Bioexact Taq DNA polymerase was used and PCR reactions set up as described in 2.8.1. 
The Cx43 exon is 1145bp long, making the approximate length of Cx43-TC 1230bp.
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PCR resulted in a band appearing at 1400bp on a DNA agarose gel as shown in Figure 
6 . 12.
6.2.3.2 Subcloning of FlAsH PCR products
Bio-x-act Taq polymerase (Bioline,UK) leaves additional 3’A residues intact during 
PCR, thus generating ideal fragments for cloning into plasmid vectors that contain the 
corresponding 3’T overhang, such as pGEM-T (Promega, UK; Figure 6.3c). Purified 
PCR products and linearised vector (pGEM-T; 50ng) were ligated according to 
manufacturer’s instruction with an insert:vector molar ratio of 3:1 proving to be the 
optimum condition. The amount of DNA insert used was calculated as shown below 
along with the ligation reaction setup:
ng of vector x kb size of insert x insert:vector molar ratio = ng of insert 
kb size of vector
Ligation reaction setup______________________________________________________
Vector DNA 50ng (1 pi)
Insert DNA* Xng
T4 DNA ligase (3U/pl) lpl
2x rapid ligation buffer (Promega, UK) 5 pi
dFLO tolOpl
* Amount added to give insert:vector molar ratio of 3:1
Reactions were performed at 4°C (pGEM-T) for 15hrs. Ligation mixtures were stored at 
-20°C prior to use.
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Following successful ligation of the Cx43-TC PCR product into the pGEM-T vector, the 
recombinant plasmid was transformed into DH5a competent bacteria and subjected to 
amplification and purification as described in section 2.8.3.
The purified DNA was then analysed by sequencing (section 2.8.5) to ensure correct 
insertion of the Cx43-TC DNA. However, only the first half of Cx43-TC was sequenced 
(Figure 6.13), causing these studies to be suspended.
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1400bp
Figure 
6.13:
Sequencing 
printout showing 
the 
successful sequencing 
of 
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first half 
of the 
Cx43- 
TC 
construct using the 
T7 
prim
er.
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6.3 Discussion
The studies described in this chapter reveal attempts to use fluorescent reporter proteins 
tagged to Cx43 to monitor its location in live beating cardiac myocytes. Work in our 
laboratory has demonstrated two connexin trafficking pathways in HeLa cells (Martin et 
al., 2001). These earlier studies indicated that Cx43 and Cx32 are trafficked to the 
plasma membrane through the secretory pathway via the Golgi apparatus, although Cx26 
was also trafficked to the plasma membrane via an alternative pathway that was highly 
sensitive to microtubule disruption (Diez et al., 1999; Martin et al., 2001). Other studies 
have shown that microtubules are necessary for enhanced assembly of Cx43 gap 
junctions (Johnson et al., 2002). We posed the question: in pathological situations, such 
as ischaemia, can Cx43 be trafficked to the plasma membrane by an alternative pathway 
or possibly by both pathways simultaneously, and designed experiments to test this 
possibility.
The studies described in this chapter although incomplete, have helped to lay a 
foundation for further work using Cx43 labelled with fluorescent reporter tags using 
primary rat neonatal cardiac myocytes to enable visualisation of the protein in live 
beating cells. The potential of the adenovirus expression system was demonstrated by the 
successful transfection of the cells with GFP. However, the expression of Cx43-GFP 
would have to be carefully controlled as connexin over-expression is likely to 
compromise cell function. Continuation of these studies would enable the trafficking 
characteristics of Cx43 to be assessed in primary neonatal cardiac myocytes under normal 
and hypoxic/ischaemic conditions.
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The FlAsH labelling system at the time would be a useful addition to the tools used to 
assess the Cx43 turnover and behaviour in cardiac myocytes during hypoxia and 
ischaemia. Continued FlAsH studies could clone Cx43-TC in two stages, thereby 
utilising smaller oligonucleotide primers to ensure successful PCR and sequencing. As 
far as I am aware, no studies using the FlAsH system for labelling connexins outside the 
Tsien lab in San Diego, USA have appeared. This, together with my abortive attempts, 
indicate that although elegant results were obtained conceiving the way CxHcs are added 
to, and removed from the gap junction (Gaietta et al., 2002), the technology is still very 
complex and in experimental infancy. To my knowledge, there have been no further 
reports of its use outside the Tsien laboratory, suggesting that refinements will be 
necessary.
A further aspect emerging is the difficulty of transfecting primary neonatal cardiac 
myocytes using conventional methods that work on most other cells. The present studies 
have underlined the difficulties associated with the transfection of primary cardiac 
myocytes. However, the studies reveal the promise of alternative approaches using viral 
expression systems, illustrated in this instance by the adenovirus expression system.
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Chapter 7
Final Discussion
The work presented in this thesis describes the properties o f Cx43 in a cardiac 
environment. One o f the major outcomes o f this work was the development o f a cellular 
model o f ischaemic heart disease which was used to examine the properties o f two 
classes o f drugs; one that stimulated connexin based communication and one that 
inhibited it. The cells used were primary rat neonatal cardiac myocytes, which retain 
their cardio-specific properties and beat synchronously when cultured as a confluent 
monolayer. The model utilised a hypoxic chamber and substrate depleted cell culture 
medium to simulate ischaemia. It is extremely difficult to find a model that mimics 
exactly the effects occurring in the adult heart during ischaemic heat disease and 
myocardial infarction as these conditions can not be reproduced and recorded effectively 
by many systems. However, the results presented using this cellular model serve to 
strengthen our understanding of cardiac cellular responses during ischaemic and hypoxic 
stress and complement in vivo models which take into account the whole organ and other 
body system.
The present model provides a more physiological model o f ischaemia and thus all effects 
observed are due to the ischaemia, unlike some traditional methods that use chemical 
inhibitors to induce ischaemia. These traditional “chemical” methods o f inducing 
hypoxia and ischaemia have made use o f iodoacetic acid (Contreras et al., 2002), 
potassium cyanide and deoxyglucose (Turner et al., 2004). These chemicals poison cells, 
and their lack of specificity is likely to mask the effects caused by hypoxia and 
ischaemia. In complementary studies, ischaemia has also been induced using whole heart 
preparation in the Langendorff (no perfusion) system (Beardslee et al., 2000). This
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method is equally effective and provides information at the organ level o f what happens 
during cardiac ischaemia. However, our model system, besides complementing heart 
perfusion systems, has proved to be an effective tool in studying specific aspects (such as 
the mechanisms o f peptide drugs in cardiomyocytes) o f Cx43 biology in detail at the cells 
level and within a cardiac context.
The results obtained using this approach showed that ischaemia caused the synchronous 
beating of cardiac myocytes to cease after 2-3 hours followed later at 5 hours by 
dephosphorylation of Cx43. Similar results were achieved using a whole heart 
Langendorf ischaemia (no perfusion) set up (Beardslee et al., 2000). In this study, the 
authors reported that gap junction uncoupling (and thereby arrest o f beating) and Cx43 
dephosphorylation occurred after approximately 30 minutes o f ischaemia (Beardslee et 
al., 2000). My observations concur with these studies, but occur more slowly, most 
likely due to the differences in experimental conditions. Another possible reason is that 
adult heart cells is more dependant on mitochondrial oxidation for ATP generation than 
neonatal cells/hearts that rely more on glycolytic production o f ATP.
The synchronous beating of cardiac myocytes and Cx43 phosphorylation state appears to 
be closely linked. My studies have revealed that synchronous contraction of 
reoxygenated ischaemic cardiac myocytes returns when Cx43 phosphorylation is 
restored. The mechanism underlying the uncoupling o f cardiac myocytes during 
ischaemia could be the dephosphorylation o f Cx43, but a causal link has not been 
demonstrated. This could be achieved by further studies using a Cx43 mutant lacking
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one or more of the serine residues that are the main targets for phosphorylation, ideally 
expressed in a mammalian cardiac cell line, such as HL-1 cells, as primary neonatal 
cardiac myocytes are currently very difficult to transfect as outlined in chapter 6.
The work carried out also revealed that cardiac myocytes exposed to simulated ischaemia 
release a transient burst of ATP that was sensitive to two gap junction inhibitors. The 
results show that this burst o f ATP release is likely to occur across Cx43 Hcs. As 
discussed previously, Cx43 Hcs remain in a closed configuration when they are un­
apposed in the plasma membrane (i.e. they have not docked to form a gap junction). 
However, in a study using astrocytes treated with metabolic inhibitors (a non- 
physiological model o f ischaemia), fluorescent dyes were shown to permeate the cell 
membrane and were sensitive to gap junction inhibitors and thus the authors concluded 
that the Cx43 hemichannels open during ischaemia (Contreras et al., 2002), as our present 
results also indicate. It was argued that opening o f CxHcs in ischaemia would exacerbate 
the pathological situation by allowing ATP to leak out o f the cell, lowering intra-cellular 
ATP levels to catastrophic levels. The present work has indicated that this is not the case, 
as a small amount of ATP is released in a controlled transient manner at a specific frame 
within the first two hours of ischaemia. Intracellular ATP levels remained constant 
during this time period, indicating that the small transient release o f ATP did not greatly 
effect overall intracellular ATP concentration.
The release of ATP from cells is a central feature in purinergic signalling between cells 
with ATP, its breakdown products and especially adenosine possessing active signalling
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capabilities via adenosine receptors and purinergic receptors. In further work, 
preliminary experiments were carried out to analyse ATP breakdown products present in 
the cell culture medium after ischaemia induced ATP release. However, the detection 
system was unable to provide the analysis required. The addition of ATPases and 5’- 
nucleotidase inhibitors could be introduced as well as newer more sensitive methods o f 
ATP and adenosine nucleotide detection would be utilised.
It has also been suggested that if  CxHc opening prevails under conditions o f extreme 
stress it could provide cells with a method o f isolating non-viable cells quickly from the 
healthy coupled cell population (Spray et al., 2006), a role that has been postulated for 
Cx43 in CNS and cardiac cell death (Contreras et al., 2004; John et al., 2003). In the 
present studies, ischaemic myocytes recovered by reoxygenation after approximately 8 
hours of continuing ischaemia and the initial transient burst o f ATP did not greatly effect 
the overall intracellular ATP concentrations. Intracellular ATP concentrations are much 
higher than extracellular (intracellular (low pM) to extracellular (low nM) for ATP 
concentrations).
The mechanism of CxHc opening during ischaemia is unknown. It is widely accepted 
that reduced extracellular Ca2+ opens hemichannels, and it has been suggested that 
reduced Ca in the ischemic tissue would be capable o f activating CxHcs. It is 
interesting to note that high intracellular Ca2+ (500nM) has also been shown to open 
Cx32Hcs (De Vuyst et al., 2006) and recently for Cx43Hcs (De Vuyst, Evans & 
Leybaert, unpublished work). It has also been proposed that alterations in Cx43
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phosphorylation or nitrosylation are important initiating events (Bao et al., 2004; 
Contreras et al., 2002; Retamal et al., 2006). In contrast, the present studies showed 
Cx43 was still phosphorylated at the time o f the ATP release, as detected by our methods, 
indicating the possibility that Cx43 phosphorylation might not be a crucial event in CxHc 
opening. However, the antiarrhythmic peptide AAP10 caused the pulsatile release of 
ATP to be exacerbated, which is proposed to operate via protein kinase C, suggesting that 
phosphorylation could be involved. A sensitive method o f detecting small changes in 
Cx43 phosphorylation, such as mass spectrometry techniques (Axelsen et al. 2006), 
would add clarification to these questions.
In ischaemia the release of ATP and its breakdown products (ADP, AMP and adenosine) 
that possess vasodilatory properties into the cardiac vasculature can potentially increase 
blood supply to the myocardium and thus alleviate many o f the symptoms o f the 
ischaemia related to oxygen/metabolite deficiency. It would be worthwhile to investigate 
the levels of ATP metabolites and achieve better analysis o f the nucleotide/nucleoside 
release during ischaemia, in order to elucidate the substances that are active as a 
consequence of ATP release from the cardiac myocytes. This could be accomplished 
using reverse phase high pressure liquid chromatography to measure adenosine and its 
nucleotides/nucleosides (Sala-Newby et al., 2000; Smolenski et al., 1990). Further 
studies would also record intracellular Ca2+ levels and the pH o f the cell culture medium 
throughout the ischaemic timecourse as this may aid the understanding o f Cx43Hc 
opening during ischaemia.
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Connexin mimetic peptides were used in this thesis to inhibit connexin based 
communication. Both GAP 26 and GAP 27 were shown to reduce dye transfer between 
neonatal cardiac myocytes and shown to attenuate the beating rate o f the cells. Dye 
transfer between cardiac myocytes was arrested after 30 minutes, but the peptides took 
longer to exert their maximal effects on the beating rate o f the myocytes. GAP 26 was 
also used to inhibit ATP release from cardiac myocytes via Cx43Hcs during ischaemia. 
These results indicate that basal ATP release from cardiac myocytes was reduced by 
approximately half within the first 10-20 minutes o f treatment. Connexin mimetic 
peptides have been hypothesised to act on CxHcs first and then followed later on gap 
junction channels (Evans et al., 2006) as illustrated in Figure 7.1.
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Figure 7.1: The proposed mechanism of action of connexin mimetic peptides
Firstly the connexin mimetic peptides bind to CxHcs restricting channel release of 
ATP. Later, CxHcs become incorporated into gap junctions thereby inhibiting 
intercellular communication between cells or diffuse into the intercellular cleft 
between the cells and induce direct blockage of gap junctions. Reproduced from Evans 
et al., 2006.
Also in the present studies, we examined the effects of two antiarrhythmic peptides, 
AAP10 (in ischaemic studies) and rotigaptide (ZP123) (in cell communication studies). 
As discussed in chapter 1, AAP10 was developed as a synthetic derivative of the 
naturally occurring peptide AAPnat which is present at relatively high levels in heart 
tissue. AAP10 in turn was chemically modified to generate an analogue, rotigaptide 
(ZP123). Rotigaptide has the same sequence as AAP10 but uses d-isoforms of the amino 
acids rather than the 1-isoforms (AAP10 = H2N-Gly-Ala-Gly-Hyp-Pro-Tyr-CONH2;
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rotigaptide = Ac-d-Tyr-d-Pro-d-Hyp-Gly-d-Ala-Gly-NH2). Rotigaptide has a protracted 
action with a half life approximately 10 times longer than its analogue AAP10, due to its 
construction from the d-amino acids and is being assessed clinically (currently in Phase II 
clinical studies, conducted by Wyeth Pharmaceuticals, USA) as a potential 
antiarrhythmic drug. In a the latest study using rotigaptide was shown to have no effect 
on blood pressure or heart rate (Hennan et al., 2006). Also, rotigaptide increased gap- 
junctional communication in HeLa cells expressing Cx43, as well as HL-1 cells and 
cardiac myocytes, but was without action on cells expressing connexins 26 and 32 
(Clarke et al., 2006). These observations pointing to connexin specificity are possibly 
due to these connexins having shorter carboxyl tails, and are therefore less interactive 
with cytoplasmic proteins such as tubulin and ZO-1 (Giepmans 2004). The derivative of 
rotigaptide, AAP10, was shown to increase the pulsatile release o f ATP from cardiac 
myocytes during ischaemia. Owing to commercial licensing agreements, rotigaptide 
could not be used officially for these studies but it is highly likely that similar data would 
be achieved. These studies with rotigaptide and AAP10 would now benefit from analysis 
of gap junction coupling in cells expressing other cardiac connexins, e.g. Cx40, Cx45 and 
Cx37.
Using a cardiac myocyte system, the sensitivity o f the Western blotting utilised was too 
low to detect any changes in Cx43 phosphorylation (Clarke et al., 2006). A more recent 
study (Axelsen et al., 2006) using mass spectrometry, MALDI (matrix-assisted laser 
desorption/ionization) and LC-MS/MS (liquid chromatography tandem mass 
spectrometry), showed that the onset of the ischaemia induced dephosphorylation of
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Cx43 and was delayed by rotigaptide (Axelsen et al., 2006). This thesis has highlighted 
the effects of antiarrhythmic peptides, such as rotigaptide (ZP123) on gap junctions and 
AAP10 on CxHcs, and shown them to be useful tools that enhance the activity o f 
channels constructed from Cx43. Also, in additional unpublished studies carried out by 
us, rotigaptide had similar effects in ischaemic myocytes as AAP10. Therefore, their 
overall effects and mechanism o f action are highly likely to be similar if  not identical. 
The mechanism of action o f both peptides has been associated with the phosphorylation 
of Cx43, specifically via the action o f PKCa (Dhein et al., 2003; Weng et al., 2002). 
Indeed, the therapeutic benefit produced by such peptides has already been recognised by 
the continuing clinical development o f rotigaptide (ZP123).
The studies described examined the potential o f several methods o f transfection of 
primary cardiac myocytes with fluorescently labelled Cx43. Although these studies 
illustrated the difficulties surrounding the transfection o f primary cells, they show that it 
can be achieved using an adenoviral expression system. The reasons for these difficulties 
in transfection in primary cardiac myocytes are presently unknown, but possible causes 
could be the extensive cytoskeletal system or limited exocytosis/endocytosis processes 
compared to other cultured cells and cells dissociated from organs. To my knowledge 
there has been little work to investigate the trafficking and assembly o f gap junctions and 
CxHcs in cardiac cells although it is likely that the trafficking and assembly o f connexin 
channels is similar in all cells. Thus, it would be o f great benefit if  these factors were 
studied further in a cardiac context using myocytes from young or old animals.
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The relationship between gap junctions and cardiac arrhythmia make regulation o f Cx43 
an important field warranting further research. The evidence implicating Cx43 and gap 
junction channels in cardiac myocyte responses to ischaemia and reperfusion indicates 
that understanding the behaviour o f channels composed o f Cx43 is a vital requirement in 
cardiac biology. The use of the model described in this thesis will allow continued in 
depth evaluation o f these processes.
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